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General introduction 
 
CHAPTER 1 
INTRODUCTION 
Health care expenditure in Australia is growing faster than other sectors of 
the economy [1]. The ageing of the population has added further concern 
about the affordability of future health care provision. Recently, the 
Treasurer commissioned the Intergenerational Report to estimate social 
expenditure over the next few decades [2]. The health care expenditure 
projections in this report were rather crude as it used a simplistic 
econometric approach to extrapolate past per capita expenditure patterns by 
age and imposed these on the projected changes in population size. A more 
informative analysis is possible taking into account that patterns of disease 
and mortality are changing and that there are differences in the ability to 
intervene depending on the underlying condition [3]. Nevertheless, the 
Report is an indication of the growing interest at the highest level of 
government in using evidence to inform social and health policy.  
Evidence based medicine has become a well-established policy tool in 
clinical medicine. This body of work has led to numerous treatment 
guidelines based largely on systematic reviews by the Cochrane 
Collaboration (http://www.cochrane.org). More recently, evidence based 
policy was introduced as a term to describe the collation of evidence to 
inform health policymaking. For instance, in the UK it is being used in the 
name of the Centre for Evidence Based Policy and Practice of the Economic 
and Social Research Council (http://www.evidencenetwork.org) and in the 
title of the Evidence-Based Healthcare and Public Health journal 
(http://www.harcourt-international.com/journals/ebhc). The Australasian 
Cochrane Centre runs an Evidence-Based Policy Network to support 
Australian health care policy makers make best use of evidence 
(http://www.cochrane.org.au/ebpnetwork/ ebpnpublic).  
The processing and presentation of evidence to inform health policy 
decision making is the topic of this thesis. Burden of Disease and Cost-
Effectiveness Analysis are the two major themes that are applied to mental 
disorders and the treatment options for depression within the context of 
priority setting in Australia. The two themes are closely linked as a thorough 
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understanding of the epidemiology of a particular disease provided by 
Burden of Disease is an essential building block to the development of 
credible models for analysing cost-effectiveness.  
Chapters 2 and 3 describe methodological issues related to estimating 
the Burden of Disease from mental disorders in Australia [4, 5]. The next 
four chapters are part of a larger series of publications on the Assessing 
Cost-Effectiveness (ACE)–Mental Health study [6-14]. The first of these 
four is a description of the epidemiological and economic modelling 
methods [8]. Two further chapters deal with the amount of depression in 
Australia that could potentially be averted with episodic or longer-term 
maintenance intervention strategies and the cost-effectiveness of these 
alternative approaches [11, 12]. Chapter 7 presents an overview of the ACE-
Mental Health study [14]. 
In this introductory chapter, a general discussion on the two major 
themes of this thesis, Burden of Disease and cost-effectiveness, follows. The 
main issues arising from chapters 2–7 are discussed in a final discussion 
chapter. 
THEME ONE: BURDEN OF DISEASE 
In the early 90s, Murray and Lopez introduced a method to comprehensively 
measure the health of populations using the Disability-Adjusted Life Year 
(DALY), a summary measure that captures loss of health from premature 
mortality and non-fatal health states. A first set of global Burden of Disease 
estimates for eight world regions in 1990 was published in the 1993 World 
Development Report followed by more refined 1990 estimates in a series of 
books published in 1996 [15-17]. A further eight volumes detailing the 
epidemiological data sources and methods were planned but only one of 
these on sexual and reproductive health has come to publication [18]. This 
has meant that many of the national studies that followed had information on 
the overall methods but could not benefit from the disease-specific 
epidemiology and modelling assumptions used in the initial Global Burden 
of Disease study. Personally, it meant that the first country Burden of 
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Disease studies I conducted in Mauritius and Australia did not benefit from 
past experiences [19-23]. While this made the task more difficult it did 
inspire developmental work and led to considerable methodological 
improvements. Subsequently, many of these improved methods have been 
fed back into later versions of the Global Burden of Disease study including 
the approach to assessing the burden of non-fatal injuries from the Mauritius 
study and the detailed assessment of mental disorders from the Australian 
studies. The latter is described in the first two publications included in this 
thesis. 
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Figure 1 Life expectancy, health expectancy and health gap described in a 
survivorship curve. 
Summary measures of population health 
Burden of Disease studies quantify a population’s health status using 
summary measures of population health (SMPH). Two classes of SMPH are 
distinguished: health expectancies and health gaps [24]. The difference 
between the two is best illustrated in a survivorship curve plotting the 
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proportion of a birth cohort on the Y-axis surviving to each age on the X-
axis (Figure 1). The top curve represents the probability of surviving to each 
age in this hypothetical population. The life expectancy is the area under this 
curve (combined areas A and B in Figure 1).  
Most commonly, life expectancy at birth is presented by calculating in 
a life table the hypothetical average amount of time lived if a cohort of 
newborns would be subjected to current age-specific mortality rates until 
they all have died. This is the so-called period life expectancy that appears in 
many annual country statistics publications such as the World Health 
Reports [25]. Life expectancy has intuitive appeal and is widely accepted 
though it is probably rarely understood that it makes the assumption of 
constant mortality rates and hence would underestimate true life expectancy 
in the majority of countries that have declining mortality trends. 
Health expectancies are an adaptation of life expectancy adjusting time 
lived by the probability of loss of health due to non-fatal diseases. Area B in 
Figure 1 represents this amount of health loss and hence the health 
expectancy is defined as area A. There are several ways in which the amount 
of health loss is defined to estimate area B with the Disability-Free Life 
Expectancy and the Health-Adjusted Life Expectancy the most commonly 
used [24, 26]. Health expectancies are not discussed further as they do not 
feature in this thesis. 
Health gaps: normative survivorship goal 
The DALY, the common measure used for the work presented in this thesis, 
is a health gap measure. Health gaps are calculated as the difference between 
a population’s current health status and a stated ideal that everyone in a 
population reaches old age free of disease. This ideal has been named the 
‘normative survivorship goal’ [24]. In the example of Figure 1 the normative 
survivorship goal is set at 100 years. The mortality component of the health 
gap is defined by area C while the non-fatal component is the aggregate of 
severity-weighted health loss from all prevalent health states in the 
population.  
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The first normative survivorship goal was posited in 1947 by Dempsey 
introducing the concept of Potential Years of Life Lost (PYLL) to give a 
greater value to loss to deaths from tuberculosis at younger ages [27]. She 
used the 1946 life expectancy of US males and females by ethnic group in 
that analysis. Subsequently, researchers have used different cut-offs to 
determine PYLL, e.g. 60, 65 or 70 years. The drawback of this method is 
that it gives zero value to deaths occurring at ages above the cut-off. Unless 
a very high cut-off is chosen the implicit message to policy makers is that 
deaths in the elderly are unimportant. In reality, however, the health system 
in Australia provides lifesaving interventions such as influenza vaccination 
even to very old people and thus, implicitly gives a value to time lived in old 
age.  
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Figure 2 Survivorship curve of Australian males, 1996, and normative 
survivorship goal based on Coale and Demeny model life table 
West Level 25. 
 
To overcome this problem, Murray used a life table approach to define 
a normative survivorship goal. At the time of the first global Burden of 
Disease study, the highest life expectancy at birth was enjoyed by Japanese 
women at around 82.5 years and mirrored that of the highest level 26 of the 
West model life tables of Coale and Demeny [28]. Arguing that the 
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differentials in life expectancy between males and females may in part be a 
reflection of a true biological difference and not all due to men’s greater 
propensity to take health risks, the next female West Level 25 model life 
table with life expectancy at birth of 80 years was used to define the male 
normative survivorship goal. A female model life table was chosen as none 
of the male Coale and Demeny model life tables approached a life 
expectancy at birth at only a few years below the 82.5 set for females [17]. 
Figure 2 shows the survivorship curve for Australian males in 1996 with the 
normative survivorship curve based on the Global Burden of Disease study’s 
standard life table and the ‘mortality gap’ defined by area C. 
The advantage of the life table approach is that a death at any age is 
valued, as the life table will continue to give a life expectancy even at 
advanced ages. If the same standard life table is used in health gap 
comparisons between populations it has the desirable property of treating a 
death at a particular age equally regardless of the true life expectancy, thus 
meeting Murray’s objective of treating ‘like as like’ [29]. I have argued 
elsewhere that there is a theoretical flaw in this method at a population level. 
If a population’s mortality decreases, a greater proportion of people survives 
to older ages and their mortality gap will be estimated against a higher 
aggregate of age at death plus the remaining life expectancy at that age. In 
other words, the normative survivorship goal shifts to the right with 
potentially the undesirable property of increasing the health gap [30]. This 
violates the basic rule for a summary measure of population health that if 
mortality is reduced in a population a summary measure should improve. 
The only way to avoid this problem is to revert to using PYLL. If we also 
want to value a death at all ages the cut-off would have to be set at a very 
high age, e.g. 120 years. Such a high cut-off would give much greater 
emphasis to mortality at older ages relative to deaths at younger ages and 
also would give less emphasis to non-fatal health outcomes in comparison to 
mortality. It is inherent to the fact that this is a social value choice rather 
than an observed demographic or epidemiological parameter that there is no 
right or wrong choice. Rather, the decision on what method to use will 
depend on the emphasis one gives to theoretical soundness or the practical 
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consequences of the choice in terms of the resulting relative weight given to 
deaths at varying ages. A further argument is that the longer the current 
method is being used in the global and national Burden of Disease studies 
the more desirable it becomes not to change this fundamental assumption 
underlying the DALY. In practice, the shift in the normative survivorship 
goal with decreasing mortality in a population only has a small impact on 
DALY estimates and may be considered trivial. This illustrates an important 
principle in Burden of Disease research, i.e. concentrating efforts on issues 
that have the greatest bearing on the final estimates [31]. 
Health gaps: severity weights 
A second important social value that has to be made in a health gap 
measure is how to value health loss from non-fatal conditions in comparison 
to health loss due to death. A plethora of methods exists to measure people’s 
health-related quality of life and to elicit valuations for defined health states. 
This lack of consensus reflects how difficult the topic of health state 
valuation is. Currently most Burden of Disease studies use a combination of 
the original Global Burden of Disease disability weights and weights from a 
Dutch study [17, 32]. Both sets of weights are based on valuation panels 
using the person trade-off method 1 to elicit health state valuations [33]. The 
global Burden of Disease disability weights have been criticised (a) for 
having been set by a small group of international health experts; (b) for using 
the person trade-off method rather than the more commonly applied time 
trade-off or standard gamble methods; and c) for ignoring cultural 
differences in health state valuations [34-37]. The Global Burden of Disease 
valuation methods were replicated in 14 different countries representing all 
World Health Organisation regions. The ranking of disability severity for 17 
                                                     
1 The person-trade-off is a technique used in economics and psychometry to ask 
people about their social values of different health care interventions. Individuals are 
asked to state how many outcomes of one kind they consider equivalent in social 
value to X outcomes of another kind [33]. 
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health states was found to be relatively stable and highly correlated with the 
original disability weights [38].  
Recently the World Health Organisation organised the World Health 
Survey in over 50 countries many of which included a health state valuation 
component (http://www3.who.int/whs/). The expectation is that this body of 
work will produce a new set of severity weights for Burden of Disease 
purposes but analyses of these data sets have yet to appear in publication. 
For comparisons of Burden of Disease across countries it is important that 
the same disability weights are used. For the first Australian Burden of 
Disease studies a conscious choice was made to concentrate on the 
epidemiological estimates and not to derive a set of Australian preferences 
for health states. At the time, that was considered the best use of limited 
analytical resources. 
Health gaps: discounting 
The Global Burden of Disease Study opted for an additional two social value 
choices, discounting and age weighting, that are not essential to SMPH such 
as the two previously discussed choices of the normative survivorship goal 
and disability weights. The issue of discounting is linked to the choice to 
base non-fatal health loss on incidence rather than prevalence. By definition, 
prevalence-based summary measures of disability are not discounted. 
Murray argues that an incidence approach for non-fatal health states fits 
better with the mortality component of DALYs which is also calculated as a 
future stream of lost health [39]. A further argument is made that it better 
reflects the potential for health gain and hence is better suited to inform 
policy making around prevention. The counterargument, of course, is that a 
prevalence approach is better suited to plan the health services response to 
current health problems. For diseases with large shifts in occurrence over 
time, such as an emerging epidemic of HIV or the decline in cardiovascular 
disease witnessed over the last few decades, incident Years Lived with 
Disability (YLD) estimates may vary considerably from prevalent YLD.  
For instance, in 1999, in Thailand, incident YLD for HIV/AIDS were 
higher in women than in men while the prevalent YLD were much higher in 
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males [40]. This is because public health campaigns have very successfully 
reduced the rate of infection in young males visiting commercial sex workers 
but have been much less successful in curbing transmission from husband to 
wife. The many young men who became infected in the early stages of the 
epidemic are still alive and contribute to prevalence. They are also a source 
of infection for their wives and hence contribute to incidence in women [41]. 
The incident YLD would be more informative for priority setting of 
prevention while the prevalent estimates are more helpful in determining the 
current need for treatment. As both approaches have utility it is good 
practice to calculate both types of measures. However, in the standard 
reporting of Burden of Disease in DALYs the argument that incident YLD 
are more consistent with the way YLL are calculated should probably 
prevail. 
 Discounting of a stream of lost health is not common in epidemiology. 
In contrast, it is common practice in economic evaluations to discount future 
health outcomes as well as future costs [42, 43]. However, discounting 
future health gains or losses is not without controversy even among health 
economists and discounting is rarely used by epidemiologists and 
demographers for summary health measures [44]. The main argument for 
discounting is that people have time preference, i.e. they prefer to benefit 
(from income or, in this case, health) sooner rather than later. There are 
some specific arguments for applying discounting to the DALY in 
measuring population health [29]: 
• to be consistent with measurement of health outcomes in cost-
effectiveness analyses; 
• to prevent giving excessive weight to deaths at younger ages; and 
• the disease eradication/research paradox: assuming that investment in 
research or disease eradication has a non-zero chance of succeeding, 
then without discounting, all current expenditure should be shifted to 
such investment because the future stream of benefits is infinite.  
Murray and Acharya conclude that the strongest argument for 
discounting is the disease eradication/research paradox [29]. They noted, 
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however, that the choice of a discount rate for health benefits, even if 
technically desirable, might result in morally unacceptable allocations 
between generations. Because the discount rate issue is not easily resolved, 
the GBD published discounted and undiscounted estimates of the global 
burden. 
Health gaps: age weighting 
A second, optional social value choice incorporated in the DALY is that of 
age weighting. The GBD Study weighted a year of healthy life lived at 
young and mid adult ages higher than at other ages. Relative to the value 1 if 
no age weighting were applied, greater weight is given to years of health life 
lost in young and middle-aged adults and lesser weight to loss of health in 
the very young and old (Figure 3). This choice was based on a number of 
studies that have indicated there is a social preference to value a year lived 
by a young adult more highly than a year lived by a young child or at older 
ages [45]. Some critics find age weights unacceptable on equity grounds 
(every year of life is of equal value a priori), others on empirical grounds 
(that the standard age weights do not well reflect actual social values) [35, 
46-48]. Murray and Acharya have argued that age weights are not in 
themselves inequitable, because everyone potentially lives through every 
age, and that they do reflect legitimate societal priorities [29]. Interestingly, 
a small study among residents of a poor satellite town of Harare in 
Zimbabwe found age preferences closely aligned to the age weighting 
function of the GBD [49].  
Because of the controversy about age weighting this social value 
choice was not incorporated in the DALYs calculated in a number of 
national Burden of Disease studies, e.g. in Australia, Thailand and the 
Netherlands [20, 40, 50]. The best argument not to include the GBD age-
weighting factors is that a time-based mortality measure like YLL is an age 
weighting of deaths already and that adding a second age weight makes the 
GBD standard DALY unnecessarily complex [48]. 
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Figure 3 Age weights applied in DALYs. 
 
Burden of Disease estimates for mental disorders  
Burden of Disease measurements for mental disorders is the topic of two 
chapters in this thesis. While most mental disorders are associated with 
increased mortality risk [51], in vital registration systems there is little 
mortality attributed to mental disorders, apart from substance use disorders, 
as the underlying cause. However, mental disorders are common and often 
chronic and hence contribute a large proportion of YLD, the non-fatal 
component of DALYs. In 1990, mental disorders contributed 8% to the 
overall Burden of Disease in the world and 24% of all YLD [17].  
When work commenced on the Burden of Disease studies in Australia 
and the state Victoria, all that was available from the GBD study related to 
its estimates for mental disorders were the disability weights and tables of 
incidence, prevalence, duration, YLD and DALYs. The background papers 
for each of the disorders prepared by expert groups assisting the GBD study 
have not been published to date.  
Two factors facilitated the large effort to improve Burden of Disease 
estimates for mental disorders in Victoria. First, the National Survey of 
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Mental Health and Wellbeing (NSMHWB) had just been released providing 
up-to-date estimates of the occurrence of the main mental disorders in 
Australia [52]. Towards the end of the study, results from two sub-
component studies of the main survey on psychotic disorders and childhood 
mental disorders also became available [53, 54]. Professor Gavin Andrews 
of the University of New South Wales was the driving force behind the main 
component of the survey. He provided invaluable assistance in 
understanding the complex questionnaire and derivation of ICD-10 and 
DSM-IV diagnoses. 
Second, a group of mental health clinicians and epidemiologists 
enthusiastically responded to a request to join an expert panel to guide the 
difficult choices and assumptions that had to be made. In consultation with 
this expert panel, a number of methodological issues were queried in the 
GBD approach to estimating the burden of mental disorders and developed 
into the following research questions addressed in the first two chapters of 
this thesis: 
1. Which mental disorders ought to be included in a comprehensive 
assessment of Burden of Disease? 
The GBD included eight mental disorders (major depression, bipolar 
disorder, schizophrenia, alcohol use, drug use, panic disorder, obsessive-
compulsive disorder and post-traumatic stress disorder) and grouped 
them together with 4 neurological disorders (dementia, epilepsy, multiple 
sclerosis and Parkinson’s disease) in one category of neuropsychiatric 
conditions [17]. Childhood mental disorders, eating disorders, very 
common anxiety disorders such as generalised anxiety disorder and social 
phobia as well as a lack of differentiation in the estimates of illicit drug 
use were identified as missing in the GBD list of conditions. 
2. Does a single disability weight per disorder suffice to describe the 
variation in severity of mental disorders? 
The GBD study used a treated and untreated disability weight for each of 
the mental disorders. If these disability weights are then used in different 
countries, an implicit assumption of a constant severity distribution is 
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made. Given the great variability in the severity of mental disorders it 
was considered desirable to make this more explicit in the calculations. 
This was possible due to the detail of information on the level of severity 
in the NSMHWB and the availability of disability weights from the 
Dutch Burden of Disease study with three or four levels of severity for 
most mental disorders. 
3. How much does a co-morbidity correction affect Burden of Disease 
estimates for mental disorders?  
The GBD 1990 study ignored the common co-morbidity between mental 
disorders found in all epidemiological surveys (e.g. [55-57]). This leads 
to considerable overestimation particularly if more mental disorders are 
included. Co-morbidity between anxiety disorders and depression is so 
common that some have questioned the boundaries between diagnostic 
categories. The fact that similar psychological and drug treatments are 
found to be effective in anxiety and depression adds a further argument to 
the hypothesis that these may actually be different expressions of the 
same disorder [58, 59].  
4. Are the GBD estimates of prevalence, incidence and average duration for 
mental disorders applicable to the Australian context? 
Without the background papers justifying the assumptions underlying the 
GBD estimates for mental disorders we could only scrutinise the actual 
estimates of incidence, prevalence and average duration [16]. The 
durations estimated in the GBD for bipolar disorder (less than 1.5 years), 
anxiety disorders (ranging from 0.75 to 2.5 years) and alcohol use (less 
than two years) did not seem to fit with findings from follow-up studies 
for these disorders [60-62]. The question then arises how sensitive YLD 
results are to different assumptions of remission. An incidence-
prevalence-mortality (IPM) model, DisMod, was developed for the GBD 
to derive missing epidemiological disease parameters and check known 
disease parameters for consistency [63]. DisMod makes use of the 
chronological sequence of disease events: incidence must precede 
prevalence and disease-specific mortality follows prevalence. If three of 
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five disease parameters (incidence, prevalence, duration, remission and 
excess mortality) are defined, DisMod will derive the missing two 
parameters. Unless case fatality for a disease is very high, remission 
largely determines average duration. Burden of Disease estimates for 
mental disorders are all based on prevalence data as incidence is rarely 
measured in studies representative of the whole population. Varying the 
remission assumption in DisMod will give different combinations of 
incidence and average duration: long duration and low incidence if 
remission is low and vice versa. YLD are the product of incidence and 
duration multiplied by a severity weight. Thus, even a great difference in 
the remission assumption causes only small variation in YLD estimates. 
When discounting is applied, the difference is accentuated a bit more as 
the combination of low incidence and long duration will be discounted 
more than that of high incidence and short duration. In other words, YLD 
estimates are not very sensitive to assumptions of remission. However, 
estimates of prevalence and incidence are important outputs from a 
Burden of Disease study in their own right used to determine health 
service needs and as inputs to economic evaluation models. Moreover, 
experts may reject the DALY estimates if they are based on implausible 
estimates of duration.  
Also, the expert panel raised doubts about the prevalence estimates for 
some disorders, e.g. the high prevalence of obsessive-compulsive 
disorder in relation to other anxiety disorders.  
THEME TWO: COST-EFFECTIVENESS ANALYSES 
A number of health economists have been vocal in their criticism of Burden 
of Disease as a tool to inform priority setting [37, 64, 65]. A central point in 
their arguments is that Burden of Disease assessments are a waste of scarce 
intellectual resources as economic evaluation of health interventions rather 
than the size of health problems should inform priority setting in health. This 
is based on a rather selective reading of the literature. From the first 
publication on Burden of Disease onwards emphasis has been given to the 
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essential link between Burden of Disease and cost-effectiveness [15]. The 
strongest argument in support of Burden of Disease as an essential 
component of evidence-based policy is that policy makers, when presented 
with economic information of what the ‘good buys’ are amongst a choice of 
health interventions, will want to know the financial consequences of 
adopting these interventions. That information can only come from 
knowledge about the number of people affected by the health problems 
addressed by each of the interventions. Moreover, the assessment of health 
benefits, a key component of cost-effectiveness analysis, requires a good 
understanding of the epidemiology (e.g. remission, severity and case-
fatality) of the diseases affected by the intervention. Of course, that is the 
‘bread and butter’ of Burden of Disease assessments. Indeed, a 
counterargument to these critics is that economic evaluation without 
knowing the size of a health problem in the population is an inadequate use 
of scarce intellectual resources. 
The literature provides little guidance on how best to conduct 
economic analyses for priority setting across multiple interventions and 
multiple areas of health. Most economic analyses have been undertaken to 
choose between two or a few alternatives addressing the same health 
problem. The broader the scope of a priority setting exercise, the more 
comparability of results becomes an essential prerequisite. The use of 
leagues tables of cost-effectiveness results derived from different studies 
using a variety of methods has rightfully been criticised [43]. However, that 
does not mean that it is impossible to meet the information needs of policy 
makers who want to set priorities across a range of interventions and disease 
areas. For valid comparisons between the interventions included in the 
league table it is paramount that the same methods have been used across all 
analyses. Despite the efforts by a consensus panel of US health economists 
and the seminal textbook on cost-effectiveness by Drummond et al. to guide 
cost-effectiveness studies there remains a great variety in essential 
components of economic evaluation methods, including [66, 67]: 
• the choice of comparator (i.e. current practice or no intervention);  
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• the perspective (i.e. government, health sector or societal 
perspective);  
• the horizon of implementation of the intervention and measurement 
of costs and benefits (ranging from the very short term to lifelong);  
• the use and level of discounting (varying from 0-10%);  
• the target population (implementing the intervention to a cohort of 
eligible recipients or modelling ‘real life’ implementation of the 
intervention over time to a population); and 
• the units of measuring benefits (i.e. natural units such as cases 
averted, QALYs, DALYs or in dollar terms). 
Traditionally, economic analyses have often been conducted in 
conjunction with randomised controlled trials examining the efficacy of 
interventions. These are expensive studies. It would be unaffordable to set up 
a large number of such trials for all information needs of policy makers for 
priority setting. Moreover, trials often exclude potentially eligible recipients 
of an intervention based on gender, race or co-morbidity; are conducted over 
short periods of time; tend to be underpowered to detect adverse effects; and 
often do not collect cost information. Hence, a modelling approach is 
advocated to make most efficient use of the evidence generated by trials and 
to make the most plausible interpolations and extrapolations to fill in 
essential data gaps [68]. For multi-intervention, multi-health problem 
economic evaluations it is inevitable that they are undertaken as modelling 
exercises making use of best available evidence on current practice, 
effectiveness, costs and outcomes from a variety of existing data sources. 
That is a practice closely resembling the principles of Burden of Disease 
studies which also collect, process and evaluate existing data rather than 
collect new information. 
The WHO-CHOICE (CHOosing Interventions that are Cost-Effective) 
project is an example of an economic modelling exercise addressing a large 
number of health problems. WHO-CHOICE uses the same methods of 
analysing the costs and benefits for hundreds of different interventions. In 
contrast to common health economic practice, it advocates generalised cost-
effectiveness (GCEA) rather than marginal analyses [69]. Its aim is to 
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formulate the most appropriate mix of cost-effective interventions to address 
a health problem regardless of current practice. This can only be done after 
back calculating a hypothetical ‘clean sheet’ or a ‘null option’ by estimating 
the burden that would exist if no health care interventions existed for the 
health problem studied. Average cost-effectiveness ratios are then modelled 
for the implementation of separate interventions and combinations thereof to 
determine the ‘ideal’ mix of cost-effective interventions addressing a 
particular health problem given fixed budget constraints.  
The WHO-CHOICE GCEA approach was developed to overcome a 
problem of marginal analysis, i.e. that replacing cost-ineffective current 
practice with a more favourable intervention option can artificially make the 
new intervention look better than it actually is. The advantage of GCEA is 
that it allows reconsideration of current practice and provides an opportunity 
to redress any major inefficiencies. The challenge is to make credible 
assumptions about the null-option and to estimate the combined effect of 
interventions. However, the objective is not to make an accurate estimate of 
the null option but to use it as a starting point to estimate the costs and 
benefits of alternative mixes of interventions. By using the same input 
parameters on effectiveness, adherence and disease in both the back 
calculation to the null option and the forward calculations of the avoidable 
burden, consistency between the two approaches can be achieved. In other 
words, if the current mix of interventions for a health problem is modelled 
from the null option it should produce the current level of burden for that 
health problem.  
Priority setting and cost-effectiveness modelling in Australia  
In Australia, all publications on the Australian Burden of Disease studies 
have reiterated the complementarity of Burden of Disease and cost-
effectiveness information to inform priority setting [4, 5, 22, 70, 71]. This 
was first put in practice in a priority setting exercise conducted in 2000 in 
collaboration with the Cancer Strategies Group of the National Health 
Priority Council in Australia [72]. Key features of this project were: 
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• an economic protocol specifically developed for a priority setting 
context; 
• an evidence-based approach with a small research team bringing 
together the best available information; 
• the choice of the Disability Adjusted Life Year (DALY) as the 
measure of health gain; 
• the use of marginal cost-effectiveness analysis defining interventions 
as opportunities for change from current practice; 
• the recognition that “benefit” is broader than just health gain; and 
• adoption of a two-stage approach to the assessment of benefit 
involving both “technical” aspects (i.e. cost per DALY recovered; 
level of evidence) and “judgment” aspects (i.e. equity; size of the 
problem; acceptability to stakeholders; and feasibility of 
implementation). 
Two subsequent economic modelling projects, ACE-Heart Disease 
and ACE-Mental Health, used and further developed the economic 
evaluation methods trialled in the cancer study. I was the lead investigator on 
both studies. Not having had formal health economic training, continued 
collaboration with Rob Carter was essential. While my original input largely 
concentrated again on the modelling methods of health outcomes, all 
decisions on the costing and overall economic protocol were jointly 
deliberated.  
The ACE-Mental Health study was conceived after a presentation on 
the first Australian Burden of Disease study findings to Department of 
Health and Ageing staff in Canberra in early 2000. After the presentation 
key policy makers showed interest in the ACE-Heart Disease project for 
which I had just received funding from the National Health and Medical 
Research Council. I sketched the challenges ahead in terms of data 
requirements and development of modelling tools to carry out comparable 
economic evaluations even in the area of cardiovascular health for which 
there are good epidemiological data and a well-established evidence base of 
effectiveness. Casually, I mentioned that a similar undertaking addressing 
the efficiency of mental health care would pose a much greater challenge 
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due to the weaker evidence base on effectiveness; and the need for 
considerable developmental work on translating effectiveness of 
interventions into a measurement of health gain. The immediate response 
was an invitation to develop a proposal as the department considered this a 
priority area. Similar discussions with Mental Health Branch staff at the 
Department of Human Services in the state Victoria led to a request for joint 
funding from the federal and state government to establish the ACE-Mental 
Health study. The main study questions were: 
1. Can the diverse measures on the impact of interventions reported in the 
international literature be summarised in a common metric for use in an 
economic evaluation modelling exercise allowing meaningful 
comparisons of the cost-effectiveness of various interventions for the 
main mental disorders affecting Australians? 
The main difference between mental disorders and most other health 
outcomes is that the disease burden is largely non-fatal. It is much easier 
to measure the impact of an intervention on mortality, as death is an 
unambiguous event. Quantifying the impact of an intervention on non-
fatal outcomes is much harder, particularly if the main goal of 
intervention is to reduce severity rather than preventing complete disease 
episodes. Few intervention studies of mental health interventions have 
reported on the impact of overall quality of life. Largely, results are 
reported as changes in disease-specific symptom questionnaires. 
Therefore, the key challenge was to find a comparable way of 
summarising these diverse measures of impact. In systematic reviews, 
mental health epidemiologists tend to use the standardised mean 
difference as the effect size to summarise results that are described as a 
change in continuous symptom scores [73]. However, for many mental 
health interventions there are no up-to-date systematic reviews and no 
consistency in summarising impact across different outcome measures 
reported in individual trials. 
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2. Can the findings from the literature on impact be translated into a 
change in DALYs, the measure of health outcomes chosen for ACE-
Mental Health? 
Despite the methodological developments in quantifying the severity of 
mental disorders described in chapters 2 and 3, the DALY remains a 
coarse instrument with between two and four levels of disability weights 
to describe the heterogeneity in the presentation of the main mental 
disorders. While for Burden of Disease measurements these coarse 
severity gradings match the limited available epidemiological data on 
disease occurrence by severity, the measurement of small to moderate 
changes in severity reported for most mental health interventions 
demands greater accuracy. Thus, new methods had to be developed for 
the ACE-Mental Health study. 
3. Focusing on interventions for depression, are there credible methods of 
comparing the effectiveness of drug and psychological interventions for 
the acute and longer-term management of depression? 
In the Australian Burden of Disease studies, anxiety disorders, 
schizophrenia and bipolar disorder are modelled as chronic or chronic 
episodic disorders. Major depression is treated as an episodic disorder 
despite considerable evidence that in most individuals it is a chronic 
episodic illness. At the time of the Burden of Disease study key 
epidemiological information on the long-term course of illness was 
missing making it difficult to model major depression as the chronic 
disease it is with incidence mostly in childhood and early adulthood and 
frequent recurrence of episodes thereafter. As longer-term maintenance 
treatment strategies aim to prevent recurrence of episodes it was 
necessary to develop methods of modelling depression as a chronic 
disorder specifying the risk of recurrence of disease following an acute 
episode. 
4. Taking into account the uncertainty around key input variable to cost-
effectiveness models can plausible differences in the cost-effectiveness of 
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different treatment approaches for mental disorders in Australia be 
distinguished? and 
5. Can mental health policy makers and experts in Australia be 
meaningfully engaged in a priority setting exercise? 
The ACE-Mental Health study aimed to combine a strong focus on the 
technical analyses of cost-effectiveness with involvement of policy 
makers and opinion leaders in framing recommendations for policy 
change by explicitly placing the results on cost-effectiveness in the 
context of other important policy considerations, the ‘judgment’ factors 
described above for the pilot study on prioritising cancer control 
interventions. Two main challenges were envisaged: (a) the complex 
financing structure of health care in Australia that is shared by state and 
federal governments; and (b) anecdotal evidence of the polarisation 
between mental health opinion leaders in the country who have a strong 
allegiance to research and services for either the severe spectrum mental 
disorders such as schizophrenia or the more common disorders such as 
depression and anxiety. 
 
The four chapters on ACE-Mental Health, mainly address the first four 
of these study questions. The first of these describes the overall economic 
and epidemiological methods. Two further chapters deal with the economic 
evaluation of intervention strategies for major depression. Chapter 7 reports 
on the study’s overall findings and final recommendations. It does not give 
much insight into the process of reaching these conclusions despite the 
competing interests often forcefully voiced by policy makers and experts 
represented in the steering committee. In the final chapter some attention 
will be given to this process although a complete policy analysis of the 
contribution of ACE-Mental Health to the priority setting debate in mental 
health care in Australia is beyond the scope of this thesis. 
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CHAPTER 2 
SUMMARY 
Background – Between 1998 and 1999, a burden of disease assessment was 
carried out in Victoria, Australia applying and improving on the methods of 
the Global Burden of Disease Study. This paper describes the methods and 
results of the calculations of the burden due to 22 mental disorders adding 14 
conditions not included in previous burden of disease estimates.  
Methods – The National Survey of Mental Health and Wellbeing provided 
recent data on the occurrence of the major adult mental disorders in 
Australia. Data from international studies and expert advice further 
contributed to the construction of disease models describing each condition 
in terms of incidence, average duration and level of severity with 
adjustments for co-morbidity with other mental disorders. Disability weights 
for the time spent in different states of mental ill health were borrowed 
mainly from a study in the Netherlands supplemented by weights derived in 
a local extrapolation exercise.  
Results – Mental disorders were the third largest group of conditions 
contributing to the burden of disease in Victoria ranking behind cancers and 
cardiovascular diseases. Depression was the greatest cause of disability in 
both men and women. Eight other mental disorders in men and seven in 
women ranked among the top twenty causes of disability.  
Conclusions – Insufficient information on the natural history of many of the 
mental disorders, the limited information on the validity of mental disorder 
diagnoses in community surveys and considerable differences between ICD–
10 and DSM–IV defined diagnoses were the main concerns about the 
accuracy of the estimates. Similar and often greater concerns were raised 
during the estimation of the burden from common non-fatal physical 
conditions such as asthma, diabetes and osteoarthritis. In comparison, 
psychiatric epidemiology can boast greater scientific rigour in setting 
standards for population surveys. 
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BACKGROUND 
Over the last two decades, Australian Health Ministers have identified 
mental health as a priority area with the potential for significant health gain 
at the population level. Initially the focus was on the development of a set of 
goals and targets for improving health and reducing inequalities [1, 2]. In 
1994, the focus shifted to four major areas for action one of which was 
mental health [3]. In a report on progress in all priority areas in 1996, the 
only indicator identified in the area of mental health was mortality from 
suicide [4]. While mortality and health facility data to a large extent describe 
the disease burden in other priority areas such as injuries, cardiovascular 
disease and cancer, this is not the case in mental health. The disease burden 
of mental disorders is largely due to non-fatal conditions and a large 
proportion of people with a mental disorder never presents to a health 
facility. Thus, routine data collection systems do not contribute much to 
analysis of the disease burden due to mental disorders. The National Survey 
of Mental Health and Wellbeing (SMHWB) of 1997, on the other hand, 
provides a wealth of information on the occurrence of mental disorders in 
Australia [5]. The Australian Burden of Disease Studies relied heavily on 
this source of information for the majority of mental disorders [6-9]. This 
paper describes the methods and results of these analyses.  
METHODS 
Two burden of disease studies were carried out in Australia between 1998 
and 1999: a national study conducted at the Australian Institute of Health 
and Welfare (AIHW) and a separate study for the state of Victoria by the 
Department of Human Services (DHS). The two studies used identical 
methods and shared a considerable proportion of the workload. The 
Victorian team was responsible for the calculation of the mental health 
burden and was guided by a panel of local mental health experts. The results 
presented in this paper are for the State Victoria. Australian estimates of the 
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burden of disease can be found at the AIHW website (www.aihw.gov.au). 
The burden of disease was calculated in disability-adjusted life years 
(DALY), a summary measure of population health developed by Murray and 
Lopez for the Global Burden of Disease (GBD) study [10]. The DALY 
combines information on mortality and non-fatal health outcomes to describe 
population health in a single number. The burden of disease in a population 
in a given year is the sum of the years of life lost due to premature deaths 
(YLL) and an estimate of the future years lost due to disability (YLD) for 
new cases of disease or injury, weighted for severity. The DALY is a health 
gap measure that extends the concept of potential years of life lost (PYLL) 
so as to also include years of ‘healthy’ life lost because a proportion of the 
population lives in states of less than full health [11]. The DALY was 
designed to allow estimates of health impact to be mapped to causes, 
whether in terms of disease and injury, or risk factors and broader social 
determinants, and to use common values and health standards for all regions 
of the world. The Australian burden of disease studies depart from the 
general GBD methodology in a number of key areas: 
1. The inclusion of a wider range of disease and injury categories than the 
GBD and a more detailed age breakdown of the burden of disease. 
2. The use of the 1996 Australian cohort life expectancy (a method that 
takes declining mortality trends into account) rather than the standard life 
table used by the GBD to calculate the years of life lost for a death at 
each age. This results in a life expectancy at birth of 85.7 years in women 
and 81.5 years in men compared to the GBD’s standard life table with a 
life expectancy at birth of 82.5 years in women and 80 years in men. 
3. The application of uniform age-weighting rather than the greater weight 
given in the GBD to loss of health in young and mid adult life to reflect a 
greater social responsibility at those ages to care for the young and old in 
society. We decided not to use age weighting because of its controversial 
nature (see, for instance [12-14]) and because GBD results were reported 
not to be sensitive to the age-weighting assumptions [10].  
4. The use of disability weights developed in the Netherlands [15] in 
addition to those generated for the GBD. The Dutch weights were 
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preferred because of their detail and their focus on health states that are 
common in Australia.  
5. Adjustments for the effects of co-morbidity between highly prevalent 
physical conditions, between mental disorders and between injuries.  
The methods used to estimate the burden of mental disorders in 
Australia have been described in considerable detail in a previous paper 
comparing the Australian and GBD methods [16]. A summary is presented 
here with additional details on the mental disorders examined in the 
Victorian and Australian studies but not the GBD study. 
Mortality 
The Australian Bureau of Statistics provided data on deaths occurring within 
Australia to people, whose usual place of residence was Victoria. We chose 
1996 as the baseline year, as this was the most recent year of mortality data 
at the start of the study. The number of deaths in Australia attributed to 
mental disorders was small with the exception of drug overdose deaths and 
to a lesser extent deaths due to alcohol dependence. We included 85 heroin 
deaths coded under the injury chapter of the International Classification of 
Diseases version nine (ICD–9) as accidental poisoning due to opioids 
because they had a similar age and sex profile to the 81 heroin deaths 
directly coded under the Mental Disorders chapter.  
Disability 
The estimation of the disability associated with mental disorders required 
information on the incidence, average duration and severity for each disease 
and its associated health states. The SMHWB was the main source of 
information to determine the burden in adults for six anxiety disorders, 
depression, most substance use disorders and borderline personality disorder. 
The survey was conducted on a representative sample of 10,641 Australian 
adults with a response rate of 78% [5]. Interviewers used a computerised 
version of the Composite International Diagnostic Interview (CIDI) [17]. 
The unit record data of the survey provided information on the prevalence of 
mental disorders by ICD–10 and the Diagnostic and Statistical Manual of 
 34
CHAPTER 2 
Mental Disorders (DSM–IV) categories [18, 19]. We chose the ICD–10 
diagnoses for consistency with our other disease categories that were largely 
based on ICD–9 categories.  
The ICD–10 criteria for post-traumatic stress disorder (PTSD) are less 
strict than the DSM–IV stipulates [20]. To avoid overestimation we used the 
DSM–IV diagnosis of PTSD, which resulted in a 60% lower prevalence of 
PTSD. Our initial estimates of psychotic disorders were based on prevalence 
data from a US study [21]. These were subsequently confirmed by the 
recently released prevalence figures (4.7 per 1,000 adults) of the Low 
Prevalence Disorders sub-study of the SMHWB [22]. We estimated a 
prevalence of heroin dependence of five per 1,000 persons 15–44 years old 
from the number of heroin users enrolled in methadone programmes 
adjusted by estimates of the proportion of regular heroin users reached by 
these programmes. This estimate was consistent with the finding of a 
national drug household survey after accounting for the likelihood of both 
underreporting of heroin use and users not being included in a household 
sample [23]. The prevalence of eating disorders, depression in childhood and 
childhood disorders such as autism and Attention Deficit and Hyperactivity 
Disorder (ADHD) were derived from international epidemiological studies 
for lack of relevant Australian data [24-30]. We classified dementia under 
the category of neurological and sense disorders and not under mental 
disorders as is the convention in ICD. 
Disease models 
For each of the twenty-two mental disorders included in our analyses, we 
aimed to model the course of the disease in the average incident case. The 
incidence of mental disorders is rarely measured and cross-sectional surveys 
tend to report one-year period prevalence. To derive incidence we made 
extensive use of the DisMod software package developed by Harvard 
University that allows the modelling of internally consistent relationships 
between estimates of incidence, prevalence, duration, remission and 
mortality [31]. The disease models for anxiety disorders and bipolar disorder 
were based on evidence from the literature which describes them as chronic 
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diseases with periods of remission and relapse [32-35]. This differs from the 
approach adopted in the GBD 1990 study in which short durations of 
between 0.75 and 2.5 years for all anxiety disorders, substance use disorders 
and bipolar disorder were assumed. We estimated the average duration for 
anxiety and bipolar disorders in the Australian studies basing our disease 
models on rates of disease remission reported in the literature [32, 33, 36, 
37]. Lacking relevant published information, we estimated the duration of 
substance use disorders, borderline personality disorder and dysthymia from 
DISMOD models that gave the best fit between the observed age pattern of 
prevalence and assumptions of incidence and remission. Disease experts 
were consulted to check the estimates for plausibility. To account for 
asymptomatic periods during the course of the chronic conditions for which 
we derived prevalence estimates from the SMHWB, we adjusted the final 
YLD estimates by the ratio of two-week prevalence and one-year 
prevalence.  
There is evidence to suggest that dysthymia—a long-term condition 
with recurrent periods of low mood— and major depressive disorder are 
different expressions of the same chronic disease entity with periods of 
greater, lesser or no symptoms [38-41]. However, the great diversity in the 
course of illness made it difficult to find a credible, ‘average’, chronic 
disease model for depression. Some people have only one episode in a 
lifetime; some have chronic unremitting disease and the majority 
experiences multiple episodes over a lifetime with no or low-grade 
symptoms in between. We therefore decided to model major depression as 
episodes and dysthymia separately but to present the results under a single 
category of depression.  
We estimated a 4–6 year average duration for borderline personality 
disorder. This may seem short for a personality disorder but there was no 
alternative DISMOD model with credible estimates of incidence and 
remission to match the prevalence observed in the SMHWB. Psychoses were 
modelled as a life long condition that generally starts in young adulthood 
and has an elevated risk of dying based on standardised mortality ratios of 
154 in males and 162 in females in the UK [42]. The estimated average 
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duration for anorexia and bulimia was 8 and 5 years, respectively, based on 
overseas follow-up studies reporting 24% persistence of anorexia after 10–
15 years and 20% persistence of bulimia after 5–10 years [43, 44]. We 
assumed an annual mortality risk of 0.58 per cent in anorexia and no 
elevated mortality in bulimia [45]. An estimate of 50 per cent remission after 
five years of follow-up led to an estimate of the average duration for ADHD 
of almost 7 years [46]. The duration for autism was extrapolated from the 
average life expectancy reported for moderate intellectual disability in 
California [47].  
Severity 
For the main mental disorders we used the Dutch disability weights (DWs). 
The DWs for drug dependence disorders, manic episodes in bipolar disorder 
and borderline personality disorder were extrapolated by panels of local 
experts in a manner similar to the way in which the GBD expert panel 
derived weights for most conditions after having determined weights for 22 
indicator conditions by person trade-off methods. Our weight for psychoses 
is a compound of 30 percent the untreated weight and 70 per cent the treated 
weight from the GBD study based on an average time spent in psychosis 
reported from a number of industrialised countries that took part in the 
International Pilot Study of Schizophrenia [48] (Table 1).  
The Dutch DWs typically describe the mental disorders to which they 
refer by two or three levels of severity. However, it was not so easy to find 
the  epidemiological data by level of severity. When that level of detail was 
available, as for instance was the case with three levels of severity of ICD–
10 diagnoses of depression and panic disorder in the SMHWB, local mental 
health experts doubted its validity. Instead, for conditions derived from the 
SMHWB we found it necessary to develop a new classification of severity 
from six questions on mental well being in the SF–12. This method has been 
described previously in detail [16].  
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Table 1.   Disability weights (DW) for mental disorders used in Australian 
burden of disease studies. 
Disease category Disability weight 
  Mild  Moderate  Severe 
Origin of DWs 
Substance use disorders 
Alcohol harmful use 
Alcohol dependence 
 
0.11 
 0.11    0.33 0.55 
 
Dutch weights 
Heroin dependence 
Marihuana dependence 
Sedative dependence 
Stimulant dependence 
0.27 
0.11 
0.18 
0.11 
Locally 
derived 
weights 
Anxiety disorders 
Panic disorder 
Obsessive-compulsive disorder 
Post-traumatic stress disorder 
Agoraphobia 
Social phobia 
Generalised anxiety disorder 
Separation anxiety disorder 
 
 0.16 0.16 0.69 
 0.17 0.17 0.60 
 0.13 0.13 0.51 
 0.11 0.11 0.55 
 0.17 0.17 0.59 
 0.17 0.17 0.60 
 0.11 0.11 0.55 
 
Dutch weights 
Affective disorders 
Major depressive episodes 
Dysthymia 
 
 0.14 0.35 0.76 
 0.14 0.35 0.76 
 
Dutch weights 
Bipolar disorder 0.18 Combined DW: 0.50 for mania (locally 
derived weight), 0.34 for depressive 
episodes (Dutch weight for moderate 
depression) and 0.14 for time in between 
episodes (Dutch weight for mild 
depression) 
Psychoses 0.43 30% untreated GBD DW (0.63) and 70% 
treated GBD DW (0.43) 
Borderline personality disorder 0.54 Locally 
derived weight 
Eating disorders (anorexia and 
bulaemia) 
0.28 Dutch weight 
Attention-deficit hyperactivity 
disorder 
 0.02 0.15 0.15 Dutch weight 
Autism 0.55 Dutch weight 
 
In comparison to the ICD–10 categories of mild, moderate and severe 
depression, our severity classification resulted in larger differentials for the 
average disability score (and in the expected direction) than measured by 
each of the other disability instruments used in the SMHWB, including the 
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mental component score of SF–12, the General Health Questionnaire, the 
Brief Disability Questionnaire and the Kessler psychological distress scale. 
This suggested that it was better than ICD–10 at discerning different levels 
of severity in depression and lent support to its use in other conditions 
derived from the SMHWB. Because of the large overall size of the mental 
health burden and the broad spectrum of severity experienced in mental 
disorders, we chose to use this unvalidated classification scheme and apply 
the graded Dutch DWs rather than the single GBD weights, which imply an 
undefined and potentially inappropriate distribution of severity. 
Co-morbidity 
Co-morbidity between mental disorders identified in the SMHWB was very 
common. The prevalence of people in Australia with a mental disorder was 
17.8%, 35% of whom qualified for two or more diagnoses. At the level of 
individual diagnoses the proportion of persons with co-morbid conditions 
was even higher. For instance, of all people with a current diagnosis of major 
depression, 61% had at least one other concurrent diagnosis. Co-morbidity 
with anxiety disorders was common, occurring in a third of people with 
depression. Co-morbidity in people with borderline personality disorder was 
even more frequent (94%): depression, anxiety disorder and substance use 
disorder occurred in 62%, 48% and 52%, respectively. There were people 
identified with up to eight different mental disorders. Calculating the 
disability for each co-morbid disorders as if it belonged to a separate person 
could result in attributing an amount of non-fatal burden in one person in 
excess of a disability weight of one or the equivalent of being dead. As this 
is obviously not credible, we decided to split the number of prevalent cases 
of anxiety disorders, affective disorders, borderline personality disorder and 
substance dependence categories equally between concurrent diagnoses. By 
capturing the level of severity separately, as described above, we allowed for 
the fact that people with multiple diagnoses were likely to experience more 
severe disease than those with a single diagnosis only. An increase in the 
number of co-morbid diagnoses was associated with a higher proportion of 
people reporting moderate and severe disability (Table 2). 
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Table 2.   Reported level of severity from SF-12 questions on mental well-
being by number of concurrent mental diagnoses, National 
Survey of Mental Health and Wellbeing 1997. 
No. of diagnoses Reported level of severity (%) 
 none mild moderate severe Total 
0 71 22 6 0 100 
1 46 29 21 3 100 
2 27 29 36 8 100 
3 or more 14 24 46 16 100 
Depression as a risk factor 
The contribution of certain diseases to the total burden of disease is not well 
captured by the mutually exclusive disease categories used in this study. 
This is because in addition to the direct sequelae from these conditions, there 
is also an increased risk for other diseases or injuries. This ‘excess’ 
attributable burden can be estimated using similar methods to those used for 
estimating the burden attributable to risk factors. We made a separate more 
inclusive calculation of the burden attributable to depression including all 
depression without adjustment for co-morbidity and part of the burden of 
suicide, self-inflicted harm and ischaemic heart disease. Estimation of the 
fraction of the burden from these conditions that is attributable to depression 
is based on the two-week prevalence of depression observed in the SMHWB 
and relative risks of 30 for suicide [49] and 2.3 for ischaemic heart disease 
[50]. 
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RESULTS 
Mental illness was responsible for about one-seventh of the total disease 
burden in Victoria in 1996, or 40,776 DALYs in men and 41,451 in women 
(Figure 1).  
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Figure 1.  The burden of disease by disorder and sex, Victoria 1996. 
 
Only 6% of this burden was due to mortality, most of which can be 
accounted for by fatal outcomes associated with substance use disorders. The 
picture is dominated by substance use, affective and anxiety disorders, which 
together constitute four-fifths of the overall burden attributable to mental 
illness (Figure 2). There were marked sex differentials in the distribution of 
the mental illness burden due to particular causes. The contribution from 
affective disorders was 50% higher in women than in men, while the anxiety 
burden was three-fifths higher. Conversely, the male burden from substance 
abuse was two and a third times higher compared with women. Eating 
disorders occurred mainly in women, with men having only 5% of the 
female burden attributable to these disorders. Childhood conditions (such as 
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autism and ADHD) were predominantly found in boys who had a three times 
higher burden from these conditions than girls. 
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Figure 2.   The burden of mental illness (YLL, YLD and DALYs) by 
disorder and sex, Victoria 1996 
 
In men, depression was the eighth leading cause of overall burden, 
while alcohol and drug use disorders were the 13th and 15th, respectively. In 
women, depression was the fifth leading cause of overall burden, while 
generalised anxiety disorder and alcohol use disorder were 12th and 17th, 
respectively (Table 3).  
A more inclusive calculation of depression as a risk factor for suicide 
and ischaemic heart disease and without adjustment for co-morbidity with 
other mental disorders increased the share of depression as a proportion of 
total disease burden making it the third largest condition in males and the top 
condition in females.  
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Table 3. Top twenty causes of burden of disease in DALYs by sex, Victoria 
1996 
Males % of 
total 
Females % of 
total 
1 Ischaemic heart disease 13.1% 1 Ischaemic heart disease 10.7% 
2 Stroke 4.8% 2 Stroke 6.1% 
3 Lung cancer 4.7% 3 Breast cancer 5.4% 
4 COPD1 4.4% 4 Dementia 4.9% 
5 Diabetes mellitus 3.3% 5 Depression2 4.7% 
6 Bowel cancer 2.9% 6 Osteoarthritis 3.3% 
7 Depression2 2.9% 7 COPD 3.3% 
8 Prostate cancer 2.7% 8 Diabetes mellitus 3.2% 
9 Suicide 2.7% 9 Asthma 2.9% 
10 Road traffic accidents 2.7% 10 Bowel cancer 2.8% 
11 Dementia 2.6% 11 Lung cancer 2.7% 
12 Hearing loss 2.6% 12 Generalised anxiety disorder 1.7% 
13 Alcohol abuse/dependence 2.3% 13 Other vision disorders3 1.5% 
14 Asthma 2.3% 14 Hearing loss 1.3% 
15 Drug abuse/dependence 2.1% 15 Ovary cancer 1.2% 
16 Osteoarthritis 1.8% 16 Parkinson's 1.2% 
17 Benign prostatic hypertrophy 1.1% 17 Alcohol abuse/dependence 1.1% 
18 Inflammatory heart disease 1.0% 18 Road traffic accidents 1.1% 
19 HIV/AIDS 1.0% 19 Peripheral vascular disease 1.0% 
20 Lymphoma 0.9% 20 Lymphoma 1.0% 
1 Chronic obstructive pulmonary disease 
2 Ignoring co-morbidity and adding an attributable fraction for suicide and ischaemic 
heart disease increases the share of the burden for depression in males to 5.0% (rank 3) 
and 11.2% in females (rank 1) 
3 Excludes cataract, glaucoma and diabetic retinopathy and mainly concerns macula 
degeneration 
 
Mental disorders accounted for the largest proportion of non-fatal 
burden of any group of diseases or injuries, representing 25.5% of disability 
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in males and 27.5% in females. Depression, alcohol dependence, generalised 
anxiety disorder, psychotic disorders, bipolar disorder and social phobia 
ranked among the top 20 causes of disability in males and females. Also 
ranked in the top 20 were borderline personality disorder and attention-
deficit hyperactivity disorder in males and eating disorders in females (Table 
4). 
 
Table 4.  Top twenty causes of disability in YLD by sex, Victoria 1996 
Males % of 
total 
Females % of 
total 
1 Depression 6.5% 1 Depression 10.7% 
2 Hearing loss 5.8% 2 Dementia 6.1% 
3 Alcohol abuse/dependence 4.9% 3 Osteoarthritis 5.4% 
4 Dementia 4.5% 4 Asthma 4.9% 
5 Asthma 4.5% 5 Diabetes mellitus 4.7% 
6 COPD 4.3% 6 Generalised anxiety disorder 3.3% 
7 Diabetes mellitus 4.0% 7 Breast cancer 3.3% 
8 Osteoarthritis 3.9% 8 Other vision disorders 3.2% 
9 Ischaemic heart disease 3.7% 9 Stroke 2.9% 
10 Stroke 3.5% 10 COPD 2.8% 
11 Benign prostatic hypertrophy 2.4% 11 Hearing loss 2.7% 
12 Prostate cancer 2.2% 12 Ischaemic heart disease 1.7% 
13 Generalised anxiety disorder 2.0% 13 Alcohol abuse/dependence 1.5% 
14 Borderline personality disorder 1.6% 14 Parkinson's 1.3% 
15 Attention-deficit disorder 1.3% 15 Eating disorders 1.2% 
16 Bipolar disorder 1.5% 16 Social phobia 1.2% 
17 Psychoses 1.5% 17 Infertility 1.1% 
18 Parkinson's 1.5% 18 Bipolar disorder 1.1% 
19 Social phobia 1.4% 19 Psychoses 1.0% 
20 Bowel cancer 1.0% 20 Rheumatoid arthritis 1.0% 
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The usual way of calculating DALYs for non-fatal outcomes is to 
multiply incident cases of disease with the average duration of disease and 
the severity weight. Thus calculated, the per capita incident non-fatal burden 
attributable to mental illness was far greater in early adulthood than at any 
other age (Figure 3). This is largely due to the peak in new cases of chronic 
mental illnesses at this life stage, the disability of which is experienced for 
many years into the future.  
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Figure 3.   Incident YLD rates per 1,000 population by mental disorder, age 
and sex, Victoria 1996 
 
Using an incidence approach, this disability is attributed back to age at 
onset. Boys experienced incident non-fatal burden from childhood disorders 
at twice the rate of girls. Sex differences in the age distribution of incident 
burden rates, however, were the most pronounced for depression, which we 
modelled as an episodic condition. In men, this burden steadily rises to half 
the male mental illness burden at middle age, after which it diminishes 
quickly. In women, the burden from depression increases rapidly to the 
highest rate for any mental illness at any age by early adulthood, after which 
it declines slightly to three-quarters the female mental illness burden at 
retirement age. 
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Figure 4.  Prevalent YLD rates per 1,000 population by mental disorder, age 
and sex, Victoria 1996 
 
Another way of presenting the burden of disease is by calculating 
DALYs for prevalent cases of disease during the one-year duration of the 
year of study again weighted for severity. This per capita prevalent non-fatal 
burden attributable to mental illness provides a substantially different picture 
to an incidence approach (Figure 4). The large burden from high incidence 
mental disorders of early adulthood illustrated in Figure 3 is reduced by 
more than a third and appears instead throughout older ages until death, this 
being the period during which chronic conditions (i.e. anxiety disorders and 
psychoses) remain prevalent. Only a proportion of substance use disorders in 
early adulthood leads to chronic mental illness, which explains the larger 
reduction in prevalent burden after this life stage for substance abuse than 
for anxiety disorders and psychoses. The difference in the picture for 
depression between an incidence and prevalence approach is not nearly as 
apparent because we modelled this condition as an episodic disorder. A 
useful way of interpreting the prevalent burden is as a measure of the 
proportion of the population experiencing disability at a particular point in 
time. Viewed in these terms, four-fifths of the burden from mental illness 
was experienced at ages between 15 and 64 in both men and women. 
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DISCUSSION 
This paper presents results from the first attempt at a comprehensive 
assessment of the burden of mental disorders in Australia. The loss of health 
due to 22 mental disorders was quantified in DALYs. The DALY is a 
summary measure of population health that allows the quantification of 
mortality and morbidity in one measure and thus allows comparisons 
between diseases of a very different nature. Mental disorders rank third in 
size of burden behind cardiovascular disease and cancer. We have reported 
elsewhere that mental disorders would have ranked first with an increase in 
its share of the total burden from 13.3% to 20.7% if age-weighting were 
applied [16]. In other low-mortality countries with most of the burden of 
physical disorders occurring at old age and a high prevalence of mental 
disorders in young and mid adult ages, burden of disease results will be 
similarly sensitive to the GBD age weighting function. This is an undesirable 
outcome for a social value in a summary measure of population health that 
does not enjoy universal support. 
Because mental disorders largely run a non-fatal course and are often 
not presented or recognised as such during contacts with health services [5], 
routine data collection systems are unable to capture the information that is 
needed to quantify the burden of mental disorders. It was fortunate that data 
from the SMHWB became available during the course of the national and 
Victorian burden of disease studies. Mental health epidemiologists have 
made considerable progress in setting standards on how to obtain and 
classify mental disorders in population surveys [51]. The CIDI performs well 
in terms of inter-rater and test-retest reliability [52]. The validity of mental 
diagnoses derived from population surveys is less well established. Most 
validity studies have examined a few selected aspects of validity and have 
been conducted on small selected clinical samples [53]. Validity studies are 
difficult because of the lack of a well-defined gold standard of psychiatric 
diagnoses and the existence of two major psychiatric classification systems. 
Discordance between ICD–10 and DSM–IV diagnostic categories in a study 
from New South Wales was 32% for all mental disorders examined [54]. 
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Analysing the SMHWB in a similar fashion shows an even greater lack of 
agreement between ICD–10 and DSM–IV diagnoses (42%). However, when 
using survey data in a burden of disease analysis it is more important to 
compare the prevalence estimates and the subsequent DALY estimates of 
mental disorders between the two classification systems. In the SMHWB, 
the prevalence of ICD–10 defined mental disorders was 14% higher than that 
of DSM–IV diagnoses. The biggest outliers were PTSD (59% more common 
in ICD–10), dysthymia (55% more common in ICD–10), OCD (51% less 
common in ICD–10), social phobia (49% more common in ICD–10) and 
agoraphobia (42% more common in ICD–10). The calculations in the 
Australian burden of disease studies were based on ICD–10 diagnoses with 
the exception of PTSD for which we opted for the DSM–IV diagnosis 
following expert advice.  
For this paper, we recalculated the DALYs for 14 mental disorders 
that were derived from the SMHWB using the DSM–IV diagnoses but 
otherwise the same methods. In comparison, the sum of DALYs for the 14 
DSM–IV defined mental disorders is 7% greater. Under DSM–IV, a greater 
burden of major depression is partially compensated by a much smaller 
estimate for dysthymia. Large differences in size between individual anxiety 
disorders cancel each other out when added together. DSM–IV also gives 
higher estimates for alcohol dependence, harmful use of alcohol and 
cannabis dependence and lower estimates of sedative dependence (Table 5). 
On balance the differences between ICD–10 and DSM–IV diagnoses are not 
great although the large differences in estimates for social phobia, 
agoraphobia and OCD challenge the accuracy of estimates for individual 
anxiety disorders. Concern about the validity of survey results is not 
restricted to mental health. In the course of collecting information for the 
burden of disease studies we were concerned about the validity of self-
reported health status measures from population surveys for common 
physical conditions such as diabetes, asthma and osteoarthritis. In 
comparison, psychiatric epidemiology can boast a much greater scientific 
rigour in setting standards for interview-based population surveys. 
Our estimates for bipolar disorder, childhood mental disorders and 
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eating disorders relied on overseas data and should be considered provisional 
until local data become available. This was also the case for psychotic 
disorders although an Australian estimate of prevalence obtained prior to 
finalising our results confirmed our initial estimate. 
 
Table 5.   The prevalence and burden in Years Lived with Disability (YLD) 
for 14 mental disorders estimated from the National Survey of 
Mental Health and Wellbeing, calculated by ICD–10 and DSM–
IV diagnostic categories. 
 Prevalence YLD 
Mental disorder ICD-10 DSM-IV ICD-10 DSM-IV Difference1  
Depression   23,330 26,145 -12% 
Major depression 5.2% 6.3% 17,288 23,261 -35% 
Dysthymia 1.1% 0.5% 6,042 2,884 52% 
Anxiety disorders   17,984 17,098 5% 
Panic disorder 1.1% 1.0% 1,497 1,441 4% 
Agoraphobia 0.9% 0.5% 1,149 756 34% 
Social phobia 2.7% 1.4% 4,548 3,175 30% 
Generalised anxiety disorder 3.1% 2.6% 7,990 7,806 2% 
Obsessive-compulsive disorder 0.4% 0.7% 1,191 2,312 -94% 
Post-traumatic stress disorder 3.3% 1.3% 1,609 1,609 -26% 
Substance use disorders   12,073 14,236 -18% 
Harmful alcohol use 3.0% 1.9% 1,243 1,807 -45% 
Alcohol dependence 3.5% 4.1% 8,912 9,375 -5% 
Sedative dependence 0.4% 0.4% 744 419 44% 
Cannabis dependence 1.6% 1.5% 1,097 1,332 -21% 
Stimulant dependence 0.2% 0.2% 78 73 6% 
Borderline personality disorder 0.4%  3,653 3,596 2% 
Total for 14 mental disorders   57,040 61,075 -7% 
1  Difference expressed as % of ICD-10 YLD  
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Co-morbidity between mental disorders is very common. For an 
estimate of the burden of disease in a population, estimating each disorder 
independently would lead to considerable overestimation. We were able to 
adjust for co-morbidity between the disorders derived from the SMHWB. 
This was the first time that adjustment for co-morbidity has been attempted 
in a burden of disease study. As we included a greater number of mental 
disorders than previously had been included in the GBD, it became more 
difficult to ignore the issue. With the results in table 2 we show that people 
with more than one mental disorder had more severe disease. Because their 
greater severity is translated into higher disability weights, people with co-
morbid mental disorders contribute more per individual to the burden of 
disease than people with a single mental disorder, even though we apportion 
them equally between conditions. We were unable to adjust for co-morbidity 
arising from mental disorders that were not derived from the SMHWB, such 
as the co-morbidity between psychoses and depression or between eating 
disorders and depression. This could have led to some degree of 
overestimation of the mental burden. We decided not to adjust for co-
morbidity between physical and mental disorders even though the SMHWB 
collected self-reported data on physical conditions because of the concerns 
we had in general about the accuracy of self-reported health status and the 
difficulty of attributing self-reported disability categories (such as ‘heart 
trouble’, ‘kidney disease’ and ‘liver trouble’) to specific causes. For the 
majority of mental disorders, the age at which they are most prevalent is 
between young and mid-adulthood when physical disorders are less 
common. Therefore, ignoring co-morbidity between mental and physical 
disorders may not lead to much overestimation of the burden of disease. 
Declining prevalence of depressive and anxiety disorders with 
increasing age is a consistent finding of population surveys of mental health. 
Four types of error in case ascertainment of depression have been suggested 
as potential explanations:  
1. Exclusion of the institutionalised and homeless, 
2. Failure of the elderly to respond adequately to the complexity of the 
interview schedule, 
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3. Failure to detect depression in the presence of chronic physical illness, 
and 
4. A lesser likelihood of elderly persons acknowledging symptoms of 
depression [54-56].  
The balance of arguments, however, leans towards accepting the 
validity of lower prevalence of depression and anxiety in the elderly. 
“Psychological immunisation”, that is increasing resistance to depression 
after prolonged exposure to adversity over a lifetime, has been suggested as 
an explanation for this phenomenon [57, 58].  
Depression in old age is commonly associated with chronic physical 
conditions such as Parkinson’s, dementia and stroke [59]. The Dutch 
disability weight study used descriptions, which included some or 
considerable depression and/or anxiety at all severity levels for these three 
diseases [15]. Thus our DALY calculations for these diseases include a 
component of depression. Not all of these depressive symptoms would 
qualify as major depression or dysthymia, the two categories of depression 
estimated in this study. In fact, it is reported that survey instruments and 
diagnostic classification systems erroneously downplay the importance of 
depression associated with physical illness [59]. 
For the Australian burden of disease studies we made a conscious 
choice to concentrate on the epidemiological inputs and not to derive 
separate DWs for Australia. Instead, we adopted DWs developed in the 
Netherlands that covered the main sources of disability in Australia. Dutch 
DWs were available for varying levels of severity for the major mental 
disorders. This had the advantage over the single DWs used in the GBD 
study that it allowed the specification of a local distribution of severity. 
However, there were no readily available data on the distribution by severity 
of mental disorders in Australia to match the description of the health states 
valued in the Dutch study. For conditions derived from SMHWB we devised 
a classification of severity based on answers to six questions on mental 
health status of the SF–12. Our assumption that the same classification 
system was valid when applied to the other conditions measured in the 
SMHWB, however, is an example of the need to improvise when 
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undertaking a burden of disease study. More accurate information about the 
natural history of mental disorders including duration and patterns of 
severity would require longitudinal studies of people identified with a mental 
disorder in community samples. The fact that such a study was not planned 
to follow-up a sample SMHWB respondents with a mental disorder 
represents a lost opportunity. Follow-up studies of clinical samples can only 
provide partial information as they report on those patients who are in 
contact with health services and therefore probably have more severe 
disease.  
CONCLUSIONS 
While there is room for improvement in our estimates of the burden due to 
mental disorders in Australia, the results published here represent a major 
step forward in our understanding of the importance of mental disorders as a 
population health problem. As a health gap measure, DALYs describe the 
unfinished health agenda, that is the amount of ill health in a population that 
currently is not addressed by health service efforts. As such, it suggests 
where opportunities for further health gain may exist. Complementary 
analyses of the cost-effectiveness of interventions are required to identify the 
mix of mental health interventions that gives greatest value for money. The 
Department of Human Services in Victoria is planning to conduct cost-
effectiveness analyses in mental health using the DALY as the measure of 
health outcome. The disease models developed for the burden of disease 
study will be a starting point to assess the scope for change and the resources 
required to reduce the size of the burden due to mental disorders. 
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ABSTRACT  
The national and Victorian burden of disease studies in Australia set out to 
critically examine the methods used in the Global Burden of Disease study 
to estimate the burden of mental disorders. The main differences include the 
use of a different set of disability weights allowing estimates in greater detail 
by level of severity, adjustments for co-morbidity between mental disorders, 
a greater number of mental disorders measured and modelling of substance 
use disorders, anxiety disorders and bipolar disorder as chronic conditions. 
Uniform age-weighting in the Australian studies produces considerably 
lower estimates of the burden due to mental disorders in comparison to age-
weighted disability-adjusted life years. A lack of follow-up data of people 
identified in cross-sectional surveys with a mental disorder poses the greatest 
challenge in determining the burden of mental disorders more accurately. 
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BACKGROUND 
The prominent position of mental disorders, particularly depression as a 
cause of disease burden is a widely quoted result of the Global Burden of 
Disease (GBD) study [1-5]. However, there has been little discussion of the 
methods used to estimate the mental health burden at either the global or 
national level. The general debate about the use of the disability-adjusted life 
year (DALY) as a summary measure of population health has largely 
concentrated on the underlying assumptions of age-weighting and 
discounting and the relevance of burden of disease measurements to policy-
making [6-11]. 
One report has challenged the severity weights for mental disorders 
used in the GBD study. Findings from a small community sample in New 
South Wales, Australia, led to a cautious conclusion that the GBD study may 
have overestimated the disability weights for depression and substance 
disorders, while underestimating the level of disability associated with 
anxiety disorders [12]. However, the epidemiological assumptions that fed 
into the GBD study’s calculation of the burden of mental disorders have not 
been scrutinised in the peer-reviewed literature. Only three of the intended 
ten volumes in the Global Burden of Disease and Injury Series have been 
published to date [13-15]; and a description of methods used in calculating 
the burden of mental disorders has not yet appeared. The only 
epidemiological information is in vol. 2 of the series, detailing for each 
disease and world region the age-specific and sex-specific values of 
incidence, prevalence, average duration and mortality. 
As part of the two recent burden of disease studies in Australia, an 
effort was made to examine critically the GBD estimates for mental 
disorders, to improve the methods and to apply them to the most appropriate 
information on the epidemiology of mental disorders in the country. The 
results of the national Australian study conducted by the Australian Institute 
of Health and Welfare and of an analysis of the burden of disease in Victoria 
carried out by the state’s Department of Human Services are available as 
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printed reports and on the Internet [16-19]. The two project teams worked 
closely together and shared methods and analyses. 
The methods used to estimate the burden of mental disorders in 
Australia are discussed below, and departures from those of the GBD study 
are identified and justified. The consequences are described and discussed of 
the methodological changes on the estimates for the state of Victoria and the 
results are compared with those of the GBD estimates for the Established 
Market Economy (EME) region. Although burden was estimated for 
dementia and other neurological conditions in the Australian studies, these 
conditions were included, together with Alzheimer's disease, in a separate 
category for nervous system disorders and they are not discussed here.  
METHODS 
The disability-adjusted life year 
Summary measures of population health combine information on mortality 
and non-fatal health outcomes to describe population health in a single 
number. The DALY was designed to provide a common measure for fatal 
and non-fatal health outcomes, to allow estimates of health impact to be 
mapped to causes, and to enable common values and health standards to be 
applied to all regions of the world [14]. 
DALYs for a disease are the sum of the years of life lost because of 
premature mortality in the population and the years lost because of disability 
for incident cases of the health condition in question. The DALY is a health 
gap measure that extends the concept of potential years of life lost because 
of premature death to include equivalent years of healthy life lost in states of 
less than full health, broadly termed disability [20].  
The Australian burden of disease studies depart from the general 
methodology used in the GBD study in the following key areas: 
• The GBD study used a standard life table (West level 26) with a life 
expectancy at birth of 82.5 years for women and 80 years for men, 
whereas the Australian studies use the Australian cohort life 
expectancy (taking declining mortality trends into account) for 1996. 
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This resulted in a life expectancy at birth of 85.7 years for women and 
81.5 years for men.  
• In the GBD study, DALYs were discounted at 3% and age-weighted. 
In the Australian studies, DALYs were discounted but were not age-
weighted. Age-weighting is intended to capture a greater social 
responsibility in young and mid adult life for the very young and old. 
Age-weighting was not used in the Australian studies because it is 
perceived as inequitable by some people and becasue the GBD 
sensitivity analyses showed that it did not essentially change the 
overall estimates of burden [14].  
• In addition to DWs developed for the GBD stduy, the Australian 
studies used those developed by Dutch researchers [21, 22] for many 
conditions because of their greater detail and their focus on the most 
common disabilities found in countries of low-mortality.  
• The GBD did not account for the occurrence of co-morbid health 
states whereas the Australian studies make adjustments for the effects 
of co-morbidity between highly prevalent physical conditions, 
between mental disorders and between injuries 
• The Australian studies included a wider range of disease and injury 
categories than the GBD study and provided a more detailed age 
breakdown of the burden of disease. 
Data sources 
Apart from deaths associated with drug overdoses and, to a lesser extent, 
deaths due to alcohol dependence, the number of deaths in Australia 
attributed to mental disorders is small. We included as heroin deaths a 
substantial number of deaths coded under accidental poisoning due to 
opioids in the International Classification of Diseases, ninth revision (ICD–
9).  
The estimation of the disability associated with mental disorders 
requires information on the incidence, average duration and severity for each 
disease and its sequelae. The incidence of mental disorders is rarely 
measured; surveys tend to report one-year prevalence (the number of people 
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who experienced relevant symptoms at any time during the past 12 months). 
To derive the incidence we made extensive use of the DisMod software 
package developed by Harvard University to examine the consistency 
between estimates of incidence, prevalence, duration and mortality [23].  
 
Table 1.   Data sources used in Australian burden of disease studies to 
estimate the incidence and/or prevalence of mental 
disorders. 
Data source Mental disorder 
National Mental Health and 
Wellbeing Survey, 1997 [24] 
Anxiety disorders (panic disorder, agoraphobia, 
social phobia, generalised anxiety disorder, 
obsessive-compulsive disorder) 
Depression (major depressive episode and 
dysthymia) 
Schizophrenia [28] 
Most substance abuse (alcohol, cannabis, sedative 
and stimulant drug dependence or harmful use)  
Borderline personality disorder 
National Drug Strategy 
Household Survey 1998 [29] 
Heroin and residual ‘other drugs’ category  
Reviews of international 
epidemiological studies 
Schizophrenia [30] 
Bipolar disorder [27] 
Eating disorders (anorexia and bulimia) [31, 32] 
Childhood disorders (attention-deficit 
hyperactivity disorder, autism and Asperger’s 
syndrome) [33-35] 
Depression and separation anxiety disorder in 
childhood [36, 37] 
 
The data sources are summarised in Table 1. The main source of 
prevalence data for adults was the National Mental Health and Wellbeing 
Survey (MHS) of 1997 [24], in which information was collected on 
symptoms experienced in the last 12 months, 1 month and 2 weeks for a 
representative sample of 10,560 adults. A computerised version of the 
Composite International Diagnostic Interview was used in this work. 
Interviews were completed for 78% of the individuals approached. The unit 
record data of the survey contained information on the prevalence of mental 
disorders by ICD-10 and DSM-IV (Diagnostic and Statistical Manual of 
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Mental Disorders) categories as well as a number of measures of disability, 
namely the abbreviated Short Form (SF-12), the General Health 
Questionnaire (GHQ), the Brief Disability Questionnaire (BDQ) and the 
Kessler psychological distress scale. We used the ICD-10 diagnoses for 
consistency with our other disease categories which were largely based on 
ICD-9 categories. The only exception was post-traumatic stress disorder 
(PTSD) for which we used the DSM-IV diagnosis, because the ICD-10 
criteria were too broad and would have resulted in overestimation due to 
misclassification of other anxiety disorders [25]. One of the modules of the 
Composite International Diagnostic Interview on mania was omitted from 
the survey, and this meant that estimates of bipolar disorder were inaccurate. 
Instead, we relied on estimates from international epidemiological studies 
[26]. 
Initially, we built our estimates of schizophrenia on overseas data as 
well [27]. The results of the Low-Prevalence Disorders sub-study of the 
MHS showed a prevalence of psychotic disorders, which was similar to our 
initial estimates [28]. The exclusion of institutionalised patients from the 
MHS sample is only important for these low-prevalence conditions, for 
which we relied on other data sources. 
We based our estimates of heroin dependence and harmful use (5 per 
1,000 15–44 year olds) on the numbers of heroin users enrolled in 
methadone programs together with expert estimates of the proportion of 
dependent users reached by these programmes. We checked the resulting 
estimates for consistency with prevalence data from the National Drug 
Strategy Household Survey 1998, making allowance for underreporting and 
for heroin users who would not be captured in a household sample [29].  
Severity 
The Dutch disability weights study [21, 22] provided weights for three levels 
of severity for most of the mental disorders. Because of the large size of the 
mental health burden we felt it desirable to use Australian information on 
severity distributions together with these weights to obtain more accurate 
estimates of burden. In using a single overall DW for the spectrum of 
 64
CHAPTER 3 
 
severity of a disease, as in the GBD study, a severity distribution is assumed 
and judgement of that implicit distribution becomes part of the DW 
estimation task.  
The use of the Dutch weights required matching of Australian 
epidemiological data to the severity levels defined in the Dutch study. Where 
level of severity was available, as with the three levels of severity of ICD-10 
diagnoses of depression and panic disorder in the National Mental Health 
and Wellbeing Survey (MHS), local mental health experts doubted whether 
the diagnostic categories were representative of the actual level of severity of 
disability.  
We used information from the SF-12 for each respondent in order to 
classify the conditions in the MHS in the mild, moderate and severe 
categories defined in the Dutch DW study, which DWs using EuroQol 5D+ 
(EQ5D+) descriptions for each of the health states valued. The EQ5D+ is an 
extended version of the EuroQol health measurement instrument with an 
additional domain of cognitive functioning. The EQ5D+ descriptions of the 
six anxiety disorders in adults distinguish mild/moderate from severe mostly 
in the third domain of usual activities and the fifth domain of 
anxiety/depression with a score of 2 for mild/moderate and 3 for severe. 
Similarly, harmful alcohol use (score of 2) differs from alcohol dependence 
(score of 3) in the usual activities domain. The difference between mild, 
moderate and severe depression involves further domains but it has the same 
split between mild/moderate and severe on the usual activities and 
anxiety/depression domains. 
We thus mapped responses to three questions (B6, B7 and B12 
relating to usual activities) in the SF-12 to the three levels of the EuroQol 
usual activities domain. Similarly, we mapped responses to three other 
questions (B9, B10 an B11 relating to anxiety, depression and energy level) 
in the SF-12 to the three levels of the EuroQol anxiety/depression domain. 
This enabled us to categorise MHS respondents in accordance with the 
EuroQol levels for usual activities and anxiety/depression and hence with the 
severity categories for the DWs.  
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In order to validate this method of determining severity, we examined how it 
compared with the way ICD-10 classifies depression into mild, moderate and 
severe levels. This involved comparing the scores of all other instruments 
used in the MHS each of which, in its limited way, describe severity of 
disability, as follows: the mental and physical component score of SF-12 
(MCS and PCS, with the latter not expected to be much affected by mental 
disorders); the overall score and Likert scores of the GHQ; reported days out 
of role from the BDQ; the main BDQ score; the Mental Outcome Study 
score of BDQ; the WHO score of BDQ; and the Kessler psychological 
distress scale. As these instruments refer to the preceding four weeks, we 
based our comparisons of scores on those reporting symptoms of depression 
in this period only. As shown in Table 2, the classification system based on 
SF-12 resulted in larger differentials for the average disability score (in the 
expected direction) as measured by each of the other disability instruments. 
This suggested that our classification system was better at discerning 
different levels of severity in depression and supports our use of this 
classification system across the conditions for which we derived estimates 
from the MHS. 
Co-morbidity 
We derived prevalence estimates from the MHS for six anxiety disorders, six 
substance use disorders, borderline personality disorder, major depressive 
episodes and dysthymia. Co-morbidity between these mental disorders was 
very common; the prevalence in Australia of people with one of them being 
17.8%, 35% of whom had two or more diagnoses. At the level of individual 
diagnoses, the proportion of persons with co-morbid conditions was even 
higher. For example, of the people with a current diagnosis of major 
depression, 61% had at least one other concurrent diagnosis. Co-morbidity 
with anxiety disorders was common, occurring in a third of people with 
depression. Co-morbidity with borderline personality disorder was even 
more frequent (94%). Depression, anxiety disorder and substance use 
disorder, occur in 62%, 48% and 52%, respectively, of people with 
borderline personality disorder.  
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Table 2. Comparison of ICD-10 and SF-12 based classification of 
severity of depression with scores from multiple 
instruments. 
 ICD-10 classification SF-12 based classification 
Instrument mild moderate severe mild moderate severe 
SF-12 MCS 46.0 34.1 29.8 46.4 30.9 21.6 
SF-12 PCS 47.9 46.5 44.2 50.3 44.7 42.1 
GHQ score 3.0 5.2 5.5 2.9 5.2 7.0 
GHQ Likert score 13.5 17.4 18.1 13.6 17.4 20.9 
BDQ - days out of role 4.8 4.8 9.1 1.6 6.8 12.8 
BDQ main score 1.7 1.8 2.2 1.4 2.0 2.4 
BDQ MOS score 4.2 4.5 6.1 2.9 5.7 6.8 
BDQ WHO score 5.9 6.3 9.1 4.0 8.3 10.2 
Kessler psychological 
distress scale 
40.1 35.3 30.4 39.0 33.9 27.3 
 
Counting each of these disorders as a separate episode could result in 
attributing disability in one person in excess of a disability weight of 1 — 
the equivalent of being dead! In order to avoid overestimation of burden, we 
shared co-morbidity between anxiety disorders, affective disorders, 
borderline personality disorder and alcohol and drug dependence equally so 
that a person with 2 or more disorders was partially counted in each 
category. On the advice of mental health experts, 75% of co-morbidity with 
harmful alcohol use was attributed to the relevant other mental disorder and 
25% was attributed to harmful alcohol use, whereas co-morbidity between 
anxiety and affective disorders was attributed equally between categories. 
Because we captured the level of severity separately, as described 
above, our estimates took into account that people with multiple diagnoses 
were likely to have greater severity than people with a single diagnosis.  
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Duration 
It is argued that dysthymia and major depressive disorder are part of the 
same disease entity as people with dysthymia frequently develop 
superimposed major depressive episodes and the symptomatic course of 
major depression commonly changes between levels of severity [38-40]. 
Modelling major depression and dysthymia as one disease proves very 
difficult because of the heterogeneity of the course of the disease: some 
people have only one episode, some people are continuously depressed for a 
long time and the majority have multiple episodes that vary in frequency. 
We therefore decided to model major depression as episodes and to model 
dysthymia separately. We added the years lost due to disability (YLD) of 
major depression and dysthymia to give total YLD for depression.  
We derived estimates of the average duration of major depressive 
episodes from the one-year prevalence (symptomatic at some time during the 
preceding 12 months) and point prevalence (symptomatic in the preceding 
two weeks) as follows:  
 
duration average
    52 weeks + average duration  x  prevalence pointprevalence  year - 1 =
 
This gave an average durations of 38.2 weeks and 24.9 weeks for 
males and females, respectively. The literature suggests that the mean 
duration of of both initial and recurrent episodes of major depression is 
consistent at 20 weeks [26, 41]. Our higher estimate of duration may be 
attributed to recall bias of those with symptoms of major depression in the 
last year who did not have current symptoms. Having no evidence to support 
or reject this hypothesis we used the estimates of duration calculated above.  
The overall YLD estimates are not very sensitive to the assumed 
duration as a shorter estimate of duration leads to a higher estimate of 
incidence derived from the same observed prevalence, and the total YLD 
values are proportional to incidence multiplied by average duration. In fact, a 
20-week duration for depressive episodes resulted in almost identical 
estimates of YLD although there was a moderate shift in the age distribution 
from younger adults to older age groups.  We used a remission rate of 0.124 
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in our DISMOD model for dysthymia based on a reported remission in 58% 
during seven years of follow-up [38]. From young adults to older ages the 
modelled average duration ranges from 8.0 to 3.8 years. 
The literature on anxiety disorders [42, 43], obsessive-compulsive 
disorder [44] and PTSD [45, 46] suggests that these disorders generally run a 
chronic course with periods of remission and relapse. This contrasts with the 
relatively short duration estimated in the GBD study of 0.75, 1.6 and 2.5 
years, for panic disorder, OCD and PTSD, respectively. To account for 
asymptomatic periods during the course of these chronic conditions we 
adjusted our durations by the ratio of point prevalence and one-year 
prevalence. 
In our DisMod models for substance use disorders, we assumed age-
specific remission rates and incidences that were consistent with the 
observed large age differences in prevalence. This leads to duration 
estimates of 2–5 years for harmful alcohol use, 3–7 years for alcohol 
dependence, 5–17 years for heroin dependence, and 3–4 years for marijuana, 
sedative and stimulant dependence. The DisMod models for alcohol 
dependence and harmful use included a twofold increased risk of death 
resulting in a number of deaths amounting to about 60% of all deaths 
attributed to alcohol in our risk factor calculations. We accepted that as 
plausible, since not all deaths attributed to alcohol occur in people who 
qualify for a diagnosis of substance use disorder. For harmful alcohol use, 
marijuana, sedative and stimulant dependence we used the same method of 
adjustment to account for asymptomatic periods as described above for 
anxiety disorders. This same method cannot be applied to alcohol 
dependence as the definition assumes a chronic unremitting state. However, 
local alcohol experts did not believe that the large numbers of people 
identified with alcohol dependence, particularly at younger ages, all 
experienced disability for the duration of the condition. We therefore 
adjusted our YLD calculations, assuming that the 47–60% per cent in males 
and 16–53% in females, depending on age, who reported higher scores on 
the SF–12 than the population average represented an equivalent to the 
asymptomatic periods estimated for anxiety disorders.  
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Table 3.   Comparison of disability weights (DW) for mental disorders used 
in the Australian burden of disease studies and in the GBD 
Disease category GBD 
DW (a)
Australian
DW (b)
Comments on Australian 
DWs 
Alcohol dependence  0.18 0.07-0.18 Dutch weights (0.11-0.55) 
Drug use 
Heroin dependence 
Marijuana dependence 
Sedative dependence 
Stimulant dependence 
0.25  
0.27 
0.11 
0.18 
0.11 
 
Locally derived weights 
Anxiety disorders 
Panic disorder 
Obsessive-compulsive disorder 
Post-traumatic stress disorder 
Agoraphobia 
Social phobia 
Generalised anxiety disorder 
 
0.15 
0.12 
0.11 
 
0.21–0.27 
0.20–0.28 
0.14–0.15 
0.14–0.16 
0.18–0.21 
0.22–0.23 
Range of Dutch weights(c)
0.11–0.69 
0.17–0.60 
0.13–0.51 
0.11–0.55 
0.17–0.59 
0.17–0.60 
Affective disorders 
Major depressive episodes 
Dysthymia 
Bipolar disorder 
 
0.50 
 
0.51 
 
0.37–0.41 
0.33–0.38 
0.18 
Range of Dutch weights  
0.14–0.76 
 
Composite of local weight 
for mania (0.50), moderate 
Dutch weight for depressive 
episodes (0.34) and mild 
Dutch depression weight in 
between episodes (0.14) 
Schizophrenia 0.41 0.43 Composite of 30% untreated 
and 70% treated GBD DW 
Borderline personality disorder  0.54 Locally derived weight 
Eating disorders  0.28 Dutch weight 
ADHD  0.02–0.15 Dutch weights  
Autism  0.55 Dutch weight 
(a) Calculated from treated and untreated DW together with proportion assumed treated [14]. 
(b) Range reflects variations by age and sex in the severity distribution. 
(c) For further details, refer to Dutch disability weights study [21, 22].  
 
We estimated durations of 4–6 years for borderline personality 
disorder. This may seem short for a personality disorder but there is no 
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alternative credible set of incidence and remission estimates that can be 
matched to the observed MHS prevalence figures using DisMod. 
Schizophrenia was modelled as a life long condition that generally 
starts in young adulthood and has an elevated risk of dying based on a meta-
analysis reporting standardised mortality ratios of 154 in males and 162 in 
females [47].  
Disability weights 
For most disorders we used the Dutch DWs (Table 3). The DWs for 
drug dependence disorders, manic episodes in bipolar disorder, and 
borderline personality disorder were extrapolated by panels of  local experts 
in the same way as the GBD study’s expert panel derived weights for most 
conditions after anchoring weights for 22 indicator conditions. The weight 
for schizophrenia is a compound of 30% for the untreated weight and 70% 
for the treated weight from the GBD study, reflecting the average time spent 
in psychosis reported from a number of industrialised countries in the 
International Pilot Study of Schizophrenia [30]. 
Comparisons with GBD estimates 
In order to make meaningful comparisons with the results of the GBD study 
for the EME region, we recalculated our results with age-weighting and 
applied the same standard model life table for years of life lost (YLL). All 
comparisons are presented as rates of DALYs per 1,000 population age-
standardised to the 1990 EME population. 
RESULTS 
According to Australian reports based on non-age-weighted DALYs, mental 
illness contributed 13.2% of the total disease burden in Victoria and 13.3% 
of that in the country as a whole in 1996 [16, 19]. Only 6% of the mental 
illness burden was attributable to mortality, mostly involving fatal outcomes 
associated with substance use disorders. Affective, anxiety and substance use 
disorders together accounted for four-fifths of the overall burden attributable 
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to mental illness (Figure 1). For men, depression was the eighth leading 
cause of overall burden, while alcohol and drug use disorders were the 
thirteenth and fifteenth, respectively. For women, depression was the fifth 
leading cause of overall burden, while generalised anxiety disorder and 
alcohol use disorder were the twelfth and seventeenth, respectively.  
 
0 5,000 10,000 15,000
DALYs
Males
YLL YLD
Eating disorders
Borderline personality disorder
Schizophrenia
Childhood conditions
Anxiety disorders
Substance use disorders
Affective disorders
Females
 
Figure 1. The burden of mental illness (YLL, YLD and DALYs) by 
disorder and sex, Victoria 1996 
  
Adding the age-weighting of the GBD study to the results for Victoria 
gave considerably more prominence to mental disorders. They thus became 
the largest group of conditions, contributing 20.7% to the burden of disease. 
This was similar to the estimate of the GBD for EMEs, in which mental 
disorders other than dementia accounted for 19.5% of the total burden of 
disease. With age-weighting, depression became the leading cause of 
DALYs for women and the second cause for men in Victoria. Alcohol 
dependence in men and women and drug dependence in men entered the top 
ten while generalised anxiety disorder, social phobia and bipolar disorder 
ranked among the top twenty conditions for both men and women; eating 
disorders and drug dependence also entered the top twenty for women. 
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Table 4.   DALY rates per 1,000 population(a) for mental disorders, EME 
region 1990 and Victoria 1996. 
Males Females 
GBD Victoria GBD Victoria 
All mental disorders 25.9 20.1 21.4 21.2 
Affective disorders 8.2 6.7 12.7 9.0 
    Depression 6.0 5.3 10.7 7.7 
    Bipolar disorder 2.2 1.4 2.1 1.3 
Anxiety disorders 2.4 4.3 3.6 6.0 
    Post-traumatic stress disorder 0.3 0.5 0.4 0.5 
    Obsessive-compulsive disorder 1.6 0.4 2.0 0.3 
    Panic disorder 0.6 0.2 1.1 0.6 
    Other anxiety disorders 0.0 3.2 0.0 4.6 
Substance abuse 12.4 6.4 2.6 3.1 
    Alcohol dependence/harmful use 9.7 4.3 1.7 1.9 
    Drug dependence/harmful use 2.7 2.1 0.9 1.2 
Schizophrenia 2.9 1.2 2.6 1.0 
Other mental disorders 0.0 1.5 0.0 2.1 
(a) Age-weighted and discounted DALYs, age-standardised to EME population 1990. 
 
Notwithstanding the close agreement on the total size of the mental 
health burden, there were substantial differences between the Victorian 
estimates and those of the GBD study for EME countries in respect of 
particular disorders (Table 4). These differences are the result of variations 
in estimates for one or more of the YLD parameters (i.e. incidence, duration 
and disability weights) for most mental illnesses (Table 5). 
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Table 5.   Estimates of prevalence, incidence and duration of mental 
disorders in GBD 1990 and Victoria (Vic) 1996  
Disorder Prevalence per  
1,000 (a)
Incidence per 
1,000 (a)
Duration in 
years(b)
 GBD Vic GBD Vic GBD Vic 
Males       
Major depression 0.9 1.0 16.3 10.9 0.56 0.73 
Bipolar disorder 0.3 0.7 2.7 0.3 1.4–1.5 21–24 
Panic disorder 0.3 0.3 3.8 0.2 0.75 10–16 
OCD 1 0.1 6.2 0.2 1.6 4–7 
PTSD 0.2 0.4 0.8 0.9 2.5 5 
Schizophrenia 0.9 0.3 0.2 0.1 52–54 21–57 
Alcohol dependence 3.9 2.7 24.0 12.9 1.5–1.7 4–5 
Drug use(c) 0.8 2.0 7.7 4.3 1 3–13 
Females       
Major depression 1.7 1.5 29.8 27.3 0.56 0.48 
Bipolar disorder 0.3 0.7 2.6 0.3 1.4–1.5 21–24 
Panic disorder 0.6 1.1 7.5 0.7 0.75 10–16 
OCD 1.3 0.2 8.2 0.3 1.6 4–7 
PTSD 0.3 0.6 1.3 1.1 2.5 5 
Schizophrenia 0.9 0.3 0.2 0.1 52–54 21–57 
Alcohol dependence 0.7 0.9 4.3 5.0 1.5–1.7 4–5 
Drug use(b) 0.2 0.8 2.5 1.7 1 3–13 
(a)  Prevalence and incidence figures include an adjustment for comorbidity with 
other mental disorders  
(b)  Ranges indicate variations in duration by age and sex  
(c)  The GBD estimated prevalence of ‘dysfunctional and harmful drug use’ as one 
category 
 
Two main factors explain most of the differences. Firstly, the 
occurrence of the disease, i.e. its prevalence, may have differed between 
Australia and the EMEs. It should be noted that almost all estimates were 
derived from prevalence data. The prevalence estimates for Victoria (Table 
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5) included the downward adjustment for co-morbidity between mental 
disorders. Secondly, the disease models may have differed, particularly in 
respect of the assumptions on the distribution of severity, DWs and average 
duration. 
Our estimates of the burden of alcohol dependence and harmful use in 
men are less than half those for the EMEs. To some extent this reflected a 
lower prevalence in Victoria (partly attributable to by the adjustment for co-
morbidity) but the main influence was the downward adjustment of the 
average level of disability, on the assumption that the proportion of survey 
respondents not reporting disability on six key questions of the SF–12 
reflected symptom-free periods during the course of illness.  
Despite taking a similar prevalence of major depression as a starting 
point and including dysthymia, we estimated a lower burden from depression 
in Victoria. This was largely because of the use of lower DWs. Our YLD 
estimates for bipolar disorder were based on a prevalence more than double 
that estimated in the GBD study. Nevertheless, the Victorian estimate of the 
associated burden was much lower because we use different DWs. The GBD 
study used a uniform weight of 0.51 for the EME region while in Victoria 
we model manic episodes at a weight of 0.50, depressive episodes at 0.34 
and the time in between episodes at 0.14, resulting in an average weight of 
0.18 for the overall course of illness. The very different estimates of the 
duration of bipolar disorder between the two studies cannot explain the large 
differences in burden estimates because the incidence and duration are 
modelled on prevalence data. Combinations of high incidence and short 
duration or low incidence and long duration that are consistent with the same 
prevalence figures lead to marginal differences in burden estimates as YLD 
are determined by the product of incidence and duration. 
Australian figures indicate higher prevalence of PTSD in both sexes 
and of panic disorder in women but much lower prevalence of OCD. The 
latter was probably overestimated in the GBD, which may have relied on 
survey results in which lay interviewers used too broad criteria to diagnose 
this disorder, as occurred in a Canadian study [48]. In contrast to the short 
durations for anxiety disorders in the GBD study, we modelled them as 
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chronic conditions with periods of remission and relapses. This leads to very 
different YLD estimates, which are also affected by the higher DWs. Our 
estimate of the burden due to PTSD was higher, mostly because of the 
higher prevalence. Our much lower estimate of YLD for OCD was mostly 
influenced by the sixfold lower prevalence estimate, the higher DW 
estimates and the MHS-based estimates indicating that men and women with 
OCD have 11% and 41%, respectively, of the time symptom-free during the 
course of their illness. Higher average DWs and an estimated 74% symptom-
free periods during the course of illness, and a higher observed prevalence, 
resulted in YLD estimates for panic disorder that were considerably lower in 
men and women in comparison with the estimates in the GBD study. With 
the inclusion of three additional anxiety disorders in adults (social phobia, 
generalised anxiety disorder and agoraphobia) and separation anxiety 
disorder in childhood, the estimates in the Victoria study for anxiety 
disorders are two-thirds higher than in the GBD study. 
The YLD estimates for schizophrenia in Victoria were 60% lower 
than in the GBD study and reflected lower estimates of prevalence as other 
assumptions of DWs and average duration were almost identical. 
DISCUSSION 
The epidemiological assumptions underlying the calculations of the burden 
of disease caused by mental disorders have not previously been examined. 
The Australian burden of disease studies developed new models for each of 
the mental disorders that were included in the GBD study and made 
estimates for ten new disease categories. Major differences in the underlying 
assumptions are outlined below. 
The use of Dutch DWs in the Australian studies allowed the 
construction of disease models with details by level of severity. In principle 
it is a great improvement if estimates can be made explicitly by level of 
severity, as each of the mental disorders shows considerable variation in 
severity. The use of a single DW for a disease implicitly assumes an average 
distribution of severity, but does not give the flexibility to adapt the weight 
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to populations with different severity distributions. The big difficulty in our 
approach lay in matching epidemiological data to the severity categories for 
which DWs have been derived.  
We decided not to derive disability weights separately for Australia in 
order to concentrate on the epidemiological inputs to the burden of disease 
calculations. This was made easier by the availability of the Dutch weights 
covering the main sources of disability in Australia. However, this left us 
with the task of finding Australian data on mental disorders to fit the Dutch 
severity levels as defined by the six domains of the EQ5D+. Because MHS 
did not use the EuroQol, we mapped six questions of the SF-12 to two 
domains of the EuroQol in order to distinguish between levels of severity. 
This was not a tested method but in comparison to ICD-10 diagnoses it 
showed greater distinction between levels of mild, moderate and severe 
depression on all other measures of disability in the survey. We then 
assumed that the same method could distinguish between levels of severity 
for the other disorders included in the same survey. The very large 
contribution of mental disorders to the overall burden of disease means that 
there is a need for longitudinal studies of people identified with a mental 
disorder in community samples. This would allow a better understanding to 
be obtained of the level of disability suffered during the course of illness. 
Our revised disease models for anxiety disorders and bipolar disorder 
as chronic conditions were more in line with the literature than the durations 
estimated in the GBD study. Follow-up studies of people with anxiety 
disorders justified our choice of disease models of long duration with periods 
of remission and relapses [43, 44, 49, 50]. As we had only cross-sectional 
data on mental disorders in Australia we used the ratio of one-year 
prevalence and point prevalence to represent the proportion of time during 
the chronic course of illness which was spent with symptoms. Because the 
one-year prevalence figures may be influenced by recall bias, it would be 
helpful to examine whether our estimates of the proportion of time 
symptomatic can be confirmed in longitudinal follow-up studies.  
Similarly, there is uncertainty about the amount of disability 
associated with alcohol dependence and harmful use. On the advice of local 
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alcohol experts, we reduced YLD estimates for alcohol dependence by 
assuming no disability for the proportion of respondents not reporting 
disability on the SF-12. That was an arbitrary decision made in relation to 
alcohol dependence but not in relation to the other mental disorders. Again 
this identifies a critical need for follow-up data on people identified in 
community surveys of mental disorders. 
Ignoring the common co-morbidity between mental disorders can lead 
to significant double counting and overestimation of the burden of disease. 
This is particularly important if a large number of mental disorders is 
included. We were able to assess the occurrence of co-morbidity between 
five substance use disorders, six anxiety disorders, two affective disorders 
and borderline personality disorder from the results of a representative 
Australian mental health survey. The proportion of co-morbidity ranged 
from 49% in people identified with social phobia to 94% in people with 
borderline personality disorder. The latter figure raised the question as to 
whether borderline personality disorder should be excluded from the burden 
of disease list of mutually exclusive conditions and, instead, valued 
separately as a risk factor for other mental disorders. Our method of 
adjusting for co-morbidity assumed that each diagnosis contributes equally 
to the overall level of disability. By capturing severity separately from the 
SF-12 we are able to allow for the fact that people with more than one 
diagnosis were likely to experience greater disability than people with only 
one of the co-morbid conditions. It is possible that in this method some 
individuals with two or more diagnoses contribute less YLD than a person 
with the severest of these conditions. A laborious procedure would be 
required in order to analyse this on a case-by-case basis for each possible 
combination of co-morbid conditions. We decided against this because we 
did not think it would make a great difference to our overall results.  
Contrary to the sensitivity analyses for the GBD study, which showed 
only a marginal difference between results that were age-weighted and those 
that were not, in Victoria age-weighting increased the contribution of mental 
disorders to overall DALYs by 57%. Thus mental disorders surpassed 
cardiovascular diseases and cancer as a leading cause of burden. Although 
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the authors of the GBD study mention that age-weighting preferentially gave 
more weight to mental disorders, their overall conclusion that results were 
insensitive to assumptions such as age-weighting did not hold for the 
Victorian study. In the debate about age-weighting in summary population 
health measures it is important to note that its impact may not be as slight as 
is commonly assumed. 
CONCLUSIONS 
Using different detailed methods and data sources, the Australian burden of 
disease studies have confirmed that mental disorders are a leading cause of 
burden of disease in developed countries. Partly as a result of 
methodological differences (including use of different weights, analysis of 
severity distributions and adjustments for co-morbidity) the Australian 
estimates show marked differences in comparison to the results of the GBD 
study for particular disorders. Lower severity weighting for alcohol 
dependence in younger men together with differences in prevalence resulted 
in lower burden in Australia. Lower estimates of burden for major 
depression were predominantly due to lower estimated severity. Despite 
using higher DWs, our estimates for OCD are less than a quarter of the 
estimates of the GBD study because of much lower prevalence estimates. 
Much lower estimates of the burden for panic disorder and higher estimates 
for PTSD were derived from disease models with higher DWs, higher 
prevalence estimates and adjustments for symptom-free periods during the 
chronic course of illness. Estimates of the total burden due to anxiety 
disorders in Australia were almost twice as high as the GBD results because 
four additional conditions were included in the Australian work. 
In conclusion, we hope that our efforts to improve disease modelling 
for mental disorders make a useful contribution to burden of disease 
methodology. We believe that our models are an improvement over those 
used in the GBD study. There is still much scope for further developments, 
particularly in the measurement of severity over the course of mental 
disorders and in dealing with co-morbidity. Full details of our calculations 
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are available from the Internet (http://www.health.vic.gov.au/healthstatus/ 
bod/daly.htm). 
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ABSTRACT 
Objective: The Assessing Cost-Effectiveness (ACE)-Mental Health Study 
aims to assess from a health sector perspective, whether there are options for 
change that could improve the effectiveness and efficiency of Australia’s 
current mental health services by directing available resources towards ‘best 
practice’ cost-effective services. 
Method: The use of standardised evaluation methods addressed the 
reservations expressed by many economists about the simplistic use of 
League Tables based on economic studies confounded by differences in 
methods, context and setting. The cost-effectiveness ratio for each 
intervention is calculated using economic and epidemiological data.This 
includes systematic reviews and randomised controlled trials for efficacy, 
the Australian Surveys of Mental Health and Wellbeing for current practice 
and a combination of trials and longitudinal studies for adherence.  The cost-
effectiveness ratios are presented as cost (A$) per disability adjusted life 
year (DALY) saved with a 95% uncertainty interval based on Monte Carlo 
simulation modelling. An assessment of interventions on ‘second filter’ 
criteria (‘equity’, ‘strength of evidence’, ‘feasibility’ and ‘acceptability to 
stakeholders’) allows broader concepts of ‘benefit’ to be taken into account, 
as well as factors that might influence policy judgements in addition to cost-
effectiveness ratios. 
Conclusions: The main limitation of the study is in the translation of the 
effect size from trials into a change in the DALY disability weight, which 
required the use of newly developed methods. While comparisons within 
disorders are valid, comparisons across disorders should be made with 
caution.  A series of articles is planned to present the results. 
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BACKGROUND 
Scarcity of funds dedicated to health care means that choices of what to fund 
are inevitable. Currently choices are driven largely by historical patterns of 
expenditure and the influence of professional, industrial and community 
interest groups. Cost-effectiveness analyses provide additional information 
that can help decision-makers set funding priorities that will improve the 
effectiveness and efficiency of health services [1].  
In the national and Victorian Burden of Disease studies, mental 
disorders ranked third behind cardiovascular disease and cancer, accounting 
for 13% of the overall burden of disease [2, 3]. This raises the question as to 
why such a large burden persists while there is subsidised access to 
potentially effective treatments for most disorders [4, 5]. This question 
prompted the Mental Health Branches of the Australian Department of 
Health and Ageing and the Department of Human Services Victoria to fund 
the Assessing Cost-Effectiveness – Mental Health (ACE–MH) study. The 
research question for the ACE–MH study is to assess from a health sector 
perspective, whether there are options for change that could improve the 
effectiveness and efficiency of Australia’s current mental health services by 
directing available resources towards ‘best practice’ cost-effective services.   
OVERVIEW OF METHODS 
The ACE–MH study uses a macro economic evaluation approach to aid 
decision-making in mental health care in Australia [6]. This approach aims 
to give policy makers and health experts in Australia a greater involvement 
in both the study design and conclusions, as recommended by the Panel on 
Cost Effectiveness in Health and Medicine [1]. Recently the Centre for 
Health Program Evaluation and the Department of Human Services, in a 
collaborative effort, trialled a similar approach in the analysis of cancer 
control priorities in Australia [7]. Concurrently, a further study, ACE–Heart 
Disease, is being conducted using the same methods.  
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The key characteristics of the ACE–MH approach are: a clear 
rationale for selection of options for change; an evidence-based approach; 
adoption of a two-stage approach to the assessment of benefit, involving 
both health gain (i.e. cost per Disability Adjusted Life Year [DALY] saved) 
and “judgement” aspects which are included as second stage filters (‘equity’, 
‘strength of evidence’, ‘feasibility’ and ‘acceptability to stakeholders’); use 
of an economic protocol specifically developed for the study, which ensures 
transparency and consistency of methods; and extensive uncertainty testing.   
The DALY was chosen as the measure of health gain for this study 
because it captures both morbidity and mortality effects across a wide range 
of disorders and intervention types and because baseline information on 
health status was available using the DALY for Australia [2, 3]. 
  ACE–MH was guided by a Steering Committee of mental health 
experts, policy-makers and representatives of community mental health 
organisations, working to the following terms of reference:  
• To select up to 30 major interventions for mental disorders, based on: 
the size of the problem addressed; importance in terms of current 
expenditure; relevance to current policy decision-making; availability 
of evidence to support analyses; indications that additional 
expenditure would lead to significant health gain or conversely, that 
decreased expenditure would lead to little or no reduction in health 
outcomes; and ability to specify the intervention in clear concrete 
terms. 
• To define ‘benefit’ and the associated criteria by which the 
interventions will be judged. 
• To critically examine the evidence and analyses presented by the 
researchers. 
• To formulate conclusions based on the presented evidence. 
The interventions chosen for analysis are shown in Table 1. The 
comparator to the interventions selected as options for change in the ACE 
studies is ‘current practice’. To determine ‘current practice’ we utilise the 
Australian National Surveys of Mental Health and Wellbeing: Adult 
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Component [8], the Child and Adolescent Component [9], the Low 
Prevalence Component [10] and expert advice. Current practice includes a 
mixture of no treatment, treatment with evidence-based medicine (EBM) and 
treatment with non-EBM. For most interventions in the ACE–MH study we 
model the effect of switching those currently on non-EBM onto an evidence-
based intervention. An intervention was classed as evidence-based if it was 
currently recommended in clinical practice guidelines and supported by 
randomised controlled trial evidence. Current contact with EBM was defined 
from self-reported receipt of interventions. 
 The perspective in ACE–MH is that of the health sector. This 
includes the government as health service provider, as well as the impact on 
patients and their families/carers. Discounting at 3% is applied to both costs 
and benefits to match the rate chosen in the Australian BOD studies [2, 3].   
The target audience for the interventions is Australians with prevalent 
disease in the year 2000. The time horizon, both for the provision of the 
interventions and for tracking the associated costs and consequences, is 
specified in the individual reports. Due to the heterogeneity in the 
illness/intervention combinations, it is not possible to have a uniform time 
horizon. Time horizons were chosen to realistically reflect how the 
interventions would be applied in real life; and to ensure tracking of all 
relevant costs and benefits. Regardless of the time horizon, it is assumed that 
all interventions are in ‘steady-state’, that is they work at their full potential 
and that trained practitioners are available. Thus, the analyses do not address 
implementation and ‘learning curve’ issues or costs. 
In addition, scoping reports were conducted for interventions for 
anorexia nervosa, dual diagnosis (drug dependence and psychoses), and 
assertive community treatment of psychoses, which showed that there was 
insufficient evidence of effectiveness for a full cost-effectiveness analysis.   
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Table 1.  Interventions selected for analysis in ACE–Mental Health 
Major depression in adults 
Individual cognitive behavioural therapy (CBT) 
Group Cognitive Behavioural Therapy (CBT) 
Selective serotonin reuptake inhibitors (SSRIs) 
Tricyclic antidepressants (TCAs)  
Bibliotherapy 
Major depression in children and adolescents 
Individual Cognitive Behavioural Therapy (CBT) 
Selective serotonin reuptake inhibitors (SSRIs) 
Schizophrenia 
Stand-alone early psychosis intervention vs generic service  
Enhanced standard care for early psychosis vs generic service  
Behavioural Family Management (BFM) 
Behavioural Intervention in Families (BIF) 
Multiple Family Groups (MFG) 
Supported employment (Individual placement and support) 
Risperidone vs typicals 
Olanzapine vs typicals 
Olanzapine vs risperidone 
Clozapine vs typicals 
Risperidone vs low dose typicals 
Generalised Anxiety Disorder 
Individual Cognitive Behavioural Therapy (CBT) 
Venlafaxine (and other antidepressants) 
Panic disorder / agoraphobia 
Individual Cognitive Behavioural Therapy (CBT) 
Selective serotonin reuptake inhibitors (SSRIs) 
Tricyclic antidepressants (TCAs) 
ADHD 
Dexamphetamine 
Methylphenidate 
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ASSESSMENT OF BENEFIT 
Benefits are calculated by a two-stage process. The first stage involves the 
estimation of the health gain that could be attributed to each intervention 
using the DALY. The second stage involves the assessment of issues that 
either influence the degree of confidence that can be placed in the cost-
effectiveness ratios (such as the level of available evidence), or broader 
issues that need to be taken into account in decision-making about resource 
allocation (such as equity and acceptability to stakeholders). 
Stage One: Measurement of the health gain 
In comparison to other health areas such as cancer and heart disease, the 
emphasis in mental health services is largely on improvement in quality of 
life of those with the mental disorder, as the current repertoire of 
interventions provides limited opportunities for primary prevention and 
improved survival. This puts a heavy emphasis on the ability to translate 
measures of impact described in the literature into a change in the DALY 
measure, and in particular, the Years Lived with Disability (YLD) 
component. YLD are determined by the incidence, duration and severity of 
disease.  Severity is measured by the DALY disability weights on a scale 
from 0 to 1, with zero being full health and one being death.  In the ACE–
MH study we use the Dutch disability weights (DWs) [11], which are also 
used in the Australian burden of disease studies [2, 3]. Most interventions 
included in ACE–MH impact on disease severity, with prevention or delay 
of relapse also being measured in some interventions (e.g. maintenance 
treatment of depression and family interventions for schizophrenia).   
The first step in measuring the health gain is to determine the efficacy 
of an intervention, i.e. the impact of the intervention on severity, duration or 
risk of relapse. When the intervention affects the severity of the mental 
disorder we use the effect size as our main measure of efficacy.  The second 
step is to transfer the measure(s) of effect into a change in the DALY DW. 
These two steps are described below.   
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Effect size 
Effect sizes are used to measure the benefit of an intervention in relation to a 
placebo or other control group. In the psychiatric literature outcomes are 
most commonly expressed as continuous measures but many different scales 
are used.  Thus, the most relevant measure of effect size for mental health 
interventions is the standardised mean difference. It quantifies the magnitude 
of the difference between two groups in a metric-free unit, by expressing the 
mean difference in standard deviation units. We use ‘Hedges’ g [12] because 
it includes an adjustment to correct for small sample bias and is used in 
Cochrane Collaboration systematic reviews.  
If there is a systematic review or meta-analysis of the intervention the 
effect size can often be obtained from this. However, for many of the 
interventions we have conducted our own meta-analysis because systematic 
reviews are not available, do not include all relevant studies or present the 
results in a form that is different to that required for ACE–MH. Wherever 
possible we use randomised controlled trials to calculate the effect size, as 
this is the best methodology for determining treatment efficacy [13]. 
We pool effect sizes using the random effects method of DerSimonian 
and Laird [12]. Firstly, an effect size is calculated for each study by 
averaging across selected outcome measures within the study. This differs 
from Cochrane systematic reviews but is consistent with meta-analyses of 
the psychiatric literature [14, 15] and allows inclusion of all relevant 
outcome measures that reflect health related quality of life in calculating the 
effect size. In practice, much of the efficacy data presented for mental health 
interventions is limited to symptom specific measures which can affect 
various aspects of health related quality of life, to varying extents. Following 
meta-analysis, any heterogeneity between trials is investigated according to 
established methods [16].   
A ‘placebo effect’ is not included in our modelling of effectiveness in 
ACE–MH due to controversy regarding its existence [17, 18]. Further, its 
inclusion has little or no impact on the relative effectiveness or cost-
effectiveness of treatments because patients in the non-evidence based 
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treatment group or the non-adherent group also get a placebo effect (but no 
treatment effect).   
Transferring the effect size into a change in the disability weight  
Translating the effect size into a change in the DALY DW is the most 
difficult methodological issue in ACE–MH, as there is no well-established 
and accepted method available. From our exploration of available methods 
we settled on the ‘conversion factor method’ and the ‘survey severity 
method’. The results of both methods are used as a range to determine the 
total Years Lived with Disability, costs and cost-effectiveness ratios for the 
interventions. Uncertainty from each of the methods is included in the 
results.   
The ‘conversion factor method’ uses a DW ‘conversion factor’ to 
translate an effect size into a change in the DW [19]. We multiply the effect 
size by the DW conversion factor for the particular mental disorder.  This 
conversion factor is an average change in DALY DWs for the equivalent of 
a standard deviation change in severity for the particular mental disorder.  
An assumption of this method is that the degree of change in effect 
size units in clinical trials reflects the degree of change in disability weights 
from application of the translation factor. While the relationship between 
disability weight and effect size change was defined for symptoms and the 
overall level of disability, the effect size from meta-analyses predominantly 
summarises changes in symptoms. While, there is a close correspondence 
between symptoms and disability in anxiety and depression [20], and in 
schizophrenia greater severity elicits less favourable preference values [21], 
it is not known if the magnitude of the change is comparable.    
For the ‘survey severity method’ a health status measure from the 
mental health survey is used to classify the severity of respondents to 
calculate an average DW. The effect size is then applied directly to this 
health status measure, severity of respondents is reclassified and a new 
average DW calculated. The difference in average DWs is the anticipated 
change due to treatment.   
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Table 2.  The survey severity method: specific steps to calculate a change in 
the disability weight due to an intervention  
1. We classify cases in the NSMHW into ‘severe’ (>2.5 SD below mean; i.e. 
<25), ‘moderate’ (>1.5 to 2.5 SD below mean; i.e. 25-34.9), ‘mild’ (>0.5 to 
1.5 SD below mean; i.e. 35-44.9) and ‘no disability’ (a score of ≥ 45).  This is 
done in the group eligible for the intervention, i.e. those having the diagnosis, 
and consulting, but currently not receiving evidence based treatment.   
2. The proportion of cases in each severity category is multiplied by the 
appropriate DW for the category to get a weighted average DW for the 
eligible group.   
3. We then multiply the effect size from trial data by the standard deviation of 
the MCS/PSS in the group with the disorder to determine the average increase 
in the MCS/PSS with the intervention.   
4. We apply this increase in the MCS/PSS to those respondents in the survey 
eligible for the intervention.  
5. These respondents are reclassified into the categories ‘none’, ‘mild’, 
‘moderate’ and ‘severe’ and a new weighted average DW is calculated for the 
group.  
6. The change in average DW before and after applying the effect size is then 
the DW change due to the treatment. 
7. Steps 3 to 6 are repeated for both the lower and upper limits of the 95% 
confidence interval of the effect size.  This gives upper and lower limits 
around the DW change due to treatment.  These are used for uncertainty 
analyses. 
DW = disability weight; MCS = mental component score; NSMHW = National Survey of Mental Health 
and Wellbeing; PSS = Psychosocial Summary Score 
 
For anxiety and depression we use the Mental Component Score of 
the SF-12 in the adult component of the National Survey of Mental Health 
and Wellbeing [8] and for ADHD we use the Psychosocial Summary Score 
from the Child Health Questionnaire in the child and adolescent component 
of the Survey [9]. Both measures are designed to have a mean population 
value of 50 and a SD of 10. The specific steps are illustrated in Table 2.  A 
similar approach is used for schizophrenia but more assumptions are 
required (see Appendix).   
An assumption of the ‘survey severity method’ is that the effect size 
calculated from clinical trials can be applied directly to a general health 
status measure such as the Mental Component Score or Psychosocial 
Summary Score. This may be a significant issue when the effect size from 
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meta-analyses is calculated from a predominance of symptom measures, as 
these are usually more sensitive to outcome than generic measures.  
Non-adherence 
The non-adherence rate is important to the cost-effectiveness ratio because 
patients who do not adhere to treatment would be expected to incur costs at 
no or reduced health benefit. For ACE–MH, we use both the dropout rate 
from trials and from longitudinal studies to determine the adherence rate.  
We use the uncertainty analysis to incorporate possible differences between 
trial results and ‘real-life’ by using a uniform distribution between the 
observations from trials and longitudinal studies. In the absence of 
longitudinal studies we assumed a lower value of 50%.      
 
Table 3.  The Second Stage Filter Criteria 
Strength of evidence: We used the NHMRC ‘Designation of levels of evidence’ 
but also highlight potential threats to the quality of the evidence by identifying 
possible biases and issues that affect the generalisability of the evidence.  Based on 
the level and quality of evidence we categorised the strength of the evidence of 
effectiveness (or ineffectiveness) as: ‘sufficient’, ‘limited’ or ‘inconclusive’ (Table 
4).  This criterion is also addressed in the uncertainty modelling.  For example, if 
the evidence on effectiveness is weak, large uncertainty is put around the size of 
the impact measure.  
Equity:  This criterion addressed the capacity of the intervention to affect inequity 
in the distribution of the mental disorder, as well as highlighting issues that may 
affect access to, or utilisation of, the intervention.  The special needs groups 
considered include those with a lower socio-economic status, non English speaking 
background, Aboriginal and Torres Strait Islanders, or rural/remote residence. 
Feasibility: This criterion addressed issues such as the availability of an 
appropriate workforce with appropriate training to conduct the intervention, 
whether the intervention could be implemented under current institutional 
arrangements, and ease of implementation.    
Acceptability to stakeholders:  This criterion referred to the anticipated 
acceptability of the proposed interventions to the various stakeholders affected by 
the intervention.  Stakeholders include consumers and their family/carers, 
clinicians, policy makers, the general community and third-party funders.     
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Table 4. Classifying the Strength of the Evidence [6] 
Strength category Strength of the evidence 
‘Sufficient evidence’ of 
effectiveness (or 
ineffectiveness): 
Effectiveness (or 
ineffectiveness) is 
demonstrated by sufficient 
evidence from well-designed 
research. 
• The effect is unlikely to be due to chance (e.g. P is < 
0.05) and 
• The effect is unlikely to be due to bias (e.g. evidence 
from: 
 a level I study design; 
 several good quality level II studies; or 
 several high quality level III-1 or III-2 studies 
from which effects of bias and confounding can 
be reasonably excluded on the basis of the design 
and analysis) 
‘Limited evidence’ of 
effectiveness (or 
ineffectiveness): 
Effectiveness (or 
ineffectiveness) is 
demonstrated by limited 
evidence from studies of 
varying quality 
• The effect is probably not due to chance (e.g. P is < 
0.05) but 
• Bias, while not certainly an explanation for the 
effect, cannot be excluded as a possible explanation 
(e.g., evidence from: 
 one level II study of uncertain or indifferent 
quality; 
 evidence from one level III-1 or III-2 study of 
high quality; 
 evidence from several level III-1 or III-2 studies 
of insufficiently high quality to rule out bias as a 
possible explanation; or 
 evidence from a sizeable number of level III-3 
studies which are of good quality and consistent 
in suggesting an effect). 
‘Inconclusive evidence of 
effectiveness (or 
ineffectiveness)’: Inadequate 
evidence due to insufficient or 
inadequate quality research. 
• No position could be reached on the presence or 
absence of an effect of the intervention (eg. no 
evidence from level I or level II studies and level III 
studies are available, but they are few and of poor 
quality, or only level IV studies are available.) 
Stage Two: the Second Filter criteria 
While evidence on cost-effectiveness is the main focus of activity in ACE–
MH, recognition is also given to broader aspects where decisions rest 
heavily on judgement and notions of ‘due process’. These additional criteria 
function as a ‘second filter’ by which each of the interventions is judged 
before recommending allocation of more or less resources. One of the roles 
of the Steering Committee was to select and apply the second filter criteria.. 
The filters chosen are described in Table 3. The main outcome of the second 
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stage analysis was a table for each intervention in which the issues were 
flagged and a qualitative judgement made explicit about each of the criterion 
and its impact.     
ASSESSMENT OF COSTS 
A common convention [22] in costing is to describe the analysis in three 
steps: 
• Identification – which activities/services and which cost impacts are 
included in the analysis? 
• Measurement – what is the extent of resource usage associated with 
these activities/services? and 
• Valuation – what is the monetary value of this resource usage? 
For ‘identification’ the health sector perspective means that costs (and 
cost offsets) impacting on government, together with costs (and cost offsets) 
impacting on patients and their families/carers are included. Costs to 
government are essentially the resources involved in organising and 
operating the services. Costs to patients and their families/carers are 
primarily identified as out-of-pocket expenses associated with visits to health 
professionals and associated treatments. The steering committee also 
expressed an interest in time costs (i.e. travelling time; waiting time; 
treatment time). These costs are calculated, where available and presented 
separately. With the exception of supported employment for people with 
schizophrenia, we do not include  production losses/gains associated with ill 
health itself (i.e. premature death; absence due to morbidity; reduced 
productivity whilst at work), nor do we include  non-health care goods and 
services. Pathway analysis is used to identify component activities of the 
various interventions and their current practice comparator, based on the 
published literature and supplemented with expert advice.   
The ‘measurement’ of resource usage is also facilitated by the 
pathway analysis. Component activities are identified and quantities 
estimated.  For example, a contact for CBT therapy usually entails a standard 
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60-minute consultation with a psychologist. The number and type of medical 
visits, drugs etc are estimated during this measurement step, with references 
documented.   
When attempting to cost non-adherence to treatment, we could find no 
information on the likely subsequent health seeking behaviour and 
associated costs. Thus, we assume that the non-adherers have the same 
health seeking behaviour, and the same costs, as those currently not 
receiving evidence based treatment. When estimating the cost of non-
evidence based treatment, we have utilised the National Surveys of Mental 
Health and Wellbeing to determine the average number of visits made to 
different health professionals in the previous 12 months (in the case of the 
adult component) or 6 months (in the case of the child and adolescent 
component). We have not included the cost of non-evidence based drugs or 
natural therapies in the cost of non-evidence based treatment. The 
conservative approach to the estimation of non-evidence based care will 
produce conservative estimates of the economic merit of options for change. 
In the ‘valuation’ step, a unit price for each of the activities, together 
with the data source, is specified. Costs to the government and to the patient 
(including family/carers) are reported separately. Costs are measured in real 
prices for the reference year (2000). Where necessary, the AIHW health 
sector deflators [23] are used to adjust prices to the reference year. Unit costs 
for doctor visits (GP, paediatrician and psychiatrists) and drugs are obtained 
from the Australian Department of Health and Ageing. For doctor visits 
costs to government (i.e. average benefit paid) and to patient (i.e. average 
difference between fee charged and benefit paid) are calculated from 
Medicare services that were processed in the 1999/2000 financial year. Both 
patient billed and bulk billed services are included but services provided in 
hospital are excluded, due to unreliability of the fee charged data.  For drugs, 
costs are for scripts filled under the Pharmaceutical Benefits Scheme and the 
Repatriation Pharmaceutical Benefits Scheme for the 1999/2000 financial 
year. The cost to the patient is averaged over ‘general’ and ‘concession’ 
patients and ‘safety net’ and ‘non safety net’ patients, in proportion to the 
number of prescriptions for each item (i.e. brand, form and quantity of the 
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drug) within a class. Cost per script is converted to an average cost per day 
for each quantity and form using the recommended dose per day. When 
costing a class of drugs we weight the cost by current usage of the individual 
brands, rather than using the cheapest brand in the class. 
INCREMENTAL COST-EFFECTIVENESS 
The cost-effectiveness ratio is determined as the incremental cost of the 
intervention divided by the incremental benefit and presented as cost (A$) 
per DALY saved. The incremental cost is defined as the cost of the 
intervention minus the cost of current practice. Likewise, the incremental 
benefit is the benefit of the intervention minus the benefit associated with 
current practice. 
UNCERTAINTY ANALYSIS 
Simulation-modelling techniques (with Monte Carlo sampling) using @Risk 
software [24] are used to allow the presentation of an uncertainty range 
around the benefits, costs, and cost-effectiveness ratios. This approach is 
recommended by the Canadian Coordinating Office for Health Technology 
Assessment [25] and also mentioned as one of a number of methods of 
exploring uncertainty in the 1996 US Consensus Panel on Cost-Effectiveness 
in Health and Medicine [1].    
The probability distributions around the input variables are based on 
standard errors quoted in, or calculated from, the literature; the range of 
parameter values quoted in, or calculated from, the literature; and from 
expert advice on the likely scenarios under Australian conditions. In addition 
to the uncertainty range, the @RISK analysis can show the input parameters 
with the greatest influence on the final results and hence is an indication of 
research priorities if greater accuracy of results is desired   
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STRENGTHS AND LIMITATIONS OF THE METHODS 
Strengths of ACE–MH include the use of a common economic protocol to 
ensure comparability of the results; extensive uncertainty testing; 
interpretation of cost-effectiveness ratios within a broader decision-making 
framework that includes consideration of second filter criteria; and use of 
Australian data for demography, health system costs and offsets, disease 
incidence/prevalence, risk factors, and disease burden.   
The main limitation in ACE–MH methods is the measurement of the 
health benefit due to the intervention. The measurement of the effect size is 
based on accepted methods and uses the best study design for measuring 
efficacy, that is systematic reviews of randomised controlled trials [13] 
(Table 4). However adjustment needs to be made to transfer trial results into 
real-life settings (effectiveness) where results may vary due to the 
motivation of clinicians and patients, the availability of skilled clinicians and 
the capacity to vary the intervention to suit the needs of the patient, among 
other things. We attempt to take these factors into account using the 
adherence rate. However, this may not explain all of the variation likely to 
be seen in real-life practise, nor does it fully address the issue of 
generalisability of trial results, which are often conducted in a very selected 
patient group.   
Translation of the effect size into a change in the DALY disability 
weight is another key issue. This required the use of new methods – the 
‘conversion factor method’ and ‘survey severity method’ – each of which 
has its own strengths and limitations. The advantage of the ‘conversion 
factor method’ is that it allows measurement of health gain in a comparable 
manner for most mental disorders. The disadvantages of the method are that: 
the health state descriptions of severity states for psychosis were less 
formally derived than those for depression and anxiety; there is no DW 
conversion factor for attention deficit hyperactivity disorder (ADHD); and it 
cannot be used when outcomes from the trials are primarily dichotomous.    
Like the ‘conversion factor method’, the ‘survey severity method’ also 
has the advantage of allowing measurement of health benefits in a 
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comparable manner for most mental disorders. An important advantage is 
that it allows dichotomous outcome data to be incorporated when only data 
on relapse are available. This is done by calculating the odds ratio or relative 
risk of relapse and converting it to a risk difference [26], which is then used 
to change the proportions in each of two or more severity states. The 
disadvantages of the method are that: for most disorders only three or four 
severity states are specified by Dutch disability weights (this reduces the 
precision of continuous measurements of impact, although applying the 
effect size to a large number of survey respondents to some degree ‘evens 
out’ the discontinuous steps); and it relies on the accuracy of the survey 
instruments for measuring severity, such as the SF-12, DIP-DIS [27] (for 
schizophrenia) and Child Health Questionnaire. Both methods have the 
disadvantage that they do not allow measurement of the impact of side 
effects, which is particularly important for drug interventions for psychosis.   
ACE–MH was also limited by the lack of health-related quality of life 
outcome data from trials and the availability of only two to four DALY 
disability weights, which coarsely describe severity for each mental disorder. 
Future work would be enhanced by the use, in trials, of a combination of 
utility-based economic instruments that facilitate comparisons across quite 
different interventions and disorders (a multi-attribute utility instrument) and 
which are sensitive to small changes (a disease-specific instrument) [28]. 
The accuracy of translating change in severity into DALY units would 
benefit from having disability weights specified for a greater number of 
different health states within each disorder the valuation study from which 
the DALY ‘conversion factor’ by severity level is derived for mental 
disorders [19] would need to be replicated to increase confidence in its 
validity. 
The limitation in the methods for translating an effect size into a 
change in the DALY disability weight mainly influences comparisons of 
interventions across disorders. However, it is important to note that the main 
driver of cost-effectiveness ratios is the effect size. Further, the effect sizes 
for different interventions for a particular disorder are comparable as the 
 102
CHAPTER 4 
 
outcome measures are consistent. Thus, comparisons of cost-effectiveness 
ratios within disorders are more valid than across disorders.   
CONCLUSIONS 
Despite the limitations in methods the ACE–MH study is providing useful 
information for policy-makers. To our knowledge there have been no similar 
attempts at determining cost-effectiveness of interventions across a wide 
range of mental health interventions in a comparable manner. Despite 
considerable uncertainty around key input variables, clear distinctions in 
cost-effectiveness between mental health interventions (particularly within 
disorders) are apparent. Nevertheless, until there is greater consensus on how 
to quantify health benefits in mental disorders our estimates should be 
considered provisional, though indicative of the relative magnitude of the 
health gain.  Results of the study will be published in upcoming papers in 
this and other journals. We hope the publication of our results will both 
encourage debate about future directions for mental health policy, and 
encourage further research to clarify those issues where current knowledge is 
lacking.   
 
CAVEAT 
The ACE-Mental Health project was jointly funded by the Australian 
Department of Health and Ageing, Mental Health and Suicide Prevention 
Branch and the Department of Human Services, Mental Health Branch, 
Victoria in recognition of the importance of research into the cost-
effectiveness of interventions in mental health treatment and care. This work 
draws upon, but is also limited by the available research and the assumptions 
necessary to complete the work. 
The results of the analyses provide valuable material, likely to 
contribute to future policy deliberations by all service providers. 
Conclusions drawn from the economic evaluations should be considered 
within the context of the second stage filter process, which qualifies the 
results taking into account issues of equity, feasibility, strength of evidence, 
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and acceptability to stakeholders. This second stage filter process addresses 
some of the practical considerations required for changes in actual service 
practice. 
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APPENDIX 
Application of the Survey Severity Method to schizophrenia 
The Low Prevalence Component of the NSMHW [10] did not use a general 
measure of quality of life with comparable psychometric validity as the SF-
12 or Child Health Questionnaire that were used for depression and anxiety.  
However, Gureje et al. [27] proposed a severity measure in the survey 
combining six DIP-DIS questions – a scale which attempts to capture overall 
functioning in the previous year in the areas of socialising, social 
withdrawal, intimate relationships, self-care, interest & information, 
participation in household activities, perceived deterioration in interpersonal 
relationships – and two questions on satisfaction with own independence and 
life as a whole. The scores on this measure range from 0 (‘well’) to 16 (‘very 
poor’).   
This summary DIP-DIS score discriminates – and in the right 
direction – between four categories describing the course of the disorder in 
the respondents in the survey (Table A). The distribution of DIP-DIS scores 
is skewed to the right with the largest concentration in the scores of 0–5. 
After log-transformation of the DIP-DIS score the higher values are 
normally distributed but not the lower values. The Dutch DWs for 
schizophrenia are for the full course of the disorder and as such are not 
suited to measure change in severity over time (or due to an intervention). 
However, we assume that the 0.98 weight for ‘several psychotic episodes, 
severe and increasing permanent impairments’ reflects the most severe state 
in schizophrenia and that the 0.21 weight for “one psychotic episode, no 
permanent impairments” is the best possible health state in schizophrenia. 
We then assume that the 0.21 weight corresponds with a score of 0 on the 
DIP-DIS and the 0.98 with a DIP-DIS score of 16 and that the DW changes 
linearly with a change in DIP-DIS score. This allows us to calculate a DW 
for each individual in the survey and to calculate mean values for different 
subgroups. Table A shows the mean DW by the variable course of disorder 
in the survey. 
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The calculated DWs distinguish between interviewer-rated course of 
the disorder categories, albeit that the difference between the least and most 
severe categories is only 0.15. It is not clear if this is due to a weakness in 
the DIP-DIS score or an insensitive rating on course of disorder. The effect 
size is then applied to the SD of the DIP-DIS score (with a preference for 
using the log transformed score as it approximates a normal distribution for 
most of the DIP-DIS score values). An effect size of 1 translates into a DW 
change of 0.113.  
 
Table A.  Mean DIP-DIS score for Schizophrenia and calculated DW by 
course of disorder 
 
Course of disorder N Mean DIP-DIS score
 (95% CI) * 
Mean DW 
(95% CI)  
Multiple episodes, good recovery † 222 2.3 (2.0, 2.6) 0.32 (0.31, 0.33) 
Multiple episodes, partial recovery 224 3.4 (3.1, 3.8) 0.38 (0.36, 0.39) 
Chronic, little deterioration 237 3.7 (3.4, 4.1) 0.39 (0.37, 0.41) 
Chronic, clear deterioration 283 5.4 (5.0, 5.8) 0.47 (0.45, 0.49) 
Total 966 3.8 (3.6, 4.0) 0.39 (0.38, 0.40) 
* Calculated from the Low Prevalence Component of the NSMHW [10] 
† Also includes single episodes, good or unknown recovery 
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ABSTRACT 
Background: Major depression is the largest single cause of non-fatal 
disease burden in Australia. Effective drug and psychological treatments 
exist, yet are underutilised. 
Objective: To quantify the burden of disease currently averted in people 
seeking care for major depression and the amount of disease burden that 
could be averted in these people under optimal episodic and maintenance 
treatment strategies. 
Design: Modelling impact of current and optimal treatment strategies based 
on secondary analysis of mental health survey data, studies of the natural 
history of major depression and meta-analyses of effectiveness data. Monte 
Carlo simulation of uncertainty in the model. 
Setting: The cohort of Australian Adults experiencing an episode of major 
depression in 2000 are modelled through ‘what if’ scenarios of no treatment, 
current treatment and optimal treatment strategies with cognitive behavioural 
therapy or anti-depressant drug treatment. 
Main outcome measure: Disability-Adjusted Life Year 
Results: Current episodic treatment averts 9% (95% uncertainty interval 6%-
12%) of the disease burden of major depression in Australian adults. 
Optimal episodic treatment with cognitive behavioural therapy could avert 
28% (19%-39%) of this disease burden and with drugs 24% (19%-30%) 
could be averted. Over five years following an episode of major depression, 
current episodic treatment patterns would avert 13% (10%-17%) of DALYs 
while maintenance drug treatment could avert 50% (40%-60%) and 
maintenance cognitive behavioural therapy could avert 52% (42%-64%) 
even if adherence of around 60% is taken into account. 
Conclusions: Longer-term maintenance drug or psychological treatment 
strategies are required to make significant inroads into the large disease 
burden associated with major depression in the Australian population.  
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INTRODUCTION 
As in other industrialised countries, depression is the commonest mental 
disorder in Australia [1]. It is the largest single cause of disability 
responsible for 6.2% and 9.8% of Years Lived with Disability, in men and 
women, respectively. It is the third largest cause of disease burden in 
Disability-Adjusted Life Years (DALY) in women and ranked eighth in men 
[2]. Treatment guidelines recommend antidepressant (AD) drugs and/or a 
specific, effective psychological therapy for major depressive disorder [3, 4]. 
Cognitive-Behavioural Therapy (CBT) and interpersonal therapy are the 
psychological treatments that have the best-documented efficacy [4]. 
However, only 59% of respondents identified with major depression in the 
1997 National Survey of Mental Health and Wellbeing (NSMHWB) had 
sought any help for their problem and 35% reported consulting a relevant 
health professional and receiving medication or psychological treatment [1].  
The high burden of depression and the poor utilisation of efficacious 
treatments mean that there is considerable potential for health gain. A 
previous analysis quantified the cost-effectiveness of an ideal mix of 
interventions for affective disorders in Australia and concluded that 
evidence-based health care is supported on grounds of efficacy as well as 
cost-effectiveness [5]. However, it did not report the scope of health gain as 
a proportion of the overall disease burden of major depression that can be 
achieved by offering effective treatment to all people with depression who 
seek care from health services. Further limitations were that no separate 
conclusion could be made about the impact of different treatment options 
and that by limiting analyses to a one-year period the impact of long-term 
treatment strategies could not be evaluated. This paper quantifies the impact 
of treatment strategies on the disease burden due to major depression. In 
particular, it answers the following questions: (1) what is the proportion of 
the depression burden averted by current treatment; (2) what is the potential 
of episodic drug and psychological treatment options to further reduce this 
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burden; and (3) what is the potential of longer-term maintenance drug and 
psychological treatment options to further reduce this burden?  
METHODS 
The impact of evidence-based psychological and drug treatment strategies is 
modelled as a change in DALY. Separate estimates are presented for short-
term treatments directed at episodes including a short continuation phase and 
longer-term maintenance treatments over five years of follow-up.  Data are 
derived from existing surveys and routine health information collection 
systems in Australia as well as findings on the epidemiology of depression 
and its treatments in the international literature. The analysis starts with a 
description of the epidemiology of depression and current health service 
utilisation patterns in Australia. The next step is an evaluation of the impact 
of effective treatments by translating outcome measures from meta-analyses 
of trials into a change in DALY. The main comparisons are between the 
amount of depression experienced under current and expanded treatment 
options versus the hypothetical disease burden in the absence of treatment.  
Our analysis applies to Australian adults who experienced an episode of 
major depression in the year 2000 and sought care from health services. 
Epidemiology of depression 
We derive parameters on the prevalence of major depression and treatment 
patterns from the 1997 National Survey of Mental Health and Wellbeing 
(NSMHWB) [1] and apply these to 2000 population figures. The main 
outcome of the survey was the one-year prevalence, i.e. people qualifying 
for a diagnosis of major depression in the twelve months prior to survey. An 
additional question on the recency of symptoms allows identification of 
respondents who are currently prevalent, i.e. having had symptoms in the 
last two weeks, the minimum duration of an episode. Of the survey 
respondents identified as having major depression as defined by the 
International Classification of Diseases, 10th Revision (ICD–10) [6], 58.9% 
had consulted a psychologist, psychiatrist and/or general practitioner for a 
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mental health problem while 35.1% fulfilled our criteria for potentially 
having received evidence based treatment (EBM): consulting at least three 
times and having had medication and/or CBT (“learning how to change 
thoughts, behaviours and emotions”) [5].  
We grade the severity of prevalent cases of depression from the 
NSMHWB by the number of standard deviations from the mean Mental 
Component Score of the 12-item Short-Form Health Survey (SF-12) [7] into 
normal (45+) mild (35–44.9), moderate (25–34.9) and severe (<25). 
Disability weights (DW) for mild (0.14), moderate (0.35) and severe (0.76) 
depression which were used in the Australian Burden of Disease Study [2] 
and derived from a Dutch study [8] are assumed to apply to these categories.  
Natural history 
Next, we use data from international follow-up studies on the natural history 
of major depression to mathematically describe the variation in duration of 
episodes and time to next episode. While there are many naturalistic studies 
of the duration of MDD episodes in clinical samples, there are few follow-up 
studies of MDD in community samples [9-13]. The four US studies show a 
similar pattern of recovery over time after the start of an episode. The 
median time to recovery in the four studies ranged from 8 to 12 weeks while 
at one year between 3 and 11% of cases had not yet recovered. The Kendler 
figures [10] have been adjusted for the 7% of excluded cases with onset 
more than 1 year prior to study. The fifth study from the Netherlands [11] 
reports a considerably longer duration of episodes. Inclusion of sub-
syndromal depression and dysthymia in life chart histories is a possible 
explanation for this higher estimate. From the data reported in the US studies 
[9, 10, 12, 13] we fit a lognormal distribution [14] that has the lowest sum of 
squared differences between modelled and observed time to recovery 
starting from a minimum duration of 2 weeks specified in the definition of 
an episode of major depression (Figure 1).  
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Figure 1.   Time to recovery in episodes of major depression from four 
community samples [9, 10, 12, 13]. 
 
Major depression is a chronic episodic disorder and hence for our 
modelling purposes, it is important to describe the pattern of time to a next 
episode following a previous episode. Over a few decades of follow-up 
major depression is reported as a recurrent disorder in 80% of cases [15]. We 
assume that over a lifetime at least 90% of cases experiences a recurrence. 
Six naturalistic follow-up studies [16-21] report on the risk of relapse during 
periods varying between six months and two years after cessation of drug 
treatment for an acute episode of major depression. We fit lognormal and 
Weibull [22] distributions that give the best fit as determined by the lowest 
sum of squared differences between modelled and observed data points 
(Figure 2). We decide to use the lognormal distribution as it gives a slightly 
better fit. In a Monte Carlo simulation model we use the lognormal 
distributions describing the length of episodes and the time between episodes 
to estimate the mean number of episodes and the mean time depressed over a 
six-month and a five-year period following an episode.  
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Figure 2.   Weibull and Lognormal distributions fitted to time to relapse 
after an episode of major depression from six naturalistic 
follow-up studies [16-21]. 
 
Impact of interventions 
We separately evaluate drug treatment for episodes of major depression plus 
a continuation phase after remission of symptoms and maintenance treatment 
of five years following remission of an episode; CBT treatment of major 
depressive episodes; and a maintenance variant of CBT with booster 
sessions over a period of five years. 
A meta-analysis reporting on 48 trials estimated an effect size (ES) of 
0.55 (95%CI 0.40-0.70) for selective serotonin re-uptake inhibitors (SSRIs) 
over placebo [23]. No differences were found between four different SSRIs. 
Meta-analyses examining the efficacy of SSRIs and tricyclic anti-
depressants (TCAs) consistently show no significant differences between the 
two drug classes [23-26]. Therefore, we assume the same efficacy for all 
anti-depressants.  
From the figures presented in a recent meta-analysis [27] of the odds 
ratios of relapse in 26 maintenance drug studies and 7 continuation drug 
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studies we derive a pooled relative risk (RR) of 0.416 (0.312 - 0.555) for 
relapse with continuation AD drug treatment and 0.437 (0.394 - 0.485) for 
maintenance AD drug treatment. 
A meta-analysis of cognitive therapy reports a pooled ES of 0.82 from 
48 studies [28]. On closer inspection, several studies included in this 
systematic review do not fit the stated inclusion criteria. Our own meta-
analysis of CBT interventions including many of the same studies as well as 
a few additional studies, gives a random effects ES of 0.77 (0.44-1.10) close 
to the Gloaguen point estimate but with wider confidence intervals. We use 
these figures in our main analyses. Excluding two outlier studies (by the 
same author) with particularly high ES estimates reduces the Q statistic for 
heterogeneity from 50.8 (df=16, P<0.001) to 22.3 (df=13, P=0.051). In a 
separate sensitivity analysis we recalculate the model using the ES (0.54; 
0.29-0.79) calculated after excluding these two outliers. 
While the effect of AD drugs ceases when treatment is stopped, there 
is evidence for a prolonged effect of CBT beyond the treatment period. From 
a review of naturalistic longer-term follow-up studies (ranging from 1.5 to 4 
years) after RCTs[17, 20, 29-31] that were set up to compare CBT with ADs 
in the acute phase we calculate a lower risk of relapse following CBT (RR 
0.64; 95% CI 0.51–0.79).  
Maintenance CBT is described in two trials. The first compares CBT 
maintenance with AD drug maintenance and over one year follow-up found 
no difference in relapse [32]. The other reports on a trial of maintenance 
CBT following acute CBT [21]. At two year follow-up the groups who had 
maintenance CBT had 25% relapse (5/20) compared to 80% (16/20) in the 
group getting case management only after CBT (AD drugs were tapered off 
and discontinued in both groups). The scanty evidence from these two trials 
suggests similar impact of maintenance strategies with AD drugs or CBT. 
Adherence  
Several meta-analyses with a large overlap in the included studies report 
discontinuation rates of between 27% and 39% with 3-6% lower rates for 
SSRIs in comparison to TCAs [23, 24, 26, 33]. However, as most trials are 
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of short duration representing what is possible with motivated patients and 
doctors, adherence rates may be lower than reported in the controlled trial 
literature. Adherence in four studies of primary care ranges from 50 to 66% 
[34-37]. We decide to model drug adherence ranging uniformly between the 
recorded adherence level in trials and an estimated lower level of 50% 
adherence in community settings. 
We have found one community study of the attrition rate of CBT for 
depression where volunteers were recruited via the local media for a 12-
week course of CBT. Total dropouts were 47% with almost half of those 
dropping out in the first three weeks [38]. As with AD drugs, we model 
adherence ranging between the estimate reported in trials (81%) [39] and a 
lower estimate of 50% in community settings.  
Translating treatment impact in DALYs 
The health benefit of interventions is measured in DALYs which is the sum 
of a non-fatal component (YLD) determined by the severity-weighted time 
lived with depression and a fatal component, Years of Life Lost (YLL), 
calculated as the stream of life lost due to suicide.  
As described elsewhere [40], we use two methods  to translate effect 
sizes from trial literature into a reduction in the DW. Briefly, the first 
method relies on an estimate of DW change for each standard deviation 
change in severity of depression which we call the conversion factor [41]. As 
the effect size quantifies the impact of an intervention in SD units, health 
gain in DALY units can be calculated as the product of the effect size, the 
conversion factor and the duration spent in the health state. The second 
(survey severity) method applies the effect size to the MCS of the SF-12 
across eligible respondents in the mental health survey after which the 
difference in average DW with and without treatment is calculated. Results 
from both methods are incorporated in our uncertainty analyses and hence 
broaden the uncertainty ranges around the results presented. 
Reductions in the DW are only applied to the time from the 
commencement of the intervention i.e. taking into account that there is a lag 
to treatment seeking after onset of symptoms. A UK study found a median 
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10-week interval between onset and seeking care for patients with an 
affective disorder [42]. We cannot assume a similar lag as the proportion of 
cases with a duration shorter than 10 weeks in a community sample is 
greater than the total proportion not seeking care in NSMHWB. Instead, 
based on expert consultation we decide to model a lag varying between 2 
and 6 weeks.  
As ESs are calculated from continuous measures and are not 
calculated on an intention-to-treat basis we apply the full non-adherence rate 
as a reduction in impact. For cases not adherent with treatment no reduction 
in DW is modelled.  
From the point prevalence of depression in the NSMHWB, a UK 
estimate of the RR for suicide of 20.4 [43] and observed suicide deaths in 
Australia in 2000, we derive suicide deaths attributable to depression by age 
and sex. We assume a RR of 1.8 from Swedish routine data collection 
systems [44] applies to time lived with depression while not effectively on 
AD drugs. In the absence of long-term studies, we assume that suicide rates 
are similar in patients on CBT as in those on AD drugs.  
From these estimates we derive suicide rates in those currently on 
effective treatment and those ineffectively treated. As in the Australian 
Burden of Disease Study, the YLL associated with a death are calculated as 
the cohort life expectancy for each age and sex category. We then divide the 
sum of YLL for suicide in treated and untreated depression by the person-
years of depression in 2000.  
The size of the burden averted by current treatment strategies requires 
a back-calculation of the burden if no treatment were given. This is done by 
applying the ES estimates for CBT and AD drugs to the mean disability 
weight of respondents in the NSMHWB on these treatments taking into 
account the estimated lag to treatment and level of adherence.  
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Table 1.   Model input parameter values and sources of information  
Parameter Value (uncertainty 
range) 
Source 
RR suicide in prevalent 
depression 
triangular distribution  
(18.2, 20.4, 22.6) 
[43] 
RR suicide on treatment vs. not 
on treatment 
triangular distribution  
(1.6, 1.8, 2.0) 
[44] 
Effect size AD drugs 
 
 CBT 
triangular distribution  
(0.4, 0.55, 0.7)  
triangular distribution  
(0.44, 0.77, 1.10) 
[23] 
 
Own meta-analysis  
RR relapse during 6 months 
continuation AD drug treatment 
triangular distribution 
(0.312, 0.416, 0.555) 
Own meta-analysis of 7 
studies reported in [27] 
RR relapse maintenance 
treatment 
triangular distribution 
(0.394, 0.437, 0.485) 
Own meta-analysis of 
placebo arms of trials 
evaluated in [27] 
RR relapse in 18 months 
following CBT 
triangular distribution 
(0.514, 0. 636, 0. 787) 
Own meta-analysis of 
follow-up studies after 
CBT  
Average duration episodes 29.9 weeks (0.57 years) Based on fitted 
lognormal distribution 
(µ2.0, σ1.6) and two 
weeks minimum 
duration 
Time depressed: 
 6 months following episode 
 5 years following episode 
Average number of episodes 
over 5 years following episode 
 
19.5% 
20.8% 
2.4 
Based on fitted 
lognormal (µ2.4, σ3.9) 
distribution of time to 
next episode and fitted 
lognormal distribution 
of duration of episodes 
Disability weight conversion 
factor 
uniform distribution  
(0.139–0.172) 
[41] 
Adherence with  AD drugs 
 CBT 
50% – 73%  
50% – 81%  
Upper values from [24] 
and [39] 
Lag to treatment uniform distribution  
(2–6) 
Reduced from 10 week 
estimate by [42]   
Proportion of cases seeking care 
  
triangular distribution 
(0.541, 0. 589, 0. 637) 
Mental health survey 
[1] 
Proportion of cases on evidence-
based treatments   
59.5% of those seeking 
care 
Mental health survey 
[1] 
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Uncertainty 
We use simulation-modelling techniques and present uncertainty ranges 
instead of point estimates that reflect all the main sources of uncertainty in 
the calculations. Details of the parameters and distributions for the 
uncertainty assumptions are shown in Table 1. The probability distributions 
around the input variables are based on (1) standard errors quoted in, or 
calculated from, the literature; (2) a range of parameter values quoted in, or 
calculated from, the literature; or (3) expert advice.  We use the @RISK 
software (Palisade Corporation, Newfield, NY), which allows multiple 
recalculations of a spreadsheet each time choosing a value from uncertainty 
distributions defined for input variables. We run a Monte-Carlo simulation 
and calculate 95% uncertainty ranges for our output variables (bounded by 
the 2.5 and 97.5 percentiles of the 4000 values generated).  
To identify the main sources of uncertainty affecting our results we 
regress the values of each of the input variables against results in each of the 
iterations of our simulation modelling. We report on input variables with a 
regression coefficient greater than 0.2 or less than –0.2. All results are 
presented to 2 significant digits only. 
RESULTS 
The fitted lognormal distribution for the duration of episodes (corresponding 
to a normal distribution with a mean of 2.049 and SD of 1.599) has a mean 
of 27.9 weeks resulting in an average duration of episodes of 29.9 weeks 
after adding the minimum 2 weeks of duration. In combination with the 
fitted lognormal distribution of time to next episode (corresponding to a 
normal distribution with a mean of 2.353 and SD of 3.876) the modelled 
mean number of episodes during five years of follow-up after an episode is 
2.4 and the mean time spent in major depression is 20.8%. The mean time 
spent with depression in six months following an episode is 19.5%. 
The mean DW for mental health survey respondents on evidence-
based treatment (0.429), those consulting but not receiving evidence-based 
treatment (0.364) and those not consulting (0.282) indicate that those with 
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more severe disease are more likely to seek care and to be offered potentially 
effective treatments. We attribute a reduction in DW from 0.490 (the 
hypothetical level of severity without treatment) to 0.429 to current 
treatment strategies. 
In the year 2000, we estimate that 555 male and 198 female suicide 
deaths are attributable to major depression in Australia (or 30% of all 
suicides). Per person-year lived with major depression the suicide risk is 
0.8% in males and 0.3% in females. For both sexes combined, the risk of 
suicide in those on medication or CBT is 0.26% and in those not treated 
0.47%. This translates on average across all ages into an annual loss of 0.093 
YLL if treated and 0.167 YLL without treatment, i.e. a net health gain of 
0.074 YLL that we attribute to treatment per year lived with depression. 
During the first year following onset of an episode of major 
depression, current treatment strategies avert 10% (95% uncertainty interval 
6%-12%) of the burden experienced by those in contact with health services. 
Treatment during the episode with an additional 6 months continuation 
treatment can raise this proportion to 28% (95% uncertainty interval 19%-
39%) with CBT and 24% (95% uncertainty interval 19%-30%) with AD 
drugs (Figure 3a).  
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Figure 3.   Proportion of time in depression averted (95% uncertainty 
interval) for episodic (a) and maintenance (b) treatment 
strategies in those in contact with health services 
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If all those seeking care for an episode are offered five years of 
maintenance treatment 52% (95% uncertainty interval 42%-64%) of the 
burden can be averted with CBT and 50% (95% uncertainty interval 40%-
60%) with AD drugs compared to 13% (95% uncertainty interval 10%-17%) 
under a scenario in which episodic treatment continues (Figure 3b).  
The results for CBT are not very sensitive to the choice of ES for CBT 
(0.54 vs 0.77). The lower ES estimates brings the estimates of burden 
averted by CBT down by less than 2 percentage points. Similarly, the 
proportion of burden averted by AD drugs is only modestly sensitive to the 
assumed effect size. Altering the effect size for AD drugs by 25% alters 
results by 3 percentage points for episodic treatment and less than one 
percentage point for maintenance treatment. 
The main sources of uncertainty in the model are the assumed 
treatment discontinuation rates; the method of calculating a reduction in 
DW; and, to a lesser extent, the ESs. Prevention of suicide contributes to 
almost a third of the amount of health gain in DALYs for each of the 4 
intervention scenarios in comparison to no treatment. In the episodic 
treatment scenarios reduction in severity is the main impact of treatments 
while in maintenance treatment the impact on preventing relapse contributes 
more to overall health gain than reduction of severity while depressed (Table 
2). 
 
Table 2.   Proportion of health gain attributed to reduced severity, relapse 
prevention and suicide prevention due to episodic or maintenance 
treatments with AD drugs or CBT 
 Prevention of 
relapse 
Reduced severity 
while in episode 
Prevention of 
suicide 
AD drugs in acute episode 
& 6 months continuation 24% 46% 31% 
CBT including impact on 
relapse over one year period 18% 53% 29% 
Maintenance AD drugs 43% 28% 30% 
Maintenance CBT 39% 33% 28% 
 123 
CHAPTER 5 
 
COMMENT 
Our results strongly support longer-term treatment strategies for depression. 
Despite assuming rates of adherence to treatment of around 60% we estimate 
that half of depression experienced in five years following an episode of 
major depression can be averted. The main reason for this favourable 
outcome is that maintenance treatment prevents relapses and that relapses 
that do occur are being treated from the start rather than being implemented 
after a lag time to seeking appropriate care. As the vast majority of people 
with depression experience multiple episodes over a lifetime and are 
particularly prone to relapses shortly after an index episode there are 
convincing arguments to treat all depression as a chronic disorder and not 
just those presenting with recurrent or more severe episodes as 
recommended in current treatment guidelines [3, 4].  
We have made a conscious choice to simplify our modelling by using 
averages, e.g. for severity of episodes, the duration of the index episode and 
by modelling all ages and both sexes together. Some of these decisions do 
not do justice to the great complexity and variation in the presentation of 
depression. However, each added complexity requires more epidemiological 
input data with associated uncertainty and is limited by the lack of efficacy 
data for different durations, severities, gender and age. We believe we have 
struck a reasonable balance. The model takes enough of the complexities 
into account but still is simple enough for others to scrutinise and apply in 
other situations. 
Elsewhere, we discuss the difficulties we encountered in translating 
trial findings into a health benefit in DALY terms [40]. To some extent we 
were able to incorporate this into our uncertainty analysis by using the range 
of results between two different methods of determining health benefit. The 
difference in burden averted between current practice and alternative 
treatment options is less affected as the same imperfect method is used for 
each treatment scenario. More accurate measurements of change in health 
status that can be attributed to interventions requires further developmental 
 124 
CHAPTER 5 
 
work such as the use of general quality of life outcome measures in trials and 
more sensitive disability weights in DALY.  
Our analyses are enhanced by the use of local epidemiological 
information. We had to rely on the 1997 National Survey of Mental Health 
and Wellbeing as the only and most recent source for much of the 
epidemiology of depression in Australia. Regular updates of the survey are 
needed to sustain this kind of analysis in the future. As this has been the only 
community prevalence study in Australia we are unable to incorporate 
temporal trends in the occurrence of depression. However, the time horizon 
over which we calculate our results is 5 years at most and hence, results are 
not much affected by the assumption of stable incidence of major depressive 
episodes. It would be very useful if a future survey identifying people with 
depression in the community endeavoured to follow-up people over time to 
examine if our modelled assumptions of duration, time to next episode and 
proportion of time with depression can be replicated in the Australian 
context.  
The studies from which we derived our mathematical descriptions of 
the average duration of episodes and time to next episode are few and of 
relatively small size. Our 20% estimate of the average time with major 
depression over five years of follow-up is higher than that from a clinical 
study in the US which found that 15% of time was spent with depressive 
symptoms at the level of major depression over nine years of follow-up [45]. 
Our results are rather insensitive to this finding as the treatment impact 
measures applied to a 15% or 20% amount of depression over follow-up 
gives similar estimates of the proportion of depression burden averted.  
We have limited our analyses to major depression ignoring that over follow-
up time many people will spend time with sub-syndromal symptoms or 
dysthymia [45]. Assuming treatments are also effective for these types of 
depression this means that we have underestimated the true impact of 
treatments. 
The measures of efficacy of maintenance treatment strategies are 
derived from studies of people who responded to treatment during an 
episode and hence it is not evident that this would apply equally to all people 
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with depression as we have modelled. However, our results are not very 
sensitive to the estimates of ES for AD drugs or CBT and hence our 
conclusions would not alter even if the effectiveness of treatment in primary 
care cases is estimated to be as much as 25% higher or lower. The 
information we used from two European studies [43, 44] to determine the 
risk of suicide is not so strong.  However, the inclusion of YLL from suicide 
in the analyses is important because it constitutes almost a third of the 
overall health benefits. Our Australian estimates of suicide are high in 
comparison to a US estimate of suicide risk in people followed up after a 
diagnosis of depression [46]. However, if we take into account that suicide 
rates in young adults are 30% higher in Australia (based on analysis of 
deaths reported to WHO; available at http://www3.who.int/whosis/mort) and 
that we estimated risk of suicide only while depressed and not for all follow-
up time, our estimates are only marginally higher (by 12% in males and 20% 
in females) than the US estimates. 
Despite the limitations associated with lack of data on the course of 
depression and the impact of treatments, our results suggest that only by 
treating depression as a chronic episodic disorder with longer-term treatment 
strategies is it possible to make a meaningful reduction in the large burden of 
depression in Australia. Similarities in community survey findings on the 
epidemiology of major depression in the US [47, 48] and Australia [1] and 
the predominantly US studies on the impact of treatments used in our model, 
make it likely that our results also have relevance to depression in the US.  
Psychological and drug treatments have similar impact on reducing 
the depression burden giving clinicians a choice of treatments. Additional 
information on cost-effectiveness is needed to complement these results in 
informing priority setting. 
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ABSTRACT 
Objective:  Antidepressant drugs and cognitive–behavioural therapy (CBT) 
are effective treatment options for depression and recommended by clinical 
practice guidelines. As part of the Assessing Cost-Effectiveness (ACE)–
Mental Health project we evaluate the available evidence on costs and 
benefits of CBT and drugs in the episodic and maintenance treatment of 
major depression.  
Method: The cost-effectiveness is modelled from a health care perspective 
as the cost per disability-adjusted life year. Interventions are targeted at 
people with major depression who currently seek care but receive non 
evidence-based treatment. Uncertainty in model inputs is tested using Monte 
Carlo simulation methods. 
Results: All interventions for major depression examined have a favourable 
incremental cost-effectiveness ratio under Australian health service 
conditions. Bibliotherapy, group CBT, individual CBT by a psychologist on 
a public salary and tricyclic antidepressants (TCAs) are very cost-effective 
treatment options falling below A$10,000 per disability-adjusted life year 
(DALY) even when taking the upper limit of the uncertainty interval into 
account. Maintenance treatment with selective serotonin re-uptake inhibitors 
(SSRIs) is the most expensive option (ranging from A$17,000 to A$20,000 
per DALY) but still well below A$50,000 considered the affordable 
threshold. 
Conclusions: A range of cost-effective interventions for episodes of major 
depression exists and is currently under-utilised. Maintenance treatment 
strategies are required to significantly reduce the burden of depression but 
the cost of long-term drug treatment for the large number of depressed 
people is high if SSRIs are the drug of choice. Key policy issues with 
regards to expanded provision of CBT concern the availability of suitably 
trained providers and the funding mechanisms for therapy in primary care.  
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INTRODUCTION 
Major depression is the commonest mental disorder in Australia [1] and 
causes more disability than any other disease [2]. Effective treatment options 
with antidepressant drugs and/or a specific, effective psychotherapy exist 
and are recommended by treatment guidelines [3, 4]. Among the 
psychotherapeutic approaches cognitive-behavioural therapy (CBT) and 
interpersonal therapy have the best-documented efficacy. In addition, there 
are self-help variants of CBT using books (“bibliotherapy”) and/or the 
Internet. However, a significant proportion of people identified with 
depression in a community survey reported not to have sought any care and 
those seeking care often did not get adequate treatment [1]. In a previous 
analysis, we have indicated that a meaningful reduction of the burden of 
depression in Australia would only take place if depression were treated as a 
chronic episodic condition requiring maintenance rather than episodic 
treatment [5]. In this paper, we present the cost-effectiveness of different 
treatment options for depression.  
There is little comparable information on the cost-effectiveness of the 
different treatment options in the literature which consists predominantly of 
drug comparison studies of tricyclic (TCAs) and newer antidepressants such 
as the selective serotonin reuptake inhibitors (SSRIs). There are a number of 
methodological problems with most of these studies and none are directly 
transferable to the Australian health care system due to differences in costs 
of these treatments.  
To overcome these shortcomings, as part of the Assessing Cost-
Effectiveness–Mental Health (ACE–MH) project and using a common 
economic protocol [6] we decided to evaluate the available evidence on costs 
and benefits of CBT and antidepressant drugs in the treatment of episodes of 
major depressive disorder and as maintenance treatment in the prevention of 
recurrence of depressive episodes.  
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METHODS 
The general methods of ACE-MH are reported elsewhere in detail [6]. In 
brief, interventions are chosen as options for change compared to current 
practice in the year 2000. Costs accruing in the Australian health sector, i.e. 
including all health service costs and patient out-of-pocket costs, are 
estimated and discounted at 3% back to year 2000 values. 
A Steering Committee of mental health experts, policy makers and 
representatives of community organisations selected the interventions for 
analysis, scrutinised the assumptions made in modelling cost-effectiveness 
and assisted in defining and applying a set of ‘second filter’ criteria (quality 
of evidence, equity, feasibility and acceptability to stakeholders) which 
potentially can influence conclusions drawn based only on cost-effectiveness 
considerations. The selected interventions for adult depression include:  
1. drug treatment with TCAs for acute major depressive episodes plus a 
six month continuation phase after remission of symptoms; 
2. drug treatment with SSRIs (including other ‘new’ drugs such as 
venlafaxine, nefazodone and mianserin)  for acute episodes and six 
months continuation; 
3. CBT treatment of acute major depressive episodes consisting of 12 
sessions analysed separately whether provided by a psychologist or a 
psychiatrist in public or private service and whether provided to 
individuals or in a group;  
4. bibliotherapy for acute episodes; 
5. maintenance treatment with TCAs for five years following an acute 
episode; 
6. maintenance treatment with SSRIs for five years following an acute 
episode; and 
7. a maintenance variant of CBT with booster sessions over a period of 
five years. 
We model the impact of the acute episode interventions (options 1–4) in 
Australians experiencing at least one episode of major depression in the year 
2000 (513,000) who sought care (302,000) but did not receive an evidence-
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based treatment (122,000). These estimates are based on the 1997 Survey of 
Mental Health and Well Being (SMHWB) [1]. The criterion for seeking care 
was consulting for a mental health problem with a psychologist, psychiatrist, 
GP, surgeon, social worker, mental health team worker or an admission to 
hospital. We defined evidence-based treatment as a minimum of three such 
consultations and having received medication and/or CBT. We assume that 
only 15% of patients are likely to take up bibliotherapy. We model the 
impact of maintenance interventions (options 5–7) in all people seeking care 
for depression in the year 2000 assuming maintenance treatment is not part 
of current practice.  
Health benefit 
The health benefit of each intervention is measured in DALYs including a 
non-fatal component, years lived with disability (YLD), determined by the 
severity-weighted time lived with depression and a smaller fatal component, 
years of life lost (YLL), calculated as the discounted stream of life lost due 
to suicide.  
Modelling health benefits requires data on the epidemiology of 
depression (duration of episodes, time to next episode and severity) and the 
impact of interventions (on severity and duration of episodes, on the risk of 
recurrent episodes and the risk of suicide while depressed). A companion 
paper focussing on the impact of treatment options on the size of the 
depression burden in Australia [5] provides detail of the methods of 
estimating health benefits summarised below  and in Table 1.  
We estimate the average duration of episodes and the proportion of 
time spent in depression following an episode from data published on 
community follow-up studies. We grade the severity of prevalent cases of 
depression from the SMHWB by the number of standard deviations (SDs) 
from the mean Mental Component Score (MCS) of the SF-12 into normal 
(>45) mild (35.1–45), moderate (25–34.9) and severe (<25) and apply 
disability weights (DW) for mild (0.14), moderate (0.35) and severe (0.76) 
depression [24] that were also used in the Australian Burden of Disease 
Study [2]. From the international literature of randomised controlled trials 
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we derive impact measures that alter the severity of depression during an 
episode or alter the duration to the next episode. The pooled effect size for 
SSRIs over placebo is 0.55 (95% CI 0.40–0.70) and no difference is reported 
between four different SSRI drugs [9]. Meta-analyses also consistently show 
no difference in efficacy between SSRIs and TCAs [21, 25, 26].  
From the published figures of a recent meta-analysis [19] we derive a 
pooled reduction in the risk of relapse for continuation and maintenance 
antidepressant drug treatment (Table 1). 
Table 1.  Model input parameter values and sources of information  
Parameter Value (uncertainty 
range) 
Source 
RR suicide in prevalent 
depression 
20.4 (SE 1.1) [7] 
RR suicide on treatment vs. not 
on treatment 
1.8 (SE 0.1) [8] 
Effect size antidepressant drugs 
 CBT 
 Bibliotherapy 
0.55 (SE 0.075)  
0.77 (0.44–1.10) 
0.98 (0.62–1.35) 
[9] 
Own meta-analysis  
Own meta-analysis of 8 
studies [10-18] 
RR relapse during 6 months 
continuation drug treatment 
0.416 (0.312–0.555) Own meta-analysis of 7 
studies reported in [19] 
RR relapse maintenance 
treatment 
0.437 (0.394–0.485) Own meta-analysis of 
trials evaluated in [19] 
RR relapse in 18 months 
following CBT 
0.636 (0.514–0.787) Own meta-analysis of 
follow-up studies after 
CBT  
Disability weight change per SD 
change in severity of depression 
0.139–0.172 [20] 
Adherence with  TCAs 
  SSRIs 
  CBT 
50% – 69% (SE 3.3%)
50% – 73% (SE 3.7%)
50% – 81% (SE 4.4%)
Upper values from [21] 
and [22] 
Lag to treatment 6 weeks (2 to 4 
weeks) 
Reduced from 10 week 
estimate in clinical 
sample [23] based on 
expert advice 
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Parameter Value (uncertainty 
range) 
Source 
% of cases seeking care   58.9% (SE 2.4) [1] 
% cases on evidence-based 
treatments   
59.5% of those 
seeking care 
[1] 
 
Types of antidepressant drugs  
  SSRIs 
  TCAs 
  MAO-
inhibitors 
  Other  
 
77% (SE 0.9%) 
15% (SE 0.7%) 
  6% (SE 0.5%) 
  2% (SE 0.3%) 
 
BEACH 
- Group CBT sessions per day 
- Participants group CBT 
- Individual CBT sessions/day 
for psychologist 
- CBT sessions per half day 
public psychiatrist 
2–3 
6–8 
5–7 
 
2–4 
Assumptions based on 
expert advice 
Uncertainty fees health 
professionals not covered by 
Medicare 
±  10% Assumption; no 
uncertainty modelled 
around Medicare fees 
 
From our own update of the Gloaguen meta-analysis of cognitive 
therapy [27] we estimate a pooled effect size of 0.77 (95% CI 0.44–1.10). 
Two outlier studies by the same author determine much of the heterogeneity 
between results. Excluding these studies reduces the effect size to 0.54 (95% 
CI 0.29–0.79) We base our main results on the first estimate but test the 
sensitivity of results if using the lower estimate. Our review of naturalistic 
longer-term follow-up studies following trials comparing CBT with 
antidepressant drugs in acute episodes [28-32] indicates a prolonged effect 
during 18 months after  the treatment period. Two small trials of 
maintenance CBT suggest similar impact of maintenance strategies with 
antidepressant drugs or CBT [31, 33]. 
Adherence  
Several recent meta-analyses with a large overlap in the studies included 
report 3-6% lower discontinuation rates for SSRIs in comparison to TCAs 
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[9, 21, 25, 34]. As most trials are of short duration representing what is 
possible with motivated patients and doctors, adherence rates for SSRIs and 
TCAs may be more divergent than what has been found in the controlled 
trial literature. Four studies of primary care report patient adherence ranging 
from 50 to 66% but do not make mention of the type of antidepressant [35-
38]. While trials of CBT on average report 81% adherence [22], a 
community study recruiting volunteers via the local media for a 12-week 
course of CBT reported 47% dropping out mostly in the first three weeks 
[39].  Consistent with other analyses in the ACE-MH project we model 
adherence to range between the recorded adherence level in trials and an 
estimated lower level of 50% adherence in community settings. 
Calculation of benefits 
As described elsewhere [6], we use two methods to translate the effect size 
into a health benefit. Briefly, the first method relies on an Australian 
valuation study which quantified a mean DW change for each SD change in 
severity of depression [20]. As the effect size quantifies the impact of an 
intervention in SD units, the product of the effect size and the mean DW 
change per SD represents the health gain. The second method applies the 
effect size to the MCS of the SF-12 across eligible respondents in the mental 
health survey after which the difference in average DW with and without 
treatment is calculated. Both methods are incorporated in our uncertainty 
analyses. This results in a broadening of the uncertainty ranges around the 
cost-effectiveness ratios reflecting the absence of an established method for 
translating effect sizes into a change in DALY DWs. 
Reductions in the DW are only applied to the time from the 
commencement of the intervention taking into account a lag to treatment 
seeking. We model that those not adhering to treatment gain no health 
benefit although they can incur some costs.  
During the continuation and maintenance treatment periods following 
an acute episode we assume that the reduction in risk of recurrence or 
relapse can be applied to the average time spent in depression. The 
comparator in the analysis for each intervention is continuation of current 
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treatment seeking patterns including a lag to treatment seeking for each new 
episode. For bibliotherapy we model health gain during the acute episode 
only. This may well be an underestimate as it is not unlikely that this self-
help variant of CBT also has benefits beyond the acute episode. We make 
this decision because we have no direct evidence for a sustained benefit and 
because the cost-effectiveness ratio is very favourable anyway due to the 
very low cost of the intervention.  
From the point prevalence of depression in the SMHWB, an estimate 
of the RR for suicide of 22.4 from a meta-analysis [7] and observed suicide 
deaths in Australia in 2000, we derive suicide deaths attributable to 
depression by age and sex. We assume a RR of 1.8 from Swedish routine 
data collection systems [8] applies to those who are not on effective 
treatment. No information is available that suggests that TCAs or SSRIs 
differ in their ability to prevent suicide and therefore we use the same 
estimate for both drug classes. In the absence of long-term studies, we also 
assume that suicide rates are similar in patients on CBT as in those on 
antidepressant drugs. As in the Australian Burden of Disease Study, the YLL 
associated with a death are calculated as the cohort life expectancy for each 
age and sex category. We then divide the total YLL for suicide in treated and 
untreated depression by the person-years of depression in 2000. 
Health Service Costs 
In our cost estimates we assume the same mix of providers as reported in the 
SMHWB, prescribing and supervising drug treatment (56% general 
practitioner (GP) only, 10% psychiatrist only and 33% GP plus psychiatrist). 
We take into account weekly visits in the first month, monthly visits for two 
months and then every three months for review. For those seeing both a GP 
and a psychiatrist we include one initial GP visit for referral, weekly sessions 
with a psychiatrist for one month and then fortnightly for another month 
before being referred back to the GP for further monitoring and management 
once every 1-2 months. We assume that cases not adherent with drug 
treatment accrue similar costs as those on non-evidence based treatments. 
 
 140 
CHAPTER 6 
 
Table 2.  Summary of unit cost information, data sources and assumptions 
Element 
costed 
Cost to 
govt 
(A$) 
Cost to 
patient 
(A$)* 
Source Assumptions 
1 month SSRI $73.54 $18.70 PBS  
1 month TCA $10.94 $4.53 PBS  
1 GP visit of 
20-40 mins 
$39.51 $1.87 MBS  MBS item 36 – for initial visit 
and/or for referral/diagnosis 
1 GP visit of < 
20 mins 
$21.88 $2.21 MBS  MBS item 23 – for second and 
subsequent visits  
1 psychiatrist 
visit of 45-75 
minutes 
$117.02 $16.47 MBS  MBS item 306  
1 psychiatrist 
visit of 15-30 
minutes 
$56.38 $5.95 MBS  MBS item 302  
1 session of 
46-60 mins 
with a private 
psychologist 
$0 $115.00 Australian 
Psychological 
Society 
The Australian Psychological 
Society recommended fee is $161 
(as of July 1 2001) but personal 
communication with the Executive 
Director suggests the fee most 
commonly charged is $110-$120. 
1 session of 60 
mins with a 
public 
psychologist 
 
$47.05 $0 Base salary 
from 
Victorian 
Hospitals’ 
Industrial 
Association 
Grade 3, Year 2 psychologist 
(PL2).  Salary effective from 1 
July 2000:  $1085.80 per week.  
On-costs of 30% have been added.  
The psychologist has 6 patient 
contacts per day with the 
remainder of the working day used 
for preparation, administration, 
professional development etc.   
1 session of 60 
mins with a 
public 
psychiatrist 
 
$129.64 $0 Base salary 
from the 
Austin & 
Repatriation 
Medical 
Centre 
Human 
Resources  
 
The psychiatrist is paid as a 
visiting medical officer (VMO).  
An average salary per session has 
been used from the range: 
Specialist to Senior Specialist.  
Salary effective from 1 July 2000:  
$260.76 to $337.60 per session.  
The psychiatrist has 3 patient 
contacts per session (of 3.5 hours).  
On-costs of 30% have been added. 
* Patients costs obtained from Department of Health and Ageing; PBS – 
Pharmaceutical Benefits Scheme; MBS -  Medical Benefits Scheme 
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Drug costs are derived from the Health Insurance Commission for 
scripts filled under the Pharmaceutical Benefits Scheme (PBS) for the 
1990/2000 financial year. The average dosage modelled for TCAs is 150 mg 
and for the group of SSRIs and related drugs 40mg (fluoxetine, paroxetine or 
citalopram, mianserin), 150mg (sertraline, venlafaxine), 200 mg 
(fluvoxamine) or 400 mg (nefazodone). The cost to the patient is averaged 
over general and concession patients and safety net and non-safety net 
patients. A summary monthly drug cost for SSRIs is calculated by weighting 
the cost for each drug by the proportion of prescriptions for each SSRI or 
TCA derived from the Bettering the Evaluation and Care of Health 
(BEACH) GP data collection system for the year 2000 [40].  
For CBT, we cost 12 one-hour sessions for five scenarios: individual 
therapy sessions by a clinical psychologist or psychiatrist in public service or 
private practice as well as group therapy by a publicly funded psychologist. 
A GP visit for referral is included in all scenarios.  Bibliotherapy is modelled 
as one long and two short visits to a GP and the purchase of a book (Table 
2).  
Depressed patients who receive non-evidence based treatment under 
current practice are costed for the mean number of visits to a GP (4.2), 
psychiatrist (0.3) and psychologist (2.2) as observed in SMHWB.  
Uncertainty 
In determining the benefits and costs associated with each intervention, we 
have assembled the best evidence available.  However, there is uncertainty 
associated with all cost and outcome estimates.  We use Monte Carlo 
simulation modelling and present uncertainty ranges as well as point 
estimates for benefits, costs, and cost-effectiveness ratios that reflect all the 
main sources of uncertainty in the calculations.  
Details of the parameters and distributions for the uncertainty 
assumptions used are shown in Table 1.  The probability distributions around 
the input variables are based on i) standard errors quoted in, or calculated 
from, the literature; ii) a range of parameter values quoted in, or calculated 
from, the literature; or iii) expert advice.  We use the @RISK software 
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which basically is a macro allowing multiple recalculations of an Excel 
spreadsheet each time choosing a value from uncertainty distributions 
defined for input variables. We calculate 95% uncertainty ranges for our 
output variables (bounded by the 2.5th and 97.5th percentiles of the 4000 
values generated). Results are presented to 2 significant digits only. 
RESULTS 
All interventions for major depression examined have a favourable 
incremental cost-effectiveness ratio (ICER) under Australian health service 
conditions. Bibliotherapy, group CBT, individual CBT by a psychologist on 
a public salary and TCAs are very cost-effective treatment options falling 
below A$10,000 per DALY even when taking the upper limit of the 
uncertainty interval into account (Table 3). 
The ICER of maintenance treatment with CBT is very favourable as 
the costs per individual are relatively low in relation to considerable benefits. 
Maintenance and episodic treatment with TCAs have similar ICERs while 
maintenance treatment with SSRIs is less favourable (ranging from 
A$17,000 to A$20,000 per DALY) but still well below the threshold of 
A$50,000 we use in the ACE-Mental Health studies as ‘affordable’.  
Maintenance treatment strategies are associated with the largest 
amount of overall health gain. The total cost of treating all people with 
depression who present for care (taking an average 62% adherence into 
account) with 5 years of maintenance treatment with SSRIs is considerable: 
close to two billion A$. The costs are less than a third of that if TCAs are 
used and CBT is again a cheaper option than drug interventions. 
 In a sensitivity analysis, we examine using a lower ES for CBT (0.56 
instead of 0.82), the pooled estimate of the impact of CBT trials for 
depression after exclusion of two outlier studies with very high effect sizes. 
This increases the ICER of CBT for acute episodes by 35% and by 6% for 
maintenance CBT. However, the overall conclusions remain the same: CBT 
is more cost-effective than drugs if provided by a publicly funded 
psychologist and particularly if done in groups; maintenance CBT is a very 
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cost-effective option; CBT by private providers has a similar ICER as TCAs; 
and SSRIs are less cost-effective, but still affordable. 
 Second filter considerations are presented in Table 4. The evidence 
base for both CBT and antidepressant drugs is sufficient although there are 
some concerns that almost all the evidence on CBT is in Anglo-Saxon 
populations and delivered by psychologists. There are moderate concerns 
about equity particularly if it would be largely available on a ‘user pays’ 
basis by private providers. Expanding access to CBT is challenging in terms 
of workforce and funding arrangements. The main issue with antidepressant 
drugs is that it is not very likely that many clinicians will go back to 
prescribing TCAs despite the fact that SSRIs give only marginal added 
benefits at much higher cost and hence the less favourable ICERs. 
 
 Table 3.   Summary of point estimates and 95% uncertainty ranges of benefits, costs and incremental cost-effectiveness 
ratios of interventions for major depression. 
145 
    Target Benefit (‘000s)# Costs  (A$ Millions)# ICER (‘000 A$ 
Intervention  group YLD YLL Intervention Comparator  
   
 per DALY)
1.  Antidepressant R/ for acute episode and 6/12 continuation R/ 
   SSRIs 
   TCAs 
Non-EBM 
  
      
      
     
6.0 (3.8–8.9) 2.1 (1.5–2.9) 
5.9 (3.8–8.6) 2.1 (1.5–2.8) 
120 (99–140) 
51 (44–58) 
7 (4–11) 
 
14 (11–18) 
5.5 (4.2–7.2) 
2. CBT including extended benefit for 18 months following episode 
Individual CBT public 
psychologist 
Non-EBM 9.0 (5.6–14) 3.0 (2.0–4.1) 50 (36–71)  3.5 (2.3–5.4) 
 
Individual CBT private 
psychologist 
Non-EBM   120 (87–150)  8.9 (6.7–12) 
Individual CBT public 
psychiatrist 
Non-EBM 130 (94–170) 10 (7.4–14)
Individual CBT private 
psychiatrist 
Non-EBM 130 (100–160)
 
10 (8.1–14)
 
Group CBT public 
psychologist 
Non-EBM
 
21 (15–31) 8 (4–12)
 
1.1 (0.5–2.0) 
3. Bibiliotherapy 15% of non-
EBM 
1.1 (0.6–1.8) 0.3 (0.2–0.4) 1.4 (1.0– 1.9) 1.2 (0.7–1.9) 0.1  
(dominant*–0.4)
4. Maintenance R/ 
SSRI 
TCA 
All seeking 
care 
 
73 (58–89) 
71 (58–85) 
 
22 (16–28) 
21 (16–27) 
 
1,900 (1,600–2,300) 
640 (530–740) 
 
220 (180–260)
 
 
18 (17–20) 
4.5 (4.1–4.9) 
 
C
H
A
PTER
 6 
 Table 3.   Summary of point estimates and 95% uncertainty ranges of benefits, costs and incremental cost-effectiveness 
ratios of interventions for major depression (continued). 
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    Target Benefit (‘000s)# Costs  (A$ Millions)# ICER (‘000 A$ 
Intervention  group 
 
YLD YLL Intervention Comparator  
     
per DALY)
5. Maintenance CBT 
Individual CBT public 
psychologist 
All seeking 
care 
84 (62–110) 23 (16–31) 190 (130–280) 220 (180–260) dominant*  
(UL 0.2) 
Individual CBT private 
psychologist 
   470 (340–600)  2.2 (1.7–2.8) 
Individual CBT public 
psychiatrist 
   520 (370–700)  2.8 (2.0–3.8) 
Individual CBT private 
psychiatrist 
   540 (420–660)  3.0 (2.6–3.4) 
Group CBT public
psychologist 
       67 (40–110) dominant*
# Costs and benefits based on offering treatment for acute episodes (intervention options 1–3) to 122,000 
people with an incident episode of major depression who sought care in the year 2000 but did not receive an 
evidence-based treatment (non-EBM). Maintenance treatment (intervention options 4 and 5) is modelled 
over 5 years in 302,000 people who sought care for an incident episode of major depression in the year 
2000. CH
A
PTER
 6 
* An intervention is dominant if it produces net health benefit and net cost saving. 
 
 Table 4.  Second stage filter considerations for cognitive-behavioural therapy (CBT) and anti-depressants. 
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    Filter CBT Anti-depressants
Evidence Sufficient evidence of adequate quality, noting however 
that there are:  
• few trials in people with non-English speaking 
background (NESB)  
• few trials for providers other than psychologists 
• no trials amongst the indigenous population 
Sufficient evidence of adequate quality.  
 
Equity Moderate equity concerns require attention, i.e. 
• appropriateness for minority groups (e.g. NESB, 
indigenous) 
• access for rural / remote consumers and in outer 
metropolitan areas 
• inequity in access if ‘user pays’ (e.g. for private 
providers) 
No important equity issues  
 
Feasibility Possible but challenging to implement in short term.  
Issues: 
• ensuring an adequate workforce, i.e. appropriately 
trained and accredited providers; adequate distribution 
• ability of health funding to enable adequate access via 
primary care 
Feasible within current workforce and institutional 
arrangements 
 
C
H
A
PTER
 6 
 
 
 
 
C
H
A
PTER
 6 
 
 
    Filter CBT Anti-depressants
Acceptability Some issues that require resolution: 
• cost to consumers if private providers 
• acceptance of treatment by clinicians and consumers  
• acceptance of a shift towards non-pharmacological 
treatments 
Issues that require resolution: 
• Worries of consumers about side effects 
particularly of long-term drug treatment 
strategies 
• Reluctance by clinicians to prescribe TCAs due 
to the perception of greater side effects (while 
trial data indicate only small differences in drop-
out rates due to side effects) 
• Pressure on clinicians to prescribe newer drugs 
(with a new generation of drugs already under 
development) 
• For depression - policy makers may be reluctant 
to endorse long-term drug treatment strategies 
particularly if the more expensive SSRIs are 
likely to be prescribed as there are already great 
pressures on the PBS budget 
Table 4.  Second stage filter considerations for cognitive-behavioural therapy (CBT) and anti-depressants (continued). 
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DISCUSSION  
A range of cost-effective interventions for episodes of major depression 
exists. Bibliotherapy is the cheapest option with net cost savings if offered 
instead of ineffective treatment options. However, bibliotherapy may be a 
treatment option for only a small proportion of people with depression. CBT 
when delivered by psychologists on a ‘public’ salary is the next best option, 
followed by TCAs, CBT by private providers and SSRIs.  
Maintenance treatment with CBT is a very favourable option but 
maintenance treatment with TCAs is also very cost-effective. However, the 
total cost for CBT would be a lot less than that for drugs. With a ICER 
around A$18,000 maintenance treatment with SSRIs is still a cost-effective 
option but the overall cost over five years is considerable if maintenance 
treatment is offered to all cases of major depression currently seeking care. 
The annual cost of maintenance treatment would be higher still as we have 
not included incident cases in the years following our baseline year of 2000. 
Our results strongly favour longer-term treatment strategies for 
depression. As the vast majority of people with depression experience 
multiple episodes over a lifetime and are particularly prone to relapses 
shortly after an index episode there are strong arguments to treat all 
depression as a chronic episodic disorder and not just those with three or 
more episodes as recommended in current treatment guidelines [3]. Unlike 
drugs, CBT conveys a longer-lasting impact beyond the time of treatment. It 
therefore seems advisable to make CBT available to all people experiencing 
depression rather than to resort to large numbers of people taking 
psychotropic drugs as first-line care over long periods.  CBT using books 
should be strongly advocated for those willing and able to use it.  
Key policy issues with regards to CBT concern the availability of 
suitably trained providers and the funding thereof. The bulk of the evidence 
on CBT is for psychologists as providers. While there may be capacity to 
increase provision of CBT services above current levels it is unlikely that 
there are enough trained psychologists to extend services to all those with 
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major depression let alone including those with anxiety disorders who would 
benefit from CBT as well [41]. There is no explicit evidence that other 
providers such as nurses and social workers can deliver CBT with similar 
effectiveness. However, the fact that bibliotherapy has similar effectiveness 
indicates that the type of provider may not be the most critical element of 
CBT. Alternative modes of delivery of computer administered CBT (e.g. via 
the Internet or at GP practices) are currently being explored. Such methods 
would in particular facilitate access to CBT in rural and outer metropolitan 
areas where there are few therapists.   
Funding is the other main policy issue. Current mental health services 
concentrate on treating the more severe and complex mental disorders. 
Large-scale provision of CBT for depression would mean a major change in 
focus of these services. Expanding services in primary care in collaboration 
with GPs and community health centres is a more feasible option. However, 
the main challenge is how to fund it. A recent initiative by the Australian 
government to improve access to psychologists through GPs (as being 
piloted in the “Better outcomes in mental health care” initiative) shows that 
funding mechanisms outside of Medicare are feasible.    
More widespread implementation of CBT could potentially lead to 
cost offsets: (i) for the PBS due to a reduction in prescription of 
antidepressant drugs and (ii) for the health system in general due to a 
decrease in resource usage resulting from a reduction in relapse and severity 
of depression.  These have not been considered in the analyses but would 
only have made the findings more favourable towards CBT. 
The cost-effectiveness analyses assume steady state operation, i.e. 
assuming interventions are fully implemented and operate in accordance 
with its efficacy potential.  In practise, resources will need to be allocated to 
implementation of the intervention, e.g. in administering a new delivery 
system and in ensuring adequate training and accreditation of providers. 
Based on cost-effectiveness TCAs should be the drug of choice for 
depression unless not well tolerated. There is some worry about the toxicity 
of TCAs when taken in overdose but there is insufficient evidence that 
prescribing TCAs leads to higher suicide rates [42]. While the ICERs for 
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giving SSRIs to those currently not treated are still within range of what is 
considered ‘affordable’ in Australia, a comparison of changing from TCAs 
to SSRIs has very high ICERs (exceeding A$250,000 per DALY). Reverting 
to widespread use of TCAs is unlikely to find favour with clinicians and 
patients despite these findings. However, the cost mainly to government 
through the PBS is very high due to the large number of people with 
depression eligible for treatment. 
Although directly observed economic data on the cost-effectiveness of 
psychotherapies is limited and based on short-term follow-up [43], 
modelling the available evidence provides very strong support for CBT 
under Australian health service conditions. The generalisability of this 
finding to other industrialised countries is largely dependent on the cost of 
delivering the interventions, as there are similarities in the epidemiology of 
depression between countries. 
Our finding that TCAs are more cost-effective than SSRIs is contrary 
to the conclusions of published drug comparison studies. There are three 
reasons for this difference. First, we model no difference in impact between 
the drugs. In contrast, a study conducted by the non-profit Canadian 
Organisation for Health Technology Assessment [44] ‘borrowed’ utility 
weights from another study [45] giving greater utility while depressed on 
SSRIs than while depressed on TCAs despite acknowledging the 
equivalence between the two drugs in reducing symptoms of depression. 
Second, we use modest differentials in adherence rates as consistently 
reported from meta-analyses. Third, most drug comparison studies estimate 
cost offsets from reduced health service use that compensate for the higher 
cost of SSRIs. We decided not to include a change in hospital costs for 
depression in our analyses. For the analyses of intervention strategies for 
acute episodes and a continuation phase this would make little difference as 
we model the changes in the group currently not receiving evidence based 
care when consulting a health professional. In the 1997 survey, they reported 
an average number of 0.05 days in hospital which is so small that omission 
of these costs could not have a sizeable effect on the results. The average 
number of hospital days reported by all cases seeking any health care for 
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their depression in the SMHWB is 1.9 days. This is our target group for 
maintenance treatments. However, we have no trial data to determine what 
proportion of hospital costs can be saved. Moreover, evidence from 
elsewhere may not apply to the health care system we have in Australia. 
Therefore, we decide to ignore any impact on hospital costs. This may have 
led to some underestimation of the true cost savings associated with 
maintenance treatment.  
Elsewhere, we discuss that translating trial findings into a health 
benefit in DALY terms is problematic [6]. Further developmental work is 
recommended such as the use of general quality of life outcome measures in 
trials and more sensitive disability weights in DALYs. Nevertheless, we 
argue that comparisons within depression are valid as the same imperfect 
methods are used to translate trial findings derived by similar means and the 
health benefit is largely driven by the effect size. Comparisons of these 
results with those for other mental or physical disorders are more affected by 
these methodological limitations. 
Our estimates of the 20% average time with major depression over 
five years of follow-up is somewhat higher than reported from a clinical 
study in the US which found that 15% of time was spent with depressive 
symptoms at the level of major depression over nine years of follow-up [46]. 
Using the lower estimate would increase the cost-effectiveness ratios for 
maintenance treatment options by 38% without altering the ranking order of 
interventions by their cost-effectiveness ratios. 
Our ability to model depression as a chronic episodic disorder rather 
than episode by episode allows the evaluation of longer-term treatment 
strategies. This is an important new development as we find such strategies 
to be cost-effective and potentially much more effective in curbing the 
burden of depression [5] even if we take ‘realistic’ adherence rates into 
account. 
 
CAVEAT 
The ACE–Mental Health project was jointly funded by the Australian 
Department of Health and Ageing, Mental Health and Suicide Prevention 
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Branch and the Department of Human Services, Mental Health Branch, 
Victoria in recognition of the importance of research into the cost-
effectiveness of interventions in mental health treatment and care. This work 
draws upon, but is also limited by the available research and the assumptions 
necessary to complete the work. 
The results of the analyses provide valuable material, likely to 
contribute to future policy deliberations by all service providers. 
Conclusions drawn from the economic evaluations should be considered 
within the context of the second stage filter process, which qualifies the 
results taking into account issues of equity, feasibility, strength of evidence, 
and acceptability to stakeholders. This second stage filter process addresses 
some of the practical considerations required for changes in actual service 
practice. 
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Classification Unit of the University of Sydney. The average cost of various 
types of medical attendances and the various forms of SSRI and TCA were 
153 
CHAPTER 6 
 
obtained from Medicare Benefits Schedule and Pharmaceutical Benefits 
Scheme data from the Department of Health and Ageing.   
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CHAPTER 7 
ABSTRACT 
Objective: We assessed, from a health sector perspective, options for change 
that could improve the efficiency of Australia’s current mental health 
services by directing available resources towards ‘best practice’ cost-
effective services 
Method: We summarise cost-effectiveness results of a range of interventions 
for depression, schizophrenia, ADHD and anxiety disorders that have been 
presented in previous papers in this journal. Recommendations for change 
are formulated after taking into account ‘second filter criteria’ of equity, 
feasibility of implementing change, acceptability to stakeholders and the 
strength of the evidence. In addition, we estimate the impact on total 
expenditure if the recommended mental health interventions for depression 
and schizophrenia are to be implemented in Australia. 
Results: There are cost-effective treatment options for mental disorders that 
are currently underutilised (e.g. cognitive-behavioural therapy for depression 
and anxiety, bibliotherapy for depression, family interventions for 
schizophrenia and clozapine for the worst course of schizophrenia).  There 
are also less cost-effective treatments in current practice (e.g. widespread use 
of olanzapine and risperidone in the treatment of established schizophrenia 
and, within those atypicals, a preference for olanzapine over risperidone). 
Feasibility of funding mechanisms and training of staff are the main second 
filter issues for CBT and family interventions. Acceptability to various 
stakeholders is the main barrier to implementation of more cost-effective 
drug treatment regimens. More efficient drug intervention options identified 
for schizophrenia would cost A$68 Million less than current practice. These 
savings would more than cover the estimated A$36M annual cost of 
delivering family interventions to the 51% of people with schizophrenia 
whom we estimated to be eligible and this would lead to an estimated 12% 
improvement in their health status. Implementing recommended strategies 
for depression would cost A$121 Million annually for the 24% of people 
with depression who seek care currently but do not receive an evidence-
based treatment. 
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Conclusions: Despite considerable methodological problems, a range of 
cost-effective and less cost-effective interventions for major mental 
disorders can be discerned. The biggest hurdle to implementation of more 
efficient mental health services is that this change would require reallocation 
of funds between interventions, between disorders and between service 
providers with different funding mechanisms. 
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BACKGROUND 
The ‘ACE approach’ to priority setting 
Although there is nothing new about the task of making difficult choices in 
health care, policy-makers are now discussing the issue of priority setting 
with renewed interest. Three main reasons are given in a growing 
international literature:  
• growing evidence that the deployment of current resources is far from 
optimal [1, 2]; 
• continued growth in health care expenditure, both in absolute terms 
and as a percentage of GDP [3, 4]; and 
• the wish to avoid ‘government failure’ in resource allocation 
decisions following government intervention in health care to achieve 
social justice objectives or to correct for ‘market failure’ [5, 6]. 
Although the importance and need for priority setting is clearly 
established, the central question of how priority setting is to be achieved 
remains contested. There are a variety of approaches and models available, 
offered from a range of disciplines. There are models offered by behavioural 
scientists based on achieving consensus; by epidemiologists/ clinicians based 
on needs assessment; by philosophers based on notions of social justice; and 
of course, there are a variety of approaches offered by economists based on 
efficiency [7]. An important step in assessing these various approaches is to 
reflect on the question of what constitutes an ‘ideal’ approach to priority 
setting. 
The logical starting point to address this question is to develop a 
checklist based on a clearly specified rationale. The literature provides few 
guidelines that focus on priority setting across multiple interventions (as 
opposed to evaluation of individual projects) or that take a suitably broad-
based approach. Carter [7] advises that a checklist be based on four general 
considerations: 
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• guidance from a review of economic theory, both applied economic 
evaluation methods, as well as their theoretical foundations in 
normative economics; 
• lessons from empirical experience with priority setting; 
• guidance from a review of literature on the role of ethics and social 
justice in priority setting; and 
• reflection on the pragmatic needs of decision-makers, evident from the 
empirical experience and key issues of setting and context. 
A central issue is the extent to which priority setting approaches focus 
on ‘technical analysis’ or ‘due process’ for their legitimacy. The ‘technical 
school’ is characterised by a reliance on rational decision rules and the 
development of technical frameworks in which they are applied. This school 
has in large part been the preserve of health economists (pursuing the goal of 
efficiency) and epidemiologists/clinicians (pursuing evidence-based 
medicine guidelines and/or needs-based equity). In the technical school, 
decisions are based on applying the correct rules whether efficiency, 
effectiveness and/or equity focused.  Provided one accepts these principles 
results should give guidance to decision-makers on how services should be 
ranked. 
In contrast, advocates of the ‘due process’ school question the 
assumption that it is possible to devise ‘rational’ decision rules and see the 
technical approaches as based on a simplistic view of the health care system. 
For the due process school the task is less to refine the technical basis of 
decision-making than to construct a process that enables proper debate and 
discussion to occur. This does not mean implicit rationing, but instead a 
system whereby decisions are made explicitly and the reasoning behind 
specific judgements is clearly explained.  
However, the debate between the two schools may be drawn too 
starkly in the literature. There is no inherent conflict between provision of 
information on the costs, outcomes and evidence base for different 
interventions, and strengthening of the processes for debating that 
information and arriving at judgements on priorities. The reality is that 
neither option alone is likely to fulfil the theoretical and practical 
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requirements of an ideal approach to explicit priority setting. Technical 
methods alone will never be able to deal with the complexity and contested 
nature of priority setting, but ‘due process’ should ideally utilise the sort of 
information on needs, efficacy/effectiveness, efficiency, and equity provided 
by technical approaches. Both elements need to be involved in any approach 
to priority setting that is seeking strong theoretical foundations and empirical 
validity. The ‘ACE Approach’ reflects our endeavours to develop such a 
joint approach. It involves close attention to technical rigour in its economic 
and epidemiological analyses, but also seeks to ensure due process by 
involving stakeholders in a steering committee; it takes into account broader 
considerations that are less amenable to quantification; and seeks consensus 
decisions after informed discussion.  
On the technical side the ACE methodology applies the key economic 
concepts of ‘opportunity cost’; ‘marginal analysis’ and a ‘clear concept of 
benefit’ [8, 9] using standardised evaluation methods clearly documented in 
an evaluation protocol. Undertaking the evaluations in this way as part of the 
priority setting exercise, addresses the reservations expressed by economists 
[10] about the simplistic use of league tables, where economic studies are 
assembled from the literature with little regard to differences in methods, 
context and setting. The key technical features of the ACE approach are:   
• the rationale for the selection of interventions is clearly explained and 
consistently applied; 
• the evaluation methods are standardised, documented and open to 
scrutiny; 
• the setting and context is common to all interventions (i.e. target 
populations within Australia); 
• Australian data have been used for demography, health system costs, 
disease incidence/prevalence, and the description of ‘current practice’;  
• information is assembled by a multi-disciplinary research team, 
preparing briefing papers to a standardised format agreed by a steering 
committee with policy makers, experts and representatives of 
community organisations as members; 
163 
CHAPTER 7 
 
• a range of results is reported (not just point estimates) reflecting 
explicitly the uncertainty and sensitivity of cost, outcome and value 
estimates; and 
• the incremental costs per Disability Adjusted Life Year (DALY) ratios 
are placed within a broader decision-making framework that includes 
‘strength of evidence’, ‘equity’, ‘feasibility’ and ‘acceptability’, which 
we have called ‘second stage filter’ criteria.  
The steering committee in ACE studies has an important role in 
achieving balance between the technical analyses and achieving due process. 
On the technical side members contribute in areas of their expertise and 
discuss issues of method and evidence. On the due process side, members 
ensure stakeholder interests and views are articulated; assist with ‘value’ 
judgement aspects of the analysis; assist with sensible interpretation of the 
technical analysis; and assist in ensuring transparency and appropriate use of 
relevant data. 
‘ACE’ applied to mental health 
Previously, the ACE approach has been applied to cancer and heart disease 
[11, 12] and further studies have commenced on obesity and prevention of 
non-communicable disease in general. The choice of mental health reflected 
a number of considerations. First, mental disorders are the largest contributor 
to the non-fatal burden of disease in Australia and rank third behind 
cardiovascular disease and cancer in terms of overall burden of disease [13, 
14].  Second, there are efficacious interventions for the main mental 
disorders [15] but, until now, there was little evidence of their cost-
effectiveness under routine Australian health service conditions.  The aim of 
the ACE–Mental Health study was to assess from a health sector 
perspective, whether there are options for change that could improve the 
effectiveness and efficiency of Australia’s current mental health services by 
directing available resources towards cost-effective services.  The overall 
methods and results of intervention-specific analyses have been published in 
a series of papers in this journal [16-23].   
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In this final paper we present an overview of the results and 
conclusions from the study. We add one new analytical component by 
estimating the impact of the recommended options for change on overall 
expenditure for depression and schizophrenia which have been the main 
focus of our analyses. The first step in doing this was to estimate the annual 
cost of current practice using the same assumptions of health service use, 
drug costs and adherence as in the cost-effectiveness models for depression 
and schizophrenia for the baseline year 2000. This ‘bottom-up’ way of 
assembling total costs based on unit costs for the various elements of an 
intervention follows usual practice in economic analysis [24].Thereafter we 
estimate the change in annual expenditure that would occur if our major 
recommendations for a shift towards more cost-effective practice were 
implemented. 
OVERVIEW OF RESULTS 
The cost-effectiveness results 
The results of the economic evaluations conducted as part of the ACE–
Mental Health study can be summarised in a ‘league table’ ranking the 
interventions in order of their economic merit (Table 1).  This is possible 
because the methodology is sound, as consistent as possible across the 
various studies (with any variations clearly specified) and applied to a 
common setting [18].    
The results of the ACE–Mental Health study show that there are cost-
effective treatment options for mental disorders that are currently under-
utilised (e.g. cognitive behavioural therapy for depression and anxiety, 
bibliotherapy for depression, family interventions for schizophrenia and 
clozapine for the worst course of schizophrenia).  There are also less cost-
effective treatments in current practice (e.g. use of olanzapine and 
risperidone in the treatment of established schizophrenia and, within those 
atypicals, a preference for olanzapine over risperidone).  
 Table 1. Interventions analysed in ACE–Mental Health: cost-effectiveness and second filter issues that require attention. 
 
Disorder and Intervention 
Cost-effectiveness ratio in 
AUD per DALY 
(95% uncertainty range)
 
Second filter issues that require attention 
Schizophrenia  Drugs: 
Behavioural intervention in families
(Tarrier) 
8,000 (4,000 – 18,000) 
Risperidone vs typicals mix for people
with troublesome side-effects 
20,000 (15,000 – 27,000)
Multiple family groups (McFarlane) 21,000 (10,000 – 53,000)
Clozapine vs typicals for those with
chronic disease and clear
deterioration 
23,000 (17,000 – 47,000)
Behavioural family management
(Falloon) 
28,000 (13,000 – 64,000)
Olanzapine (15mg/day) vs typicals
mix for people with troublesome
side-effects 
38,000 (28,000 – 50,000)
Clozapine vs typicals for those with
chronic disease and little
deterioration 
42,000 (31,000 – 62,000)
Risperidone vs typicals 48,000 (27,000 – 110,000)
Risperidone vs low dose typicals 80,000 (36,000 – infinity)
Olanzapine (15mg/day) vs typicals
mix 
92,000 (53,000 – 170,000)
Olanzapine (15mg/day) vs risperidone 
 
160,000 (44,000 – infinity)
 
• Acceptability to clinicians – although effectiveness known 
for many years, intervention not widely provided 
• Quality of the evidence: trials suffer from absence of patient 
rated quality of life measures, high attrition rates, short 
duration, frequent use of excessively high dose levels of the 
typical comparators (thus biasing the results towards a better 
outcome for risperidone and olanzapine) 
• Return to the widespread use of typicals not likely to happen 
• The apparent tolerability advantages of olanzapine and 
risperidone in the short term make them more acceptable to 
patients and clinicians than typical neuroleptics 
Family interventions: 
• Quality of evidence: i) mostly small trials, ii) only relapse 
rate reported, not continuous measures of symptoms / quality 
of life 
• Rural and remote access 
• Implementation of Behavioural Interventions in Families is 
more feasible due to the short nature (9 months) of this 
intervention 
• Appropriateness for NESB and indigenous families not 
known 
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Disorder and Intervention 
Cost-effectiveness ratio in 
AUD per DALY 
(95% uncertainty range) 
 
Second filter issues that require attention 
Generalised Anxiety Disorder  
CBT by psychologist (public) 6,900 (4,000 – 12,000) 
CBT by psychologist (private) 20,000 (12,000 – 33,000) 
CBT by psychiatrist (private) 23,000 (15,000 – 38,000) 
CBT by psychiatrist (public) 23,000 (14,000 – 38,000) 
 
 
 
Venlafaxine 
 
 
 
23,000 (16,000 – 40,000) 
  
Venlafaxine: 
CBT: 
• Generalisability of results to minority groups and all 
providers 
• Equity in access if ‘user pays’, access in rural/remote and 
outer metropolitan areas 
• Ensuring an adequate workforce 
• Development of implementation arrangements 
• Acceptability to stakeholders 
• Not available on the PBS for GAD 
• Consumer concern about side-effects 
 
Panic Disorder  
CBT by psychologist (public) 6,800 (2,900 – 14,000) 
TCAs  17,000 (9,700 – 42,000) 
CBT by psychologist (private) 26,000 (15,000 – 45,000) 
CBT by psychiatrist (private) 27,000 (19,000 – 48,000) 
CBT by psychiatrist (public) 30,000 (18,000 – 55,000) 
SSRIs  38,000 (27,000 – 89,000) 
CBT:   
• Same as for Generalised Anxiety Disorder 
TCAs and SSRIs: 
• Antidepressants less effective than CBT 
• Consumer concern about side-effects 
• Reluctance by clinicians to prescribe TCAs due to the 
perception of greater side-effects 
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Disorder and Intervention 
Cost-effectiveness ratio in 
AUD per DALY 
(95% uncertainty range) 
 
Second filter issues that require 
attention 
Major Depression (adults)  
Group CBT by psychologist (public) – maintenance 
treatment 
Dominant 
CBT by psychologist (public) – maintenance treatment Dominant (dominant – 230) 
Bibliotherapy 160 (dominant – 460) 
Group CBT by psychologist (public) – acute episode 1,300 (600 – 2,300) 
CBT by psychologist (private) – maintenance 
treatment 
2,200 (1,700 – 2,800) 
CBT by psychiatrist (public) – maintenance treatment 2,800 (2,000 – 3,800) 
CBT by psychiatrist (private) – maintenance treatment 2,900 (2,600 – 3,400) 
CBT by psychologist (public) – acute episode 4,100 (2,700 – 6,200) 
TCAs – maintenance treatment 4,500 (4,100 – 4,900) 
TCAs – acute episode 5,700 (4,400 – 7,500) 
CBT by psychologist (private) – acute episode 10,000 (7,600 – 14,000) 
CBT by psychiatrist (public) – acute episode 12,000 (8,300 – 16,000) 
CBT by psychiatrist (private) – acute episode 12,000 (9,200 – 16,000) 
SSRIs for acute episode 14,000 (11,000 – 19,000) 
SSRIs for maintenance treatment 
 
 
18,000 (17,000 – 19,000) 
 
 
CBT:   
• Same as for Generalised Anxiety 
Disorder 
• Long-term treatment more effective 
and cost-effective than treatment of 
the acute episode 
Bibliotherapy: 
• Only suitable for some patients 
TCAs and SSRIs: 
• Antidepressants less effective than 
CBT, particularly for longer-term 
treatment strategies 
• Consumer concern about side-
effects, particularly for long-term 
treatment 
• Reluctance by clinicians to 
prescribe TCAs due to the 
perception of greater side-effects 
• Reluctance by policy makers to 
endorse long-term treatment due to 
cost pressures on PBS 
168
C
H
A
PTER
 7 
 
 
 
  
AUD – Australian dollars; CBT – cognitive behavioural therapy (individual unless otherwise specified); GAD – Generalised Anxiety Disorder; 
DALY – disability adjusted life year; NESB – non-English speaking background; PBS – pharmaceutical benefits scheme; SSRIs – selective 
serotonin reuptake inhibitors; TCAs – tricyclic antidepressants 
 
Disorder and Intervention 
Cost-effectiveness ratio 
in AUD per DALY 
(95% uncertainty range) 
 
Second filter issues that require attention 
Major depression (children and adolescents)  
CBT by psychologist (public) 9,000 (39,000 – 24,000) 
SSRIs – 1st line treatment 23,000 (13,000 – 53,000) 
SSRIs – 2nd line treatment 23,000 (13,000 – 54,000) 
CBT by psychologist (private) 28,000 (13,000 – 70,000) 
CBT by psychiatrist (public) 34,000 (16,000 – 82,000) 
CBT by psychiatrist (private)  
 
34,000 (16,000 – 82,000) 
 
 
 
• Less effective than CBT 
 
• Ethical concerns about drugs (which have side effects) as the first 
line treatment while more effective treatment (i.e. CBT) is 
available with no side effects 
CBT:   
• Same as for Generalised Anxiety Disorder 
• Only 1 trial in children < 13 years 
SSRIs: 
• Parental concerns about using drugs in children and adolescents 
• Worries about increased suicide risk associated with SSRIs 
Attention Deficit Hyperactivity Disorder  
Dexamphetamine  4,100 (dominant - 14000) 
Methylphenidate 
 
15,000 (9,100 – 22,000) 
  
 
 
 
• Short duration of trials (average 4 weeks) 
• Access to specialist treatment in remote or rural areas 
• Methylphenidate not available on the PBS – which is an issue for 
those children who do not respond to dexamphetamine 
• Concern about over-prescription CH
A
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Impact on annual expenditure for schizophrenia and depression 
We estimate A$119M was spent in 2000 on pharmaceuticals for 
schizophrenia based on the proportions of people with schizophrenia using 
different types of neuroleptic drugs from the 1998 Low Prevalence Disorder 
Study and adjusting for the change in volume of scripts for each drug under 
the Pharmaceutical Benefits Scheme since 1998. This estimate is close to the 
A$110M reported by the Australian Institute of Health and Welfare (AIHW) 
as total expenditure on pharmaceuticals for schizophrenia for the financial 
year 2000/2001 [25] using a method referred to as ‘top-down’ costing or 
‘gross-costing’ [24]. These estimates include costs to government as well as 
patient contributions.  
Changing treatment in those currently on olanzapine to risperidone 
would result in A$27M cost saving. Implementation of all our recommended 
drug treatment strategies [21], i.e. giving (i) clozapine to the 15% of patients 
with the worst course of schizophrenia; (ii) risperidone to those who 
experience moderate to severe side effects on typicals; and (iii) low dose 
typicals to all others, would cost A$42M or a cost saving compared to 
current practice of A$68M with virtually no change in health status. These 
savings would more than cover the estimated A$36M annual cost of 
delivering family interventions to the 51% of people with schizophrenia 
whom we estimated to be eligible and this would lead to an estimated 12% 
improvement in their health status [22]. 
We estimate A$153M was spent in 2000 on out-of-hospital medical 
services (largely general practitioner and specialist care) and A$190M on 
pharmaceuticals for depression taking into account a change in prescribing 
patterns since 1997 (the year of the National Survey of Mental Health and 
Wellbeing [26]) as indicated by the change in volume of scripts for each 
drug under the Pharmaceutical Benefits Scheme. These amounts are 
considerably lower than the A$276M for out-of-hospital medical services 
and A$340M for pharmaceuticals AIHW attributed to depression in 2000/01 
[25]. This difference in cost estimates can be explained by two reasons. First, 
our estimates are based on a cross-sectional survey asking respondents about 
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health service use in the last 12 months and a sizeable proportion of 
respondents identified with depression would not yet have completed their 
episode Thus we underestimate the true costs of health care for depression. 
Second, it is not easy to apportion total expenditure on anti-depressant drugs 
to individual disorders as they are also widely used for other disorders, such 
as anxiety disorders, dysthymia and subsyndromal depression not included 
in our estimates. This would lead to overestimation in the AIHW costs for 
depression.  
Our cost-effectiveness analyses of anti-depressant drugs and CBT 
targeted the 24% of people with depression who seek care from a health 
professional but do not receive an evidence-based treatment. We estimate 
that in 2000, these people accrued A$ 27M out-of-hospital medical costs. 
Providing them with the same mix of therapy and/or drugs by the same mix 
of providers as those currently receiving evidence-based care the annual cost 
would be at least A$172M based on our low estimate of total costs. This 
amount would reduce to A$121M if: (i) GPs supervise drug treatment; (ii) 
psychologists in public service provide CBT; and (iii) prescribed anti-
depressants were equally split between tricyclic antidepressants and newer 
drugs such as selective serotonin-reuptake inhibitors (rather than the 36% – 
61% split recorded in 2000-01 which has become a 81% – 17% split in 
2003/04). All these estimates are considerably higher than the current 
expenditure on non-evidence based treatments and would be higher still if 
we take into account that some of the difference between our total cost 
estimates and AIHW estimates for depression is due to the fact that we 
underestimate costs in respondents who had not yet completed treatment at 
the time of measurement in the cross-sectional survey. Moreover, it is not 
clear how much of current expenditure on non-evidence based treatment 
would cease if evidence-based treatment were offered instead.  
The total amount of expenditure estimated for funding evidence-based 
care in just a proportion of people with depression exceeds expenditure on 
medical and pharmaceutical services for people with schizophrenia because 
of the much higher prevalence of depression. While our recommendations 
for depression are costly, it would result in a 20% reduction in disease 
171 
CHAPTER 7 
 
burden for treatment of depressive episodes including six months 
continuation of drug treatment after the episode. Providing all those seeking 
care for their depression in the baseline year 2000 with drug maintenance 
treatment following an episode would cost A$312M over five years and 
A$160M if maintenance CBT were offered instead. Both types of 
maintenance treatment are estimated to reduce the disease burden of 
depression by around 50% [27] 
A shift towards our recommended strategy to improve health services 
for people with depression and schizophrenia is not easy because it relies on: 
(i) changing the practice of clinicians; (ii) flexibility in financing mental 
health care between different types of health care and between different 
health care funders; and (iii) addressing opinions of patients, care givers, 
health care workers and advocacy groups about the relative merits of 
different treatments in an environment influenced by intensive marketing 
efforts of pharmaceutical companies. We have tried to address these issues 
by shaping our recommendations in discussion with the steering committee 
taking into account four ‘second stage filter’ criteria. 
The second stage filters 
To date, ACE steering committees have endorsed the value judgement that 
in the health sector, it is appropriate to maximise ‘health’ (defined using 
DALYs), subject to acceptable performance on other criteria (such as the 
health gain being fairly distributed). While there are different techniques for 
taking such broader considerations into account, steering committees have so 
far chosen to adopt what we have called the ‘second stage filter’ process. 
Under this process the broader considerations are selected, clearly defined 
and presented as qualifying statements together with the evidence of cost-
effectiveness for each intervention [18].   
Second stage filter issues in ACE–Mental Health that require attention 
for each of the interventions are summarised in Table 1.  For example, 
provision of CBT to all eligible patients with depression and anxiety requires 
the development of implementation arrangements.  Resources would need to 
be committed to ensuring providers have adequate training and are available 
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in sufficient numbers and this would be a greater challenge in rural and outer 
metropolitan areas. Also, funding mechanisms for psychological care would 
need to be extended to ensure equitable access in primary care. For 
schizophrenia, major issues are the acceptability of the side effects of typical 
neuroleptics to various stakeholders and overcoming the inertia in mental 
health services failing to implement family therapy despite two decades of 
evidence of efficacy. 
Selection of the interventions 
In addition to the interventions included in Table 1, five other interventions 
were selected for analysis by the steering committee.  However, we found 
insufficient evidence of efficacy to justify a full cost-effectiveness analysis. 
First, we found limited evidence for specialist versus generalist services for 
eating disorders. Two randomised controlled trials of in-patient versus out-
patient care [28-30] indicated no clear advantage of either.   
Second, integrated treatment for clients with the dual diagnosis of 
severe mental illness and substance abuse showed a greater availability of 
evidence at the level of controlled trials, including 7 randomised and 6 non-
randomised controlled trials, summarised in one systematic review [31] and 
one narrative review of the literature [32].  However, these studies gave no 
clear support for integrated programs over standard care due to the lack of 
differential impact on health-related quality of life.   
Third, a review of the evidence for assertive community treatment 
(ACT) of psychoses including 30 studies, 25 of which are randomised 
controlled trials found no clear health benefit with ACT nor sufficient 
evidence to suggest overall health system cost savings associated with ACT.  
However, greater satisfaction was reported by clients of ACT and this may 
make ACT a preferred option as has been reported previously by advocates 
[33].  
Fourth, a cost-comparison analysis was conducted for supported 
employment in schizophrenia due to the lack of evidence for a clinical 
benefit [16].This analysis showed that, largely due to disincentives in 
welfare legislation to taking up full-time employment, supported 
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employment costs more than it saves from both a patient and government 
perspective.   
Finally, we investigated a stand-alone early psychosis intervention and 
enhanced standard care for early psychosis versus standard care.  The 
evidence for the effectiveness of the two interventions from a non-
randomised controlled trial was inconclusive, thus preventing a full cost-
effectiveness analysis.  However, a comparison of average first year costs 
showed that the two interventions were not significantly more expensive 
than standard care [34]. 
DISCUSSION 
Despite considerable uncertainty around key input variables, clear 
distinctions in cost-effectiveness between mental health interventions 
(particularly within disorders) are apparent.  The results suggest that 
substantial opportunities exist to improve efficiency within our current 
mental health resources, if resources were shifted towards more cost-
effective interventions. We have also identified a significant amount of 
under-treatment, particularly for depression and anxiety, which would 
require considerable additional resources but which would lead to sizeable 
improvements in health outcomes. A previous study found similar order of 
magnitude findings of the cost-effectiveness of interventions for 
schizophrenia and depression and draws the same conclusions about the 
potential for greater efficiency in mental health services [35-37]. Results 
between the two studies are not directly comparable because of some 
differences in methodology (we use a longer time horizon, include mortality 
outcomes and have not included hospital costs) and presentation of results 
(we present cost-effectiveness ratios for individual interventions while the 
other study presents the cost-effectiveness of the current and an optimal mix 
of interventions per disorder). However, the main underlying data sources 
describing the epidemiology of mental disorders in Australia and the 
effectiveness of interventions are the same and hence the similarity of results 
is not surprising. 
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The brief analysis of the impact of our recommendations for more 
efficient services for depression and schizophrenia shows the value of 
combining information on cost-effectiveness with the size of health 
problems, thus refuting the criticism of some health economists that burden 
of disease studies are a waste of valuable resources [38-40]. Clearly, the 
quantification of the potential impact on mental health budgets of 
implementing change is essential to policy makers and this requires basic 
burden of disease information on prevalence, incidence and duration of 
disease. 
However, the cost-effectiveness results of this study need to be 
considered in the context of the second stage filter criteria and the limitations 
of data and methods. 
Limitations in the selection of disorders and interventions  
The ACE–Mental Health study is limited to interventions for major 
depression, panic disorder, generalised anxiety disorder, schizophrenia and 
related conditions, and ADHD.  Clearly some important mental disorders 
with significant health burden were not included, such as substance use 
disorders, bipolar disorder, dysthymia, borderline personality disorder, 
eating disorders, post-traumatic stress disorder, social phobia, obsessive-
compulsive disorder and conduct disorder.  Although the steering committee 
expressed interest in these disorders, given the two-year time constraint and 
limited project budget it was simply not possible to cover all mental 
disorders.  Preference was given to disorders for which the disease burden 
was greatest, current practice could be quantified and for which evidence-
based interventions could be specified.  Thus, the ACE–Mental Health study 
did not intend to provide a comprehensive strategic plan for mental health, 
but rather to suggest options for directing available resources towards cost-
effective services. 
Within the disorders included in the study, not all possible 
interventions were analysed.  Important omissions include physical exercise 
[41] and electroconvulsive treatment [42] for depression, cognitive 
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behavioural therapy for schizophrenia [43] and benzodiazepines for anxiety 
disorders.  
We failed to complete full analyses for a number of interventions with 
limited and inconclusive evidence of effectiveness. This raises the point of 
selection bias in economic analyses towards interventions with a stronger 
evidence base and often these include pharmacological and surgical 
interventions driven by commercial interests. 
An important simplification made in the ACE–Mental Health study 
was to ignore comorbidity with other physical and mental disorders because 
evidence of efficacy for interventions for comorbid disorders is lacking.  
Randomised controlled trials (RCTs) often exclude subjects with comorbid 
conditions and/or do not present the results stratified by comorbidity. This 
raises doubts about the applicability of trial findings to patients in routine 
health services as comorbidity between mental disorders is very common 
Limitations in the cost per DALY results 
As mentioned in the individual papers, there were limitations in the methods 
used to calculate the cost per DALY, the most significant being the 
measurement of health benefits.  While the measurement of the effect size is 
based on accepted methods [44, 45], the translation into a change in the 
DALY disability weight required the development of new methods [18]. The 
absence of an established method of translating effect size into health gain in 
DALY units is further compounded by the lack of health-related quality of 
life outcome data from trials and survey data and the availability of only two 
to four DALY disability weights, which coarsely describe severity for each 
mental disorder.  However, it is important to recognise that the effect size is 
usually the main driver of the cost-effectiveness ratio and that, within 
disorders, the method for translating the effect size into a change in the 
DALY disability weight is the same. Thus, comparisons within disorders 
have greatest validity but it is more problematic to compare results between 
mental disorders.  Furthermore, comparison of mental health interventions 
where health gains are dominated by non-fatal outcomes, with interventions 
for heart disease and cancer where extension of life dominates health 
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outcomes, are less certain even though the studies have been conducted with 
comparable methods [12, 46]. 
Second stage filters process 
The second stage filter process involved the assessment of issues that either 
influence the degree of confidence that can be placed in the cost-
effectiveness ratios (such as the level of available evidence), or broader 
issues that need to be taken into account in decision-making about resource 
allocation (such as equity and acceptability to stakeholders).  The second 
stage filter process was facilitated by the involvement of policy-makers in 
the steering committee.  This helped ensure that the research was conducted 
from within a policy context, thus having ‘real-life’ applicability.  However, 
this also challenged specific interests.  For example, the recommendation 
that patients with established schizophrenia be switched to low dose typicals 
(rather than olanzapine or risperidone) goes against current practice and was 
not supported by all members of the steering committee.  It would also not 
be supported by pharmaceutical companies which are gradually withdrawing 
typicals from the market and continuing to introduce newer and higher cost 
atypicals.  Thus, for some interventions and for some criteria, the steering 
committee could not reach complete consensus.  Where this was an issue, 
the researchers were guided by the weight of evidence and by the majority 
view.   
A significant limitation of the process was the limited consumer input 
into the project.  The Steering Committee included a representative from 
SANE Australia (a community advocacy organisation) and a representative 
from the Mental Health Council but no consumers.  Thus the view of 
consumers is incorporated indirectly only, from data presented in trials on 
side-effects and drop-outs, from consumer perceptions recorded in survey 
data [26, 47] and from the perception of the mental health experts and 
representatives from community organisations.   
Overall, the cost-effectiveness analyses conducted in the ACE–Mental 
Health study are all based on Level I evidence of efficacy, i.e. systematic 
reviews of all relevant randomised controlled trials [48].  The number of 
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patients/trials included for each intervention was good for CBT and drug 
interventions but modest for family interventions for schizophrenia.  An 
issue relevant for all intervention trials is the lack of patient-rated quality of 
life measures. The quality of trials was reasonable, but there are worries 
about the validity of some of the trial results.  This was a particular problem 
with drug interventions for schizophrenia, which are mostly funded by drug 
companies and suffer from multiple reporting, which is not always obvious 
to the reader [49, 50].  A more insidious issue is the use of high dose levels 
of the typical comparators, which bias the results to a better outcome for 
atypicals [51].  Not only does this inflate the apparent benefit of atypicals on 
extrapyramidal side effects, it may also inflate the apparent symptom 
benefits.  In the analysis of the risperidone versus haloperidol RCTs from a 
Cochrane systematic review [52] and supplemented with a more recent RCT 
[53], we found an effect size (based predominantly on symptom measures) 
of 0.35 (95% CI 0.08 to 0.62) for trials in which risperidone was compared 
to 12mg or greater of haloperidol and a lower, non-significant effect size of 
0.13 (95% CI -0.11 to 0.36) for trials which used mean haloperidol doses of 
less than 12mg.  This finding is consistent with that found for atypicals in 
general in the systematic review by Geddes et al. [54].  
As well as the second filter criteria of ‘strength of evidence’, ‘equity’, 
‘feasibility’ and ‘acceptability’, the steering committee proposed a filter 
based on ‘severity of the disorder’.  Such a criterion would have to apply 
similarly to all interventions for the same disorder unlike the other second 
filter criteria which are intervention-specific. As the greatest validity of 
comparisons is for intervention options addressing the same disorder we 
decided not to incorporate severity as an additional second filter. However, 
while conventional economic analysis does not accord any weight to the 
severity of the illness per se, there is evidence [55-58] that people often do 
wish to give greater priority to treatment of those who are worse off, above 
and beyond the priority it already has within a cost-effectiveness analysis as 
captured by the incremental health gain. For example, given the greater 
disability associated with schizophrenia, policy-makers may decide to accept 
a higher willingness-to-pay threshold for interventions for schizophrenia. 
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Alternatively, greater weight may be given to minor health gains associated 
with severe conditions, thus increasing the health benefit associated with any 
particular effect size change.  In fact, there is evidence to suggest that even 
when more severely ill patients are clearly receiving less benefit than 
patients with less severe illnesses, there remains a distinct preference for 
treating the more severe illnesses [59]. 
What next? 
The results of these cost-effectiveness analyses provide valuable material 
likely to contribute to future policy deliberations by all service providers in 
mental health.  The recommendations should not be seen as ‘one size fits 
all’.  Not all patients respond to any one treatment and patients (and doctors) 
have their own preferences for treatment, which will inevitably impact on its 
effectiveness.  For example, some people with depression may prefer 
antidepressants while others prefer psychological approaches to treatment. 
Further, CBT may not be appropriate for all people who prefer psychological 
therapies.  Bibliotherapy (a self-help form of CBT) is also cost-effective and 
suitable for some patients [23].  Interpersonal therapy may also be an 
efficacious treatment [60] that may better suit some patients.  A combination 
of antidepressant and psychological therapies may be appropriate for others.  
Thus, the results of the study should not be seen as prescriptive. However, 
current practice patterns in mental health services indicate that there are 
inadequate incentives to promote efficiency. The intention of the ACE-
Mental Health project was to raise awareness about these inefficiencies. We 
realise that presenting these results and recommendations will not 
automatically translate into changed practice. With our discussion of second 
filter criteria we have identified potential barriers to implementing change. 
Policy could benefit from a more comprehensive analysis of mental 
health care including analyses of the efficiency of services for other mental 
disorders, for prevention and for high-cost services (e.g. hospital care), 
which we have not included in this study. The value of these analyses will be 
further enhanced by comparison with interventions in other areas of health if 
the same methods are used. That will indicate if there are cost-effectiveness 
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arguments to change the share of total health funding dedicated to mental 
health services. 
Caveat 
The ACE–Mental Health project was jointly funded by the Australian 
Department of Health and Ageing, Mental Health and Suicide Prevention 
Branch and the Department of Human Services, Mental Health Branch, 
Victoria in recognition of the importance of research into the cost-
effectiveness of interventions in mental health treatment and care. This work 
draws upon, but is also limited by the available research and the assumptions 
necessary to complete the work. 
The results of the analyses provide valuable material, likely to 
contribute to future policy deliberations by all service providers. 
Conclusions drawn from the economic evaluations should be considered 
within the context of the second stage filter process, which qualifies the 
results taking into account issues of equity, feasibility, strength of evidence, 
and acceptability to stakeholders. This second stage filter process addresses 
some of the practical considerations required for changes in actual service 
practice. 
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INTRODUCTION 
Each of the chapters 2–7 in this thesis have been published as stand-alone 
papers in peer-reviewed journals. There is no need to repeat the discussion 
and conclusions already presented. However, what remains is to evaluate the 
combined body of work. The emphasis of this last chapter is on the technical 
feasibility of assembling the evidence on the size of mental health problems 
in Australia and the efficiency of the mental health services response to 
major depression. The main questions to be answered are: 
1. to what extent have the methodological questions raised in the 
introductory chapter been addressed? 
2. what have been the scientific achievements?  
3. what are the main deficiencies in methods and available data? and 
4. what are the opportunities to improve the quality and accuracy of 
the evidence? 
In the following sections these questions are addressed separately for 
the two main topics, i.e. burden of mental disorders and cost-effectiveness of 
mental health interventions.  
While these technical aspects are the focus of this thesis, this body of 
work has been much more than an academic endeavour. The explicit aim 
was to provide relevant evidence to Australian policy makers and service 
providers to improve the health services response to mental disorders. While 
this thesis was not set up as a formal health policy analysis it is appropriate 
to finish with some statements about the process of collating the evidence 
and the impact so far on influencing mental health policy and practice in 
Australia. 
BURDEN OF MENTAL DISORDERS 
The Victorian and Australian burden of disease studies have made multiple 
contributions to the methods of measuring the size of mental disorders in 
populations. Many of these developments have subsequently been 
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incorporated into revisions of the Global Burden of Disease (GBD) study 
(facilitated by the fact that Colin Mathers who was the lead researcher on the 
Australian study took up a post to work on the GBD at WHO) and a host of 
national burden of disease studies facilitated by the fact that we provided 
transparency of methods and data sources in publications and by posting all 
Excel workbooks on the world wide web. 
Survey data 
Access to the National Survey of Mental Health and Wellbeing (NSMHWB) 
was essential [1]. Without such a survey neither burden of disease nor cost-
effectiveness modelling would be possible. As many mental disorders 
remain untreated, health service data collection systems fail to capture the 
true occurrence and characteristics of mental illness in the population. This 
is not only the case for common mental disorders such as depression, anxiety 
and ADHD for which the survey found that between 40% and 60% of cases 
had not sought any health care for their mental health problem. It also 
applies to schizophrenia. The Low Prevalence Disorder study, a sub-study of 
the NSMHWB, identified people with psychotic disorder by contacting a 
range of mental health service providers in four selected urban settings [2]. 
Due to the poor response of general practitioners contacted to take part in the 
survey, a very low proportion of cases identified under their care but not 
other mental health services. For the ACE-Mental Health study we identified 
a study in Newcastle, New South Wales, that found a third of people with 
schizophrenia under the sole care of their GP [3]. Assuming that this pattern 
of care is representative of the country, it means that the survey 
underestimates the true prevalence. 
While the diagnosis of psychotic disorders in the Low Prevalence 
Study is that reported by mental health practitioners, there is no such 
equivalent for most other mental disorders. Hence, the NSMHWB relies on 
responses to a diagnostic survey instrument to identify people in the 
population who meet the criteria for a range of mental disorders. Experience 
from burden of disease studies has led to considerable scepticism about self-
reported health status. A common finding is that self-report survey data 
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suffer from low sensitivity (e.g. type 2 diabetes), low specificity (e.g. 
asthma, angina), systematic bias (e.g. height and weight) or a combination 
these problems [4, 5]. For many physical disorders, measurements can 
provide a more accurate diagnosis in surveys. This is not the case for mental 
disorders. Inevitably the diagnosis rests on self-report. Mental health 
epidemiologists have a long history of developing and validating survey 
instruments. The Composite Diagnostic Interview Schedule developed by 
WHO [6] has been used in several large mental health surveys, including the 
NSMWHB, and has been shown to have variable validity when compared 
with diagnosis by a psychiatrist depending on which mental disorder is 
examined [7-12]. All of these validation studies were conducted on clinical 
samples rather than community samples as in surveys. It is therefore not 
clear how valid these population estimates are. However, surveys are the 
only way of collecting population data on mental disorders, as routine health 
service data collection systems do not capture the large proportion of people 
with a mental disorder who never seek care. 
Problematic is also that there are two major classification systems for 
mental disorders, the ICD-10 by WHO and DSM-IV by the American 
Psychiatric Association [13, 14]. Responses to the CIDI allow diagnosis by 
either classification. In the NSMHWB there was lack of agreement between 
the ICD-10 and DSM-IV in 42% of diagnoses. At the population level, 
differences in prevalence are smaller. We estimated a small difference of 7% 
in the overall size of the mental health burden in Victoria if we would have 
chosen the DSM-IV rather than the ICD-10 diagnostic categories. For 
individual mental disorders, the differences were much greater [15]. Until a 
consensus is reached on a single classification system it is important that 
burden of disease studies clearly specify on what diagnostic system results 
are based. 
Choice of mental disorders 
Twenty mental disorders were included, 12 more than in the global burden 
of disease study. New conditions included childhood disorders, eating 
disorders and a greater number of substance abuse and anxiety disorder 
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categories. These conditions represented 36% of the mental health burden in 
Victoria in 1996. This is an important finding as it indicates that the 
selection of conditions for inclusion in a burden of disease study may have 
more than a trivial impact on the ranking of mental disorders relative to other 
disease categories.  
There is no such problem with the mortality component of DALYs as 
there is a set total amount of deaths recorded in the Australian vital 
registration system. While there can be arguments about the attribution of 
deaths by cause, the total amount of YLL is fixed by the ‘envelope’ of age-
and-sex specific counts of death. For non-fatal outcomes there is no such 
‘envelope’ and hence it is important to carefully examine if the most 
important potential contributors to YLD are included. For some disease 
categories it is possible to define a rest category and thus avoid 
underestimating YLD. For instance, cancer registers provide information on 
all cancers allowing an estimation of YLD for a rest category ‘all other 
cancers’. For other disease categories, an approximation of YLD for a rest 
category has been advocated by applying a YLD to YLL ratio to deaths 
within a larger disease category but not assigned to a specific disease.  
This method does not work for largely non-fatal disease categories 
such as mental disorders [16]. The aim of a burden of disease study is to be 
comprehensive in its measurement of mortality and disability. Hence, if 
there is no recognised disability envelope and no measurable estimate or 
approximation of the disability due to excluded disorder categories, the 
choice of which disorders to include in the study is critical. The choice for 
20 conditions comes close to being comprehensive. Future studies could still 
contemplate including conduct disorder in childhood; other personality 
disorders apart from borderline personality disorder; and cocaine and ecstasy 
as substance use categories. While information on prevalence is available for 
each of these conditions in the 1997 adult or child mental health surveys [1, 
17] and/or the more recent national drug and alcohol household survey [18], 
their inclusion in a future burden of disease study would require additional 
data on remission or average duration as well as the development of 
disability weights for the associated health states. 
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Co-morbidity corrections 
The addition of many new mental disorders to the burden of disease list 
made it imperative to deal with the very common co-morbidity between 
mental disorders. Previous burden of disease studies had ignored co-
morbidity, implicitly assuming an additive model of disability. If individuals 
have several co-morbid conditions, this can mean that the total amount of 
disability in a particular individual adds to more than 1 or more than the 
equivalent of being dead. While there may be some arguments for the 
existence of health states that some people might consider worse than being 
dead, these are probably rare and limited in duration.  
The correction for co-morbidity was restricted to the mental disorders 
identified in the adult mental health survey, i.e. anxiety disorders, 
depression, substance use disorders and borderline personality disorders. At 
the time of analysis the survey estimates for bipolar disorder were 
considered inaccurate, as one module on mania had been excluded from the 
interview schedule. Subsequently, a further analysis of the data indicated 
that estimates are possible for bipolar disorder type 1 and hence also its 
inclusion in corrections for co-morbidity[19]. A choice was made to make 
simple adjustments allocating prevalence equally between co-morbid states. 
This decision followed consultations with mental health experts failing to 
reach agreement on the likely direction of causality between co-morbid 
mental disorders. For instance, anxiety experts thought that those with 
anxiety and alcohol dependence would have started drinking to alleviate 
their anxiety, while alcohol experts indicated that their clients often develop 
anxiety or depression while already dependent on alcohol. 
As the allocation of co-morbid prevalence between disorders was 
done at the unit record level of the survey it implicitly dealt with the relative 
frequency of combinations of co-morbid mental disorders. In contrast, the 
corrections for common physical disorders in the elderly assumed 
independence between the occurrence of co-morbid conditions. Taking the 
dependence between co-morbid physical disabilities into account was not 
possible due to time constraints and was flagged as a potential improvement 
in methods for further burden of disease studies.   
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Another advantage of making the adjustment at the level of prevalent cases 
was that we could take into account the potentially greater severity of co-
morbid states as we derived severity independently of the ICD-10 diagnoses 
from questions on the Medical Outcomes Study short form (SF-12) 
questionnaire [20] included in the survey [15].  
The disadvantages of the chosen approach are that (a) it artificially 
reduces the prevalence of mental disorders (and prevalence is an important 
output from a burden of disease study in its own right); and (b) that it 
deviates from the chosen method of adjusting disability weights rather than 
prevalence or incidence for co-morbidity between physical disorders. Further 
shortcomings are that no corrections were made for co-morbidity with 
mental disorders not included in the adult survey (such as childhood 
disorders, eating disorders and psychotic disorders) and that co-morbidity 
between mental and physical disorders was ignored. In future analyses, a 
number of improvements in a more integrated approach to corrections for 
co-morbidity can be made, including: 
1. using uniform methods of correction for co-morbidity between 
mental disorders, and between mental and physical disabilities with 
a preference for adjusting disability weights rather than prevalence 
or incidence;  
2. adding corrections for co-morbidity for mental disorders currently 
not included, particularly for co-morbidity between schizophrenia 
and depression or substance use disorders making use of data from 
the Low Prevalence Disorders survey [2]; and  
3. taking into account the dependence between disabling conditions. 
In the absence of surveys that capture co-morbidity between all major 
contributors to the non-fatal disease burden, it is inevitable that information 
on the probability of disabilities being co-morbid will have to come from 
disparate data sources. It also is unlikely that disability weights can easily be 
derived for the multitude of potential co-morbid states. Instead, we 
introduced a multiplicative model to adjust the level of disability avoiding 
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the problem of awarding a combined disability weight greater than 1 to some 
individuals[4, 5] and that still seems the most reasonable approach.  
Choice of disability weights 
At the time of study two sets of disability weights were available: (a) from 
the GBD study with a treated and untreated weight for each condition and an 
assumption of the proportion of cases under treatment [21]; and (b) from a 
Dutch study with between 2 and 4 severity levels per mental disorder [22]. 
We chose the Dutch DWs because (a) epidemiological data on the severity 
distribution of mental disorders showed great variability in severity between 
individuals; and (b) weights were available for a greater number of mental 
disorders. A major problem with the GBD approach of using treated and 
untreated weights is best illustrated with an example from the adult mental 
health survey. The Dutch DWs are 0.14, 0.35 and 0.76 for mild, moderate 
and severe depression. The average Dutch DW calculated for individuals 
who consulted a health professional for their depression (0.403) is higher 
than the DW for those with depression who did not consult (0.282). 
Furthermore, the DW for those reporting having had CBT or drugs 
prescribed (0.429) is higher than the DW for those consulting a health 
professional but not receiving treatment with an evidence base (0.364). If 
one believes that treatment is effective –or at least not harmful–, the 
conclusion must be that the more severe cases of depression are more likely 
to seek treatment and receive treatment with an evidence base. Clearly, the 
GBD DWs for treated (0.302) and untreated depression (0.600) would not 
have described this pattern of severity in the Australian population very well.  
For burden of disease analysis one can argue that this does not matter 
as long as the DW reflects the average case in the population. Using the 
Dutch DWs the average DW for depression was 0.41 in men and 0.37 in 
women and would have been 0.50 assuming the treated weight applies to the 
35% receiving an evidence-based treatment or 0.42 if the treated weight 
applies to the full 58% reporting to have consulted a health professional for 
their depression. There is no correct DW level as this is one of the social 
value choices that underpin the DALY. However, if over time the underlying 
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severity of depression would remain constant in the population but access to 
treatment would improve, use of the GBD weights would implicitly assume 
that the additional cases seeking treatment on average had moved from the 
untreated to the treated DW level. This does not reflect the finding that those 
previously not seeking treatment have less severe disease. The Dutch DWs 
with three levels of severity can better capture the change in severity after 
such a shift in treatment access.  
For burden of disease analyses it may be sufficient to describe the 
average severity of depression in the population even though they are just 
three values across a wide spectrum. Cost-effectiveness models of 
interventions that ameliorate disabling health states demand greater accuracy 
in measuring the difference in severity with and without treatment as 
discussed in the papers on the ACE-Mental Health study [23, 24].  
Conclusions 
In conclusion, the Victorian and Australian burden of disease studies made 
significant improvements in the methods of estimating the size of mental 
health problems. As indicated above, a number of further improvements are 
possible including better corrections for co-morbidity and inclusion of a few 
more disorders. However, the main issue is to have up-to-date data from a 
representative mental health survey. There currently are plans to do another 
mental health survey in Australia in the year 2007, ten years after the first 
survey. Repeats of the child and psychotic disorder components of the first 
survey are unlikely to be included. For a group of conditions with such a 
dominant share of disease burden where surveys are the only reliable data 
source, a frequency of one survey per decade is not enough. Another 
recommendation for the future survey is to design a follow-up component to 
re-interview respondents to get data on episode duration, relapse and time 
spent in symptomatic disease. These epidemiological parameters are crucial 
to the current estimates and are derived from isolated international studies 
that often are conducted on clinical samples rather than community samples. 
Lastly, given the equivocal results of validation studies of the main survey 
instrument (the CIDI) in clinical samples, validating diagnoses in a sub-
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sample of the survey against diagnosis obtained from a formal psychiatric 
interview would provide important information of the accuracy of current 
estimates in Australia. 
 
ECONOMIC EVALUATION OF INTERVENTIONS FOR MAJOR 
DEPRESSION 
Estimating effectiveness 
The main outcome measures of randomised controlled trials of mental health 
interventions are responses to symptom-based questionnaires. Very rarely, 
quality of life measures are used. Recently, a few randomised controlled 
trials for depression have emerged that measured overall quality of life [25-
27] but the vast majority of trials report on limited symptoms only. Hence, a 
major assumption is that differences on the symptom-based measures reflect 
the magnitude of change in overall quality of life, which is what we want to 
capture in the DALY measure. There is some supportive evidence that 
disorder-specific symptoms correlate with overall psycho-social disability 
[28, 29].  
The next issue is that disparate rating scales are being used between 
trials with the Beck’s Depression Inventory and the Hamilton Depression 
Rating Scale most commonly used for depression [30, 31]. In meta-analyses 
of mental health interventions, the effect size based on the standardised 
mean difference is the recommended measure to pool study results if the 
outcome measure is continuous [32, 33]. The method relies on the 
assumption that the change in a symptom rating scale between an 
intervention and a control group can be expressed in standard deviation 
units. This allows pooling of results even if studies used different scales as 
long as the scales measured the same construct. Not all statisticians accept 
this method [34, 35] and the Cochrane systematic reviews only report pooled 
results for the same rating scale. Adhering strictly to this position would 
have ruled out a considerable amount of evidence and would have 
necessitated a difficult choice of what rating scale to include or exclude. We 
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argued that exclusion of a substantial amount of evidence would lead to a 
greater potential for error than making the decision to pool results obtained 
from different rating scales.  
For many of the interventions we evaluated there were existing meta-
analyses. We endeavoured to update these results if significant new studies 
had become available since. We followed established methods in meta-
analysis to (a) examine the data for heterogeneity; (b) apply the random 
effects method to estimate the effect size and its confidence limits; and (c) 
do a meta-regression if the data shows considerable heterogeneity [32]. For 
example, we did a meta-regression of studies on CBT for depression, panic 
disorder and generalised anxiety disorder [36]. The main finding was that 
CBT is less effective in patients with severe disease.  
Translating effectiveness into a change in DALY 
While there are well-established methods to pool data from trials of mental 
health interventions that have used disparate measures of outcome into an 
effect size, the translation of an effect size into a change in DALY disability 
weight units is more problematic. The main problem is that there are 
disability weights for three severity levels in major depression while the 
effect size is a continuous measure of change in severity. We used two 
approaches to make this translation. The first relies on a study by Sanderson 
et al. that used time trade-off methods to estimate the amount of change in 
disability weight that is equivalent to one standard deviation change in 
severity [37]. As the effect size is also expressed in standard deviation units 
health gain in DALY terms is simply the product of effect size and that 
estimated change in disability per standard deviation change in severity. 
Thus it avoids having to make the transition from a continuous to a 
categorical measure. When we discussed this method with the ACE-Mental 
Health Steering Committee, the Sanderson study had not yet been published. 
Committee members felt uneasy about using a new but not peer-reviewed 
method and encouraged the researchers to explore another method.  
We developed an alternative method estimating for each individual in 
the Australian mental health survey an average reduction in severity due to 
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an intervention by altering the Mental Component Score (MCS) of the 
Medical Outcomes Study Short Form (SF–12) [38]. This average reduction 
in severity was determined by the product of the effect size of the 
intervention and the standard deviation of the MCS. The next step was to 
recategorise survey respondents into mild, moderate and severe depression 
and calculate an average disability weight in those modelled to receive the 
treatment. We called this the ‘survey severity method’ as opposed to the 
initial ‘conversion factor method’.  
In the absence of an established method and in consultation with the 
steering committee it was decided to incorporate both methods into 
uncertainty analyses, thus widening the uncertainty interval around our cost-
effectiveness ratios by using either method in half of all simulations. The 
advantages of the conversion factor method are that (a) it is easier to use; (b) 
it avoids having to translate a continuous measure into change in 
categorically defined disability weights; and (c) conversion factors for most 
common mental disorders are available, thus increasing the comparability of 
cost-effectiveness results across mental disorders. However, the conversion 
factors were derived from a small pilot study with a convenience sample of 
general practitioners as the valuators and it used a different health state 
valuation method from the person trade off method used to derive the DALY 
disability weights [37]. Confirmation of its findings in a larger study would 
give more credence to the method. 
The drawback of the alternative ‘survey severity method’ is that it 
required a change from a continuous measure (the effect size) into a 
categorical measure (the disability weights). At the level of individual survey 
respondents, it meant that after applying the effect size only some would 
make the transition into a less severe category. We then argued that if this 
were done over enough cases in the survey it would approximate the true 
average impact of the intervention. In hindsight, we could have refined the 
method by interpolating disability weight levels between the three anchoring 
points for mild moderate and severe depression (which we defined as 0.5, 
1.5 and 2.5 standard deviation levels below the population mean of the 
MCS). That would have allowed a continuum of disability weights across 
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the full spectrum of severity as measured by MCS in the survey rather than 
for three categories only. 
These methodological difficulties are less influential when comparing 
cost-effectiveness ratios between different interventions for the same 
disorder as the same method of translating change into DALYs is 
consistently applied. The conversion factor method is consistently derived 
for different mental disorders and hence increases the validity of 
comparisons of cost-effectiveness results between mental disorders. 
Comparisons are more problematic between depression and schizophrenia 
for the severity survey method as there were no common measures of 
severity in the main mental health survey and the low prevalence disorder 
survey.  
Comparisons between ACE-Mental Health results and cost-
effectiveness results of interventions for physical disorders where extension 
of life is the dominant health outcome are more problematic. If making such 
comparisons it is important not to over-interpret small differences in cost-
effectiveness but to concentrate on large difference, e.g. by classifying 
interventions into a few broad categories such as ‘very cost-effective’, 
‘probably cost-effective’, ‘probably not cost-effective’ and ‘certainly not 
cost-effective’. 
Modelling cost- effectiveness of interventions for depression 
There are two main treatment options for major depression: psychological 
and drug interventions. Treatment guidelines for general practitioners in 
Australia recommend treatment to continue for at least one year for first 
episodes and for at least two years for repeat episodes [39]. Specialist 
guidelines recommend the same for first episodes but extend the 
maintenance treatment period to three years [40]. These guidelines were 
mainly based on evidence of effectiveness rather than economic arguments.  
The ACE-Mental Health project has provided such additional 
evidence of cost-effectiveness on (a) the choice of psychological or drug 
treatment; and (b) the merits of episodic versus maintenance treatment 
options. This required the development of a model of depression as a chronic 
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episodic condition rather than the more simplistic modelling of depression, 
episode by episode. Thus, information was needed on the duration of 
episodes and the probability of repeat episodes occurring after an initial 
episode. There were only a few studies that had followed up people 
identified with depression from a community sample. Lognormal 
distributions best described the data points on duration of episodes and on 
risk of recurrence of an episode. There were only seven data points from six 
studies on the risk of a recurrent episode over a period of two years (see 
figure 2 in [41]). It clearly is desirable to have more data and hence, the 
recommendation made earlier that a next mental health survey in Australia 
include a follow-up component. Assuming these mathematical functions are 
a valid description of the course of depression over time, we were able to 
estimate the average number of episodes and the average amount of time 
with depression over a follow-up period in a micro-simulation model. 
Having defined the course of the depression over time following an episode 
we were able to examine the impact of various treatment options. The 
Archives of General Psychiatry paper [41] compared the impact of episodic 
and maintenance treatment on the amount of disease burden from depression 
experienced over a 5 year period following an episode. It demonstrated that 
maintenance treatment could avoid up to half of all depression burden while 
episodic treatment would only avoid a quarter. There was not a lot of 
information on a maintenance variant of the main psychological 
intervention, Cognitive Behavioural Therapy (CBT), for which there is best 
evidence of effectiveness during or following an episode. Thus, our 
conclusions about maintenance CBT are more speculative. Also, the 
evidence base for the impact of maintenance drug treatments is rather slim 
and more long-term and independent trials are needed to verify the impact. 
In the cost-effectiveness analyses that followed we found CBT to be 
more cost-effective than drug treatments particularly if provided by a 
psychologist in public service and, more so, if delivered as group therapy. Of 
the two main drug treatment options the cheaper tricyclic agents (TCAs) 
were more cost-effective than the newer SSRIs and related drugs. All these 
conclusions held after examining the uncertainty ranges around each result 
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derived from our multivariate sensitivity analyses. The cost-effectiveness 
ratios for episodic and maintenance treatment were similar but the total costs 
and benefits were much greater. Maintenance CBT had an even more 
favourable cost-effectiveness ratio than CBT during an episode due to the 
relatively lower cost of only a few booster sessions per year.  
The cost-effectiveness ratios of all treatment options fell well below 
the A$50,000 threshold commonly used in Australia to demarcate cost-
effective from cost-ineffective interventions. However, the incremental 
analysis of SSRIs as an alternative to TCAs gave a cost-effectiveness ratio of 
more than four times this threshold. This is because SSRIs are six times 
more expensive than TCAs while there is no difference in effectiveness on 
depressive symptoms and only a small documented difference in adherence 
due to side effects. This example illustrates that simply analysing the cost-
effectiveness of individual interventions and sticking them in a league table 
can mask the inefficiency of an intervention option if there is a more cost-
effective alternative. This is the argument strongly put forward by the WHO-
CHOICE project that the cost-effectiveness results of individual intervention 
options for a particular health problem need to be put along an intervention 
pathway that will determine the most cost-effective mix of interventions for 
a particular budget level [42]. We did not perform such analyses within the 
ACE-Mental Health project, as we did not yet have the expertise to do so. In 
future analyses, this is the strongly recommended strategy. 
A further refinement of the cost-effectiveness modelling would be to 
use micro-simulation techniques rather than modelling the ‘average case’. 
That would do better justice to the wide variation in presentation of 
depression and the differences in treatment response between individuals. 
For instance, we did not take into account the lesser impact of CBT in 
patients with severe depression [36] nor did we take into treatment-resistant 
depression account [43]. 
Engagement of policy makers and experts 
From the start of ACE-Mental Health we engaged mental health policy 
makers and mental health experts in a Steering Committee. The mental 
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health experts came from around the country and included many prominent 
mental health researchers. There was also representation from the mental 
health lobby groups SANE and the Mental Health Council. The main tasks 
of the Steering Committee were to guide the choice of interventions for 
analysis, scrutiny of the methods and applying a set of ‘second filter criteria’ 
to help formulate policy recommendations. The latter are policy relevant 
criteria other than cost-effectiveness that were deemed necessary to take into 
account before formulating policy recommendations. Four second filter 
criteria were selected: equity, feasibility, acceptability to stakeholders and an 
overall judgment of the quality and strength of the evidence. Meetings were 
held twice a year over the three-year project period.  
At the onset of the project it was anticipated that there would be 
tension between a number of different groups on the Steering Committee. 
First, the policy makers from the federal Department of Health and Ageing 
(DoHA) and Victorian Department of Human Services (DHS) were likely to 
have different interests in the project as the States fund hospital and 
community mental health services (largely dealing with more severe 
psychotic disorders) while the federal government directly funds 
pharmaceuticals and doctor visits. Initially, there was great enthusiasm in the 
Mental Health Branch of DHS but this subsided after the director left who 
had provided half of the project funds from her budget. It was only a year 
later that a successor gave any attention to the project and, as a true 
bureaucrat, first looked at the potential risks to the Branch’s interests from 
the project. The new director frankly stated that she would never have part-
funded such a study with the federal government. The ACE-Mental Health 
project was located in another part of the same department and therefore 
could not as easily be ‘neutralised’ as would have been the case with 
research commissioned from a university or private company. After many 
heated discussions a semblance of cooperation was found after we agreed to 
accompany all our publications with a caveat around the interpretation of 
results. The policy makers from the federal DoHA were much keener 
participants. This reflected their policy interests which included concern 
about the high expenditure on anti-depressant drugs and a pilot initiative to 
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allow financing of psychological treatments in primary care by non-
physicians (there are no provisions for reimbursing the cost of visits to allied 
health workers in primary care in Australia). 
Second, we expected tension between the mental health experts who 
mainly research psychotic disorders and those with an interest in depression 
and anxiety. Gavin Andrews as a proponent of the latter group had seriously 
ruffled feathers of the former group by presenting his (at the time not yet 
formally published) work comparing the cost-effectiveness of treatment 
options for various mental disorders [44]. His conclusions were there are a 
lot of under-utilised cost-effective treatment options for depression and 
anxiety while there are few cost-effective options in the treatment of 
schizophrenia. The ACE-Mental Health results, using more sophisticated 
analyses but largely the same underlying data sources, confirmed Gavin 
Andrews’ findings. This set the scene for many heated discussions during 
each of the steering committee meetings. My impression is that with time the 
worst critics came to (possibly reluctantly) accept that these findings were 
based on currently available evidence. The second filter discussions allowed 
the critics to voice some of their concerns. In particular, the acceptability 
criterion was at times invoked to voice concerns about advocating cheap and 
old drugs over new and expensive drugs. There was some suspicion that part 
of the expert criticism of our results could have been influenced by the fact 
that most mental health research in Australia is heavily reliant on funds from 
pharmaceutical companies.  
It is hard to judge how much influence the ACE-Mental Health project 
has had on policy decision-making and this thesis did not intend to answer 
that question. Nevertheless, the nature of burden of disease and cost-
effectiveness work is that it is intended to inform policy. Within the 
Department of Human Services in Victoria, it is unlikely that the Mental 
Health Branch policy makers have made much direct use of the results given 
their reluctant participation in the project. Elsewhere in the department, the 
work has received much greater recognition and led to the development of 
another cost-effectiveness modelling project, ACE-Obesity. At the level of 
the federal government the favourable results for CBT gave support to the 
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new initiatives to find alternative funding streams for brief psychological 
interventions. For drugs to be listed under the Pharmaceutical Benefits 
Scheme there are strict criteria including cost-effectiveness that need to 
demonstrate the merits of a new drug. After listing, however, there is no 
established mechanism to restrict use of less cost-effective drugs or to 
promote use of cheaper drug alternatives. Hence, there has been no 
immediate impact on policy regarding drug options for the treatment of 
mental disorders. In other parts of the DoHA there is growing recognition for 
the need to support resource allocation decisions with evidence on the 
economic credentials of alternative health service options. There is 
considerable interest in the cost-effectiveness of prevention in the hope that 
strengthening cost-effective prevention option can lead to containment of the 
large increases in health expenditure projected over the next few decades due 
to the ageing of the population and the introduction of new technologies 
[45]. This strong interest has been influential in obtaining a large 5-year 
grant from the National Health and Medical Research Council (NHMRC) to 
evaluate the cost-effectiveness of prevention of non-communicable disease 
in Australia that has now been called the ACE-Prevention project. Having 
also secured 5-year funding from the UK Wellcome Trust and NHMRC for a 
similar project in Thailand is further recognition that the work on burden of 
disease and cost-effectiveness described in this thesis is perceived as useful 
and informative.  
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The cost of providing health care is rising faster than other sectors of the 
economy in Australia. For this reason, government, as the main providers of 
health services, is under increasing pressure to justify its health expenditure. 
This also applies to the provision of health services for people suffering 
mental disorders.  
In the nineties, the Global Burden of Disease study identified mental 
disorders as a large, hitherto often neglected, health problem. The use of the 
Disability-Adjusted Life Year (DALY) – a summary measure of population 
health, i.e. a combined measure of mortality and morbidity – revealed the 
large non-fatal health burden associated with mental disorders. For the first 
time in the late nineties, the Burden of Disease methods were applied to the 
Australian context. The mental health component of this study is the topic of 
chapters two and three. 
As the methods of measuring the burden of mental disorders were still 
rather crude, the study put a particular emphasis on development of new 
methods. The main improvements were a) the inclusion of a greater number 
of mental disorders; b) more accurate disease models reflecting the chronic 
course of most mental disorders; c) greater detail in describing the 
distribution by severity; and d) a correction for the very common co-
morbidity between different mental disorders. 
Mental disorders were the third largest disease category, ranking behind 
cardiovascular disease and cancer. Depression was the largest cause of 
disability in men and women with another seven mental disorders ranking 
among the top-twenty causes of disability. 
Recent mental health survey data provided good information on the 
prevalence and severity of disease. As the DALY is an incidence-based 
measure, it required further information from the scarce follow-up studies of 
community samples of people with a mental disorder. DALY estimates are 
based on a generalisation of the ‘average’ case of disease in the population, 
and hence, cannot do full justice to the great variety in duration and severity 
which characterises most mental disorders. A further problem is that there is 
lack of consensus in the definition of mental disorders. For instance, we 
found considerable differences in the size of mental disorders between the 
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International Classification of Disease version 10 (ICD–10) and the 
Diagnostic and Statistical Manual version 4 (DSM–IV) defined diagnoses. 
Moreover, the common co-morbidity between disorders and the similarities 
in treatment approaches put in doubt the validity of the diagnostic distinction 
between e.g. depression and anxiety disorder. Psychiatric diagnoses in 
community surveys by definition are based on self-report. For physical 
disorders, there is a strong preference for measured health status data as self-
reported health information is often a poor proxy for true disease. However, 
it must be emphasised that mental health epidemiologists have put greater 
scientific rigour in setting standards for population surveys in comparison to 
epidemiologists studying the non-fatal physical conditions. 
Large health problems are not necessarily priorities for health 
intervention. Prioritising health service action requires further evidence on 
the effectiveness and costs of different intervention options. Following on 
from the Burden of Disease studies the federal government and the state 
government of Victoria commissioned an economic evaluation study, the 
Assessing Cost-Effectiveness (ACE) – Mental Health study, to identify 
opportunities to address the large mental health burden with cost-effective 
interventions. Over a period of two years, the main treatment options for 
depression, anxiety, schizophrenia and Attention-Deficit and Hyperactivity 
Disorder were analysed. 
Most health economic evaluation studies compare a limited number of 
alternative intervention options addressing the same health problem. Often 
these studies are tagged onto randomised controlled trials during which 
costing information has been collected. If the aim is to evaluate multiple 
interventions for different disorders, as was the case with ACE-Mental 
Health study, modelling of available epidemiological and economic data 
sources is the only option. Superficially, modelling may seem a less accurate 
evaluation method than using observed data from trials. However, most trials 
collect data on selected patient groups that are not representative of the 
distribution by age, gender and severity of the disease in the whole 
population. A modelling approach thus can better reflect the reality of the 
context in which decisions are to be made. Moreover, if multiple 
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comparisons are to be made, comparing results from existing economic 
evaluation studies in a ‘league table’ often is not valid as methods between 
studies can vary widely.  
Chapter four describes the standard methods applied to all 
interventions evaluated in ACE-Mental Health. The main modelling 
principles include the use of a) systematic reviews and meta-analysis to 
estimate the effect size; b) Australian epidemiological survey data to 
describe disease and treatment patterns; c) appropriate costing data from 
routine government collection systems and patient surveys; d) extensive 
uncertainty testing around the cost per DALY results using simulation 
techniques; e) intensive consultations with policy makers, disease experts 
and community representatives throughout the study; and f) other policy-
relevant criteria (equity, strength of evidence, feasibility and acceptability to 
stakeholders) to formulate policy recommendations. 
Results of the evaluation of interventions for major depression are 
presented in Chapters five and six. The first of these compares the impact of 
the more commonly implemented short-term episodic treatment approaches 
with maintenance pharmacological or psychological treatments. This 
analysis demonstrates the value of combining burden of disease analyses 
with economic evaluations countering the arguments of some health 
economists who consider burden of disease studies a waste of analytical 
resources. Current treatment averts only 9% of the total burden of depression 
in Australia. Optimal provision of episodic treatment could avert a quarter of 
disease burden while maintenance treatment options potentially could halve 
the disease burden even if adherence of only 60% is factored into the 
analyses. Drug and brief psychological intervention by Cognitive-
Behavioural Therapy (CBT) are equally effective. The main conclusion of 
the superiority of maintenance treatment remains after taking all uncertainty 
around input variables into account. Results suggest that to make significant 
inroads into the large burden of depression health service providers need to 
recognise and treat depression as a chronic disorder. However, the evidence 
base for the impact of maintenance treatments is rather slim and more long-
term trials are needed to verify the impact. 
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The analyses are taken to full economic evaluation in Chapter six. 
Specifically, we chose to examine the cost-effectiveness of targeting 
intervention options to those with major depression who seek care but 
currently are not receiving evidence-based treatment. We made this choice 
because we did not have any evidence for interventions addressing 
depression in people who do not present to, or are not recognised as 
depressed by health services.  
All intervention options for depression were found to have a 
favourable Incremental Cost-Effectiveness Ratio (ICER) in comparison to 
the current inadequate treatment options received. The most cost-effective 
options were bibliotherapy (CBT through a book), group CBT, individual 
CBT provided by psychologists in government service and the tricyclic anti-
depressants (TCAs) with an ICER well below A$10,000 per DALY. 
Maintenance treatment with the more expensive Selective Serotonin-Uptake 
Reinhibitors (SSRIs) was the most expensive option with an ICER of around 
A$20,000 per DALY in comparison to non-evidence based treatment. 
However, if compared to TCAs (rather than non-evidence based treatment) 
SSRIs have a very high ICER (>$200,000 per DALY) reflecting the high 
price, lack of differential effectiveness and only modestly better adherence 
rates that are ascribed to a better side effect profile.  
The main conclusions are that a range of cost-effective treatment 
options exists for major depression and that these options are currently 
under-utilised. Maintenance and episodic treatment options have similar 
economic credentials. The total cost associated with maintenance treatment 
is high particularly if SSRIs are the drug of choice.  
During the ‘second filter’ criteria discussion, key policy issues were 
identified with regards to the expanded provision of CBT concerning the 
availability of suitably trained providers and the funding mechanism for 
therapy in primary care. Given the proven effectiveness of bibliotherapy in 
some patients new delivery forms of CBT such as via the Internet need to be 
evaluated. 
Chapter seven is a discussion of the overall ACE-Mental Health 
project placing the results for major depression together with those of other 
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mental disorders. While for schizophrenia a more efficient drug treatment 
strategy could pay for the introduction of family therapy, recommended 
treatment strategies for anxiety and depression would require significant new 
resources. A caution was made that the study results should not be seen as 
prescriptive as not all treatment options were evaluated and the analyses are 
based on ‘averages’ ignoring the diversity of patients and treatment 
responses in clinical practice. However, current practice patterns in mental 
health services indicate that there are inadequate incentives to promote 
efficiency. 
Measurement of health benefits in DALYs is identified as the main 
methodological problem. While the estimation of the effect size is based on 
accepted methods, the translation of effect size into DALY units required the 
development of new methods basically forcing a continuous outcome (effect 
size) into a small number of categorical values for different levels of severity 
of disease. This makes comparisons between interventions for the same 
disorder most valid as the same translation –regardless of how inadequate – 
applies to all results. Comparisons of interventions for different disorders are 
more difficult due to differences in available epidemiological data and hence 
variations in the translation methods from effect size to DALYs. 
Furthermore, comparison of ACE–Mental Health interventions where health 
gains are dominated by non-fatal outcomes with interventions for heart 
disease and stroke where extension of life dominates health outcomes, are 
less certain even though these were analysed in a companion project, ACE–
Heart Disease, using comparable evaluation methods. 
Chapter eight wraps up the discussion on these two large research 
endeavours that aimed to provide an evidence base for policy making of 
mental health services in Australia. Major achievements are evident in the 
development of credible methods of measuring disease burden and cost-
effectiveness in the area of mental health. Nevertheless, further 
improvements are possible and recommendations for future work are made. 
The chapter concludes with a brief analysis of the impact of this body of 
work on mental health policy. 
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De kosten van de gezondheidszorg stijgen sneller dan die van andere 
sektoren in de economie in Australië. Als gevolg hiervan neemt de druk toe 
op de overheid om de verdeling van het gezondheidsbudget te 
rechtvaardigen. Dit is zeker ook het geval als het gaat om de geestelijke 
gezondheidszorg. 
De Global Burden of Disease studie trok in de negentiger jaren de 
aandacht voor de tot dan toe vaak genegeerde, maar belangrijke rol van 
psychiatrische aandoeningen. De toepassing van de Disability-Adjusted Life 
Year (DALY) – een samengestelde volksgezondheidsmaat waarin mortaliteit 
en morbiditeit gecombineerd worden – bracht aan het licht dat psychiatrische 
aandoeningen een grote hoeveelheid morbiditeit bijdragen aan de totale 
ziektelast in de wereld. In de tweede helft van de negentiger jaren werd de 
ziektelast voor het eerst in Australië gemeten. De geestelijke ziektelast is het 
onderwerp van hoofdstuk twee en drie.  
Indertijd waren de methoden om de ziektelast van  psychiatrische 
aandoeningen te meten nogal rudimentair. Daarom werd speciale nadruk 
gelegd op het ontwikkelen van een nieuwe aanpak. De belangrijkste 
verbeteringen waren: a) de beschrijving van een groter aantal psychiatrische 
aandoeningen; b) ziektemodellen die beter het chronische verloop van de 
meeste psychiatrische aandoeningen weergeven; c) meer aandacht voor de 
verdeling naar ernst van ziekte; en d) een correctie voor de zeer vaak 
voorkomende comorbiditeit tussen psychiatrische aandoeningen. 
Psychiatrische aandoeningen vormden de op twee na grootste 
ziektecategorie, volgend op hart- en vaatziektes en kanker. Depressie was de 
grootste oorzaak van de morbiditeitscomponent van de ziektelast bij mannen 
en vrouwen en zeven andere psychiatrische aandoeningen staan in de top 
twintiglijst van morbiditeit. 
Een recente geestelijke gezondheidsenquête leverde goede informatie 
over de prevalentie en ernst van ziekte. Omdat de DALY gebaseerd is op 
incidentie, was er behoefte aan aanvullende informatie uit de weinige 
beschikbare vervolgstudies van mensen bij wie in een enquête een 
geestelijke aandoening was vastgesteld. Voor de DALY schattingen wordt 
een generalisatie gemaakt voor het gemiddelde geval in de bevolking. Het is 
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daarom onvermijdelijk dat geen rekening gehouden kan worden  met alle 
verscheidenheid in duur en ernst van psychiatrische aandoeningen. De 
definitie vershillen van psychiatrische diagnoses is een bijkomend probleem. 
Wij vonden, bijvoorbeeld, aanzienlijke verschillen in de ziektelastschatting 
als we de diagnose van psychiatrische aandoeningen in de enquête baseren 
op de International Classification of Disease versie 10 (ICD–10) of de 
Diagnostic and Statistical Manual versie 4 (DSM–IV). Bovendien zijn er 
twijfels of er een diagnostisch verschil bestaat tussen depressie en 
angststoornissen, omdat er zoveel overlap bestaat tussen deze aandoeningen 
en de behandelingsstrategieën grotendeels hetzelfde zijn. Nog een probleem 
is dat psychiatrische aandoeningen in bevolkingsenquêtes worden gemeten 
op grond van zelf-gerapporteerde symptomen. Voor lichamelijke ziektes is 
er een sterke voorkeur voor meer objectieve gezondheidsmaten omdat de 
ervaring leert dat zelf-gerapporteerde symptomen vaak een slechte 
aanduiding zijn van de echte ziekte. Het moet echter gezegd worden dat over 
het algemeen psychiatrische epidemiologen meer aandacht hebben besteed 
aan het opzetten van wetenschappelijke grondregels voor enquêtes dan hun 
collegas die zich bezig houden met het onderzoeken van niet-fatale 
lichamelijke aandoeningen. 
Grote gezondheidsproblemen zijn niet noodzakelijk prioriteiten voor 
gezondheidszorginterventie. Daarvoor is meer informatie over de 
effectiviteit en de kosten van verschillende interventieopties nodig. Als 
vervolg op de ziektelaststudies financierden de federale regering en de 
staatsregering in Victoria een economische evaluatiestudie, de Assessing 
Cost-Effectiveness (ACE) – Mental Health studie, om te onderzoeken wat de 
kosteneffectieve mogelijkheden zijn om de grote ziektelast van 
psychiatrische aandoeningen aan te pakken. In een project van twee jaar 
werden de belangrijkste behandelingsmethodes voor depressie, 
angststoornissen, schizophrenie en Attention-Deficit and Hyperactivity 
Disorder (ADHD) onderzocht. 
De meeste economische evaluaties in de gezondheidszorg vergelijken 
maar een beperkt aantal interventies voor eenzelfde gezondheidsprobleem. 
Vaak worden deze studies uitgevoerd als onderdeel van een randomised 
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controlled trial waarbij extra informatie over kosten wordt verzameld. Als 
het doel is, zoals in de ACE–Mental Health studie, om meerdere interventies 
voor verschillende aandoeningen te bestuderen dan is de enige optie om te 
modelleren met beschikbare epidemiologische en economische 
informatiebronnen. Oppervlakkig gezien lijkt modelleren een minder 
nauwkeurige manier van evalueren dan  evaluatie op grond van data uit een 
trial. De meeste trials, echter, verzamelen data in geselecteerde 
patiëntengroepen die niet representatief zijn voor leeftijd, geslacht en de 
ernst van ziekte in de hele bevolking. Via modelleren kunnen  de werkelijke 
omstandigheden van de bevolking waarvoor beslissingen genomen moeten 
worden beter worden weergegeven. Het bijelkaar zetten van gepubliceerde 
evaluatiestudies in een ranglijst is geen goed alternatief omdat de methodes 
erg verschillen van studie tot studie. 
De gestandardiseerde evaluatie methodes in ACE-Mental Health zijn 
het onderwerp van hoofdstuk vier. De belangrijkste basisregels voor de 
modellen zijn het gebruik van a) systematisch literatuuronderzoek en meta-
analyse om de effectgrootte te bepalen; b) Australische epidemiologische 
enquêtedata om het ziekteverloop en behandelingstrajecten te beschrijven; c) 
kosteninformatie uit routinematig verzamelde informatie en 
patiëntenenquêtes; d) uitgebreide onzekerheidsanalyses rond de kosten per 
DALY uitkomsten met behulp van simulatietechnieken; e) intensieve 
raadpleging van beleidsmakers, ziektenexperts en vertegenwoordigers van 
patientenorganisaties gedurende de hele studie; en f) andere criteria van 
belang voor het formuleren van aanbevelingen (rechtvaardige verdeling, 
sterkte van het bewijsmateriaal, uitvoerbaarheid en de mate waarin 
beleidsaanbevelingen acceptabel zijn voor verschillende belangengroepen). 
De resultaten van de evaluatie van interventies voor depressie worden 
besproken in de hoofdstukken vijf en zes. In hoofdstuk vijf wordt een 
vergelijking gemaakt tussen de gebruikelijke kortetermijn 
behandelingsaanpak en een langer durende onderhoudsbehandeling met 
medicijnen of cognitieve gedragstherapie. Deze analyse toont de waarde aan 
van het combineren van ziektelast en economische evaluatie in tegenstelling 
tot de beweringen van sommige gezondheidseconomen dat 
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ziektelastmetingen een verspilling van analytische capaciteit zijn.De huidige 
behandelingsaanpak die gericht is op het behandelen van patienten die zich 
melden met een episode van depressie voorkomt slechts 9% van de totale 
ziektelast van depressie in Australië. Optimaal gebruik van de episodische 
behandeling zou ongeveer een kwart van de ziektelast kunnen wegnemen 
terwijl onderhoudsbehandeling potentieel de helft kan voorkomen, zelfs 
wanneer aangenomen wordt dat maar 60% van patienten de behandeling 
voortzet. Medicijnen en kortdurende psychologische behandeling met 
cognitieve gedragstherapie hebben eenzelfde uitkomst. De belangrijkste 
conclusie dat onderhoudsbehandeling meer ziektelast voorkomt blijft 
overeind ook als alle onzekerheid over de ingevoerde variabelen 
meegerekend wordt. Deze resultaten suggereren dat een aanzienlijke 
vermindering in de ziektelast van depressie alleen kan gebeuren als 
behandelaars het chronische verloop herkennen en de ziekte als zodanig 
behandelen. Een caveat is dat het bewijsmateriaal voor de uitkomsten van 
onderhoudsbehandeling nogal zwak is. Er zijn meer en langere trials nodig 
om de resultaten te ondersteunen. 
De analyses worden tot een volledige economische evaluatie 
uitgewerkt in hoofdstuk zes. We besloten om met name de kosten-
effectiviteit te onderzoeken van  verschillende interventiekeuzes gericht op 
diegenen met depressie die wel hulp zoeken en als depressief herkend 
worden, maar geen bewezen effectieve behandeling ontvangen.  Deze keuze 
werd bepaald door het feit dat we geen informatie  hadden over  interventies 
voor depressieve mensen die geen hulp zoeken bij de gezondheidszorg of 
daar niet als zodanig herkend worden. . 
Alle behandelingsopties voor depressie hadden een gunstige 
kosteneffectiviteitsratio in vergelijking met de huidige inadequate 
behandeling. Bibliotherapie (cognitieve gedragstherapie uit een boek), 
cognitieve gedragstherapie in een groep of individueel door een psycholoog 
in overheidsdienst en de tricyclische antidepressiva (TCAs) waren het meest 
kosteneffectief met een ratio onder de A$10,000 per DALY. 
Onderhoudsbehandeling met de duurdere Selective Serotonin-Uptake 
Reinhibitors (SSRIs) was de duurste optie met een ratio van rond de 
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A$20,000 per DALY in vergelijking met de huidige inadequate behandeling. 
Als we echter een directe vergelijking maken met TCAs vinden we een erg 
hoge ratio voor SSRIs (>A$200,000 per DALY) als gevolg van de hoge 
kosten van SSRIs, het ontbreken van een betere uitkomst voor depressie en 
een slechts bescheiden voordeel in termen van behandelingstrouw vanwege 
een iets mindere bijwerkingen.  
De belangrijkste conclusies zijn dat er een aantal kosteneffectieve 
behandelingsopties bestaat voor depressie en dat deze behandelingen op dit 
moment te weinig worden gebruikt. In termen van kosteneffectiveit zijn 
onderhoudsbehandeling en episodische behandeling gelijkwaardig. De totale 
kosten van onderhoudsbehandeling zijn echter veel groter, vooral als voor 
SSRIs gekozen wordt.  
Na de economische analyses was het op uitgebreide schaal invoeren 
van cognitieve gedragstherapie het belangrijkste discussiepunt, met name het 
gebrek aan opgeleide therapeuten en het ontbreken van een 
vergoedingensyteem voor psychotherapie door niet-dokters in de 
eerstelijnszorg. Omdat cognitieve gedragstherapie uit een boek ook effectief 
is bij  sommige patienten is het aan te raden om alternatieve toepassingen, 
zoals bijvoorbeeld via het Internet, te onderzoeken. 
Hoofdstuk zeven is een bespreking van het hele ACE-Mental Health 
project waarbij de resultaten voor depressie naast die van andere 
psychiatrische aandoeningen gelegd worden. Voor schizofrenie kan een 
meer efficiente medicijnbehandelingsstrategie genoeg geld uitsparen om de 
introductie van gezinstherapie te financieren. Voor de aanbevolen 
behandelingen voor depressie en angststoornissen zijn aanzienlijke nieuwe 
fondsen nodig. De discussie waarschuwt voor een te letterlijke uitleg van de 
resultaten omdat niet alle behandelingsopties geëvalueerd zijn en omdat de 
analyses gebaseerd zijn op het ‘gemiddelde geval’ waarbij de diversiteit van 
patienten en reacties op behandeling niet optimaal ingebouwd zijn. Aan de 
andere kant zijn er overduidelijke tekenen dat de huidige geestelijke 
gezondheidszorg efficientie veel te weinig beloont.  
Het meten van gezondheidswinst in DALYs wordt aangeduid als het 
belangrijkste methodologische probleem. Er bestaan geaccepteerde 
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methodes om de effectgrootte te meten in meta-analyses van trials. Het was 
echter noodzakelijk om nieuwe methodes te ontwikkelen om de effectgrootte 
om te zetten in DALY-eenheden , zodat de continue schaal van de 
effectgrootte vertaald kon worden naar  een klein aantal categorische DALY 
waarden voor de ernst van ziekte. Daarom zijn de vergelijkingen voor 
dezelfde aandoening het meest valide  omdat dezelfde (al dan niet adequate) 
omzetting gebruikt werd in alle analyses. Vergelijkingen tussen depressie en 
schizofrenie zijn minder geldig vanwege verschillen in de beschikbare 
epidemiologische data en als gevolg daarvan enigszins  andere methodes om 
de effectgrootte om te zetten in DALYs. Vergelijkingen tussen de ACE-
Mental Health resultaten, waarbij de gezondheidswinst met name morbiditeit 
betreft, en met die van een zusterproject, ACE-Heart Disease, zijn ondanks 
eenzelfde aanpak nog onzekerder omdat de gezondheidswinst voor hart- en 
vaatziektes met name door een vermindering in sterfte bepaald wordt. 
De thesis besluit in hoofdstuk acht met een bespreking van de twee 
grote onderzoeksprojecten die als doel hadden om grondslagen te leveren 
voor de besluitvorming in de geestelijke gezondheidszorg in Australië. Er 
grote vooruitgang gemaakt in de ontwikkeling van geloofwaardige methodes 
om de ziektelast en kosteneffectiveit op het gebied van de geestelijke 
gezondheid te meten. Niettemin zijn verdere verbeteringen mogelijk en 
aanbevelingen voor toekomstig onderzoek worden gemaakt. Het hoofdstuk 
beëindigt met een korte analyse van de invloed van het hier gepresenteerde 
onderzoek op de besluitvorming in de geestelijke gezondheidszorg.
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PROPOSITIONS 
Stellingen 
1. Research on priority setting in health is most likely to influence health 
policy decision-making if undertaken in close collaboration with 
government  
2. Rational arguments for efficient use of health resources face formidable 
counterarguments by industry, politicians, bureaucrats, media, disease 
advocates and consumers trying to influence resource allocation. 
3. Ignoring basic burden of disease information on prevalence, incidence 
and duration of disease when presenting marginal cost-effectiveness 
results to policy makers is an inadequate use of precious analytical 
resources. 
4. Mental health epidemiologists ought to avoid measuring ‘lifetime 
prevalence’ at the expense of point or 12-month prevalence. 
5. Frequent co-occurrence and similarity in treatment approach are two 
strong arguments to treat depression and anxiety disorders as a single 
mental disorder. 
6. There is an inverse relationship between the frequency at which self-
report health surveys are being conducted and their value to quantifying 
population health. 
7. Epidemiologists should not assume that respondents have the same level 
of interest in the survey topic as they do. 
8. The Australian ‘no worries, mate’ culture does not translate into lower 
rates of depression. 
9. The public defense and the dissemination of the thesis’ findings as a 
book make a PhD in the Netherlands much more rewarding than a PhD 
in Australia. 
10. Research on burden of disease and cost-effectiveness is conducted in the 
spirit of Voltaire’s ‘Le mieux est l’ennemi du bien’ — ‘The best is the 
enemy of the good’. 
11. The frequent accusations that the national broadcaster, the Australian 
Broadcasting Corporation, has a left-wing bias show the arrogance of the 
Liberal Party in a country where the media are dominated by the right-
wing Packer and Murdoch empires,. 
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